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3 Abstract 
The renin-angiotensin system (RAS) is known to be the main regulator of blood pressure 
and fluid balance. Within the RAS, angiotensin (Ang)-(1-7) is known to have cardiovascular 
protective effects. It represents the opponent of the often detrimental Ang II, which is 
known to stimulate the angiotensin receptor type 1 (AT1), causing negative effects such 
as a pathological rise in blood pressure. Beside the well accepted fact that the G-protein 
coupled receptor Mas is a receptor for the heptapeptide, it was not possible to 
characterise the ligand/receptor pharmacology or to identify further receptors, since 
there was a lack in the understanding of the initial intracellular signalling pathways 
stimulated by Ang-(1-7). 
In this study, cyclic adenosine monophosphate (cAMP) was identified as a second 
messenger stimulated by Ang-(1-7). The heptapeptide elevates cAMP concentration in 
various cell lines, as well as in Mas transfected HEK293 cells, confirming that Mas is a 
functional receptor for Ang-(1-7). Even more important, MrgD was identified as a second 
receptor for the peptide, while AT2 could be excluded to be targeted by the 
heptapeptide. 
It was also examined, if there are any changes in the intracellular signalling if the first 
amino acid of the peptide is decarboxylated. The receptor fingerprint for Ala1-Ang-(1-7) 
was dicovered, and the consequences for pharmacodynamics characterised. The dose-
response curves were clearly different from the curves generated with Ang-(1-7). They 
showed a much lower EC50 and a bell-shaped curve for Ala1-Ang-(1-7). Furthermore, 
pharmacological proof was provided that both, Mas and MrgD, are functional receptors 
for Ala1-Ang-(1-7). 
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Interestingly, it was also discovered that the AT2 receptor blocker PD123319 is not AT2 
specific, but can also block the effects of Ang-(1-7) and Ala1-Ang(-1-7) in Mas and MrgD-
transfected and in primary cells. This raised the question whether the selective non-
peptidic AT2 receptor agonist, Compound 21 (C21), is also unspecific and stimulates Mas 
and MrgD too. This hypothesis was supported by the fact that the chemical structure of 
C21 is similar to the Mas receptor specific, non-peptidic agonist AVE0991. Using cAMP 
and downstream molecules as readouts, pharmacological proof that Mas and MrgD are 
functional receptors for C21 was generated. 
The last part of the study examined the role of Ang-(1-7) and its receptors in diabetes 
mellitus (DM). Previous studies demonstrated that the ACE2/ Ang-(1–7)/ Mas axis has 
beneficial effects on glucose homeostasis, but the underlying mechanisms remained 
unknown. The effects of Ang-(1–7) and its receptor Mas on the function of β-cells were 
investigated. Islets isolated from Mas-deficient and wild-type mice were stimulated with 
Ang-(1–7) or its antagonists and effects on insulin secretion were determined. It was 
found that Ang-(1–7) was able to increase the insulin secretion from wild-type islets, but 
not from islets derived from Mas deficient animals. Interestingly, Ang-(1-7) antagonist D-
Pro, but not A779 could block the Ang-(1-7) mediated effects indicating the involvement 
of another Ang-(1-7) receptor. However, the heptapeptide did not affect the insulin gene 
expression or the excitation-secretion coupling, but increased intracellular cAMP 
involving exchange protein activated directly by cAMP (EPAC), leading to a higher insulin 
secretion by the β-cells.  
Ang-(1–7) was also applied to normo-glycaemic mice for 14 days using osmotic pumps. 
The effects of the heptapeptide in vivo had only marginal effects on glucose tolerance in 
wild-type mice. However, Ang-(1-7) had improved the insulin secretion in islets isolated 
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from these mice. Interestingly, although less pronounced than in wild-types, Ang-(1–7) 
still affected insulin secretion in islets derived from Mas deficient mice. The effect of Ang-
(1-7) in mice with STZ-induced diabetes was marginal, as in normo-glycaemic mice.  
Taken together, these results lead to an expansion and partial revision of the renin-
angiotensin system, by identifying a second receptor for Ang-(1-7), and by excluding AT2 
as a receptor for the heptapeptide. Furthermore, the identification of Ala1-Ang-(1-7) as a 
peptide with specific pharmacodynamic properties can be used as a basis for the design 
of more potent and efficient Ang-(1-7) analogues, which can be useful in therapeutic 
interventions in a rapidly growing number of diseases. The proof that C21 and PD123319 
are not AT2 receptor specific as generally assumed, but also interact with the two Ang-(1-
7) receptors, Mas and MrgD, might be an explanation for the partial overlap in beneficial 
effects of both compounds. Thus, the better understanding of the interaction of small 
molecules like C21 with their receptors, lays the foundation for the development of small 
molecules which stimulate all or just one of the Ang-(1-7) receptors, which may be 
beneficial in diseases like diabetes mellitus. Since it could be shown that Ang-(1–7) plays a 
significant role in the regulation of insulin secretion from mouse islets in vitro and in vivo, 
mainly, but not exclusively, by Mas-dependent signalling, modulating the accessory 
pathway of insulin secretion via increase in cAMP, makes clear that Ang-(1-7) and its 
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4 Introduction 
4.1 The renin-angiotensin system 
4.1.1 General structure of the renin-angiotensin system 
Historically, the renin-angiotensin system (RAS) was believed to be a system with 
endocrine properties, whose active metabolite angiotensin (Ang) II was also the final 
product of the system [1, 2]. After activation, the first step is the secretion of renin by 
specialised cells in the kidney tissue, known as the juxtaglomerular apparatus [3]. The 
juxtaglomerular apparatus responds to blood pressure changes in vas afferens, the salt 
content of the urine, signals from the autonomic nervous system and various hormones. 
Renin is stored in myoepithelial cells of the vasa afferentia. Decreased blood flow, 
reduced blood pressure, reduced glomerular filtration rate, lower concentration of  
chloride ions in the urine (measured by the salt sensors of the macula densa) and the 
activation of the sympathetic nervous system lead to an increased release of renin [4, 5]. 
Whereas renin is secreted by the kidneys, the precursor of angiotensin, the 452 amino 
acid long angiotensinogen, is secreted by the liver and circulates free in the blood. The 
pro-hormone is cleaved by renin in to the 10 amino acid long Ang I (Ang-(1-10)), which 
then is cleaved by the angiotensin converting enzyme (ACE) to the octapeptide Ang II 
(Ang-(1-8)) [6]. 
Two receptors have been identified as targets for Ang II, the angiotensin receptor type I 
(AT1), and the angiotensin receptor type II (AT2) [7, 8] (Figure 4.1.1). The induced 
intracellular signalling then results in different physiological effects such as increase in 
blood pressure, cardiac contractility, vascular and cardiac hypertrophy, and proliferation 
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[7, 8]. While the mentioned effects are AT1 mediated, AT2 opposes most of these effects 
[7, 8]. 
 
Figure 4.1.1 The general structure of the renin-angiotensin system 
The kidney secretes renin when blood pressure drops or the glomerular filtration rate decreases. In 
the blood circulating angiotensinogen is cleaved by renin to Angiotensin I (Ang I). The angiotensin 
converting enzyme (ACE) cleaves two amino acids from the c-terminal end of Ang I to generate 
Ang II [6], which then interacts with the AT1 and AT2 receptor. 
 
4.1.1.1 The carboxypeptidase ACE 
The glycoprotein ACE is the key enzyme for the production of Ang II. It is a zinc 
metalloprotease and converts the inactive decapeptide Ang I into the biologically active 
Ang II by cleaving the n-terminal dipeptide histidine-leucine [9]. ACE has been found in 
several tissues, such as heart, blood vessels, kidneys, and intestine [10]. A soluble form 
also exists, which has been found in blood plasma, amniotic fluid, seminal plasma, and 
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ACE inhibitors were initially used to treat hypertension, but are also very effective in 
cardiovascular events such as acute myocardial infarction (heart attack), cardiac failure 
(left ventricular systolic dysfunction), but also in kidney complications (diabetic 
nephropathy). ACE inhibitors lower arteriolar resistance and increase venous capacity. 
Furthermore, they decrease the cardiac function (cardiac output, cardiac index, stroke 
work, and volume) and increase excretion of sodium in the kidney tubules, by decreasing 
the Ang II production which results in reduced aldosterone release [12]. 
 
4.1.1.2 Angiotensin II and its receptors AT1 and AT2 
The functions of Ang II include the regulation of blood pressure and electrolyte balance, 
release of aldosterone and vasopressin, sympathetic activity, as well as the control of 
thirst and water intake [13].  
The effects of Ang II are mediated by AT1 and AT2. Both receptors are G-protein coupled 
receptors (GPCRs) of the rhodopsin subclass with comparable properties in ligand binding 
(see Chapter 4.2.1). The difference between them lies in their tissue distribution, as well 
as their transcriptional regulation and signal transduction [14]. The AT2 receptor will be 
further discussed in Chapter 4.2.2.  
The AT1 receptor is the major receptor for Ang II [7, 15]. It interacts with various 
heterotrimeric G-proteins and activates second messengers, such as inositol 
trisphosphate (IP3), diacylglycerol (DAG) and reactive oxygen species (ROS). The binding 
of Ang II to AT1 activates receptor and non-receptor tyrosine kinases, serine/threonine 
kinases, mitogen-activated protein kinases (MAPKs), p70S6K, protein kinase B (PKB/ AKT), 
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and protein kinase C (PKC) and has a negative effect on adenylyl cyclase (AC) [16]. In 
general, the activation of the AT1 receptor induces strong vasoconstriction. It stimulates 
the release of aldosterone from the adrenal glands, which in turn promotes sodium 
reabsorption. In the kidney, the activation of the receptor is associated with renal 
vasoconstriction and anti-natriuresis [3, 17]. In addition, AT1 activates the sympathetic 
nervous system and is involved in the development of hypertension, arteriosclerosis and 
heart failure [18, 19]. In the heart, AT1 stimulates hypertrophy and the proliferation of 
cardiac fibroblasts [20]. The ACE/ Ang II/ AT1 axis is seen as the harmful arm of the RAS. 
 
4.1.2 The circulating and local renin-angiotensin system 
Since the first description of renin by Tigerstedt and Bergmann in 1898 [21], the RAS has 
been the focus of intense research. Researchers came to the understanding that the RAS 
has not just endocrine, but also paracrine functions [22]. They concluded that the primary 
function of the circulating RAS was not the delivery of Ang II to tissues, but rather the 
delivery of renin and angiotensinogen [23]. The generation of Ang I and Ang II then occurs 
in the target tissue through ACE, respectively. 
Two systems can be distinguished, the circulating RAS and the local (tissue specific) RAS 
[24]. In the 1970s, components of the RAS could be identified in different tissues such as 
heart [25], lung [26], kidney [27, 28], blood vessels [29, 30], adrenal glands [31-33], brain 
[34, 35] and even reproductive organs [36]. Although, those findings initially faced big 
criticism, with the development of new techniques it was no longer deniable that local 
RAS exists. 
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Whereas the plasma RAS is responsible for short-term changes and the regulation of the 
cardiovascular system, the local RAS can cause long-term effects. Those effects include 
changes in cell proliferation, protein synthesis and organ function. The local RAS seems to 
work independent from the circulating system [3, 37]. 
 
4.1.3 The “new” renin-angiotensin system 
For a long time, Ang II was believed to be the final product and functional component of 
the RAS. The discovery of other components such as new receptors, angiotensin peptides 
and alternative ways of generating them, fundamentally changed the understanding of 
the RAS in the past 100 years (Figure 4.1.2).  
These new components contain the peptides Ang III (Ang-(2-8)), Ang IV (Ang-(3-8)), Ang-
(1-9) and Ang-(1-7) (see also Figure 4.1.2) [38, 39]. Enzymes responsible for the 
generation of these angiotensin peptides are primarily, but not exclusively, the carboxy 
peptidases ACE and ACE2, the neutral endopeptidase (neprilysin, NEP), and the 
aminopeptidases (AP) APA, APN and APD [39]. 
Jankowski et al. have been the first who described Ala1-Ang II in human plasma [40]. Also 
known as Ang A, this peptide is generated by the decarboxylation of the first amino acid. 
The detailed mechanism and the enzyme responsible remain unknown. Ang A acts 
through the same receptor as Ang II, AT1 [41]. 
In 2013, Lautner et al. identified Ala1-Ang-(1-7). This peptide can be generated through 
the decarboxylation of the first amino acid of Ang-(1-7), as the authors have 
demonstrated by analysing Ang-(1–7) perfused rat heart [42]. Additionally, they also 
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demonstrated that the peptide can be converted from Ang A through ACE2, by cleaving 
the last amino acid from Ang A. The effects of Ala1-Ang-(1-7) seem to be the same as 
those from Ang-(1-7), such as vasorelaxation and anti-hypertensive effects, as 
demonstrated in spontaneous hypertensive rats [42]. 
 
Figure 4.1.2 Biologically active angiotensin peptides and their generation 
Schematic overview of the biologically active angiotensin peptides and their generation through 
the main targeting peptidases [43, 44]. (AP: amino peptidase, ACE: angiotensin converting 
enzyme, NEP: neutral endopeptidase)  
 
Additionally, the number of receptors within the RAS has expanded over the past 70 years 
(Figure 4.1.3). Researchers have found that Ang III, like Ang II, can stimulate AT1 and AT2 
and has the same, if not better potency compared to Ang II [44]. The hexapeptide Ang IV 
can bind to AT1 and AT4 (later identified as the insulin regulating amino peptidase (IRAP)) 
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the Mas receptor. However, in certain circumstances and tissues, AT2 seemed to be 
involved in the Ang-(1-7) mediated effects [48, 49]. The receptor identified for the newly 
described Ala1-Ang-(1-7) was MrgD, a Mas like receptor [42]. 
 
Figure 4.1.3 The receptors of the RAS 
Schematic overview of the receptors of the RAS and the estimated ligands. 
 
In contrast to Ang II, Ang III and Ang IV, have vasoconstricive properties, while Ang-(1-9) 
and Ang-(1-7) are vasorelaxant [43, 50]. 
Nowadays, the RAS is divided into two antagonistic axes, as the discovery of ACE2 and the 
Mas receptor extended the concept of RAS. Now the RAS no longer just consists of the 
“bad” ACE/ Ang II/ AT1 axis, but also the “good” ACE2/ Ang (1-7)/ Mas axis. While the 
classical axis is characterised by proliferative, fibrotic, vasoconstrictive, and hypertrophic 
effects, the “new” axis opposes those effects [51].  
 
4.1.3.1 The carboxy peptidase ACE2 
ACE2 was first described in 2000 by two independent research teams [52, 53]. Like ACE, it 
is a zinc dependent metallopeptidase. Both show 42 % identity in their catalytic domain 
[52, 53]. In addition, the catalytic mechanism of both peptidases is quite similar. The 







Ang A Ang IV
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difference from ACE is the number of amino acids cleaved from the substrate. ACE splits 
two amino acids from the C-terminal end, while ACE2 is a mono-carboxy peptidase and 
cleaves only one amino acid from the C-terminal end.  
At first, it was assumed that ACE2 expression was restricted to heart, kidney, and testis 
[53, 54], as Donoghue et al. could show. They cloned the human ACE2 from a cDNA 
library and performed northern blot analysis with several human tissue [53]. However, 
recent findings demonstrated that it is expressed in a wide variety of cardiovascular 
tissues (myocytes, lung epithelial cells, vascular smooth muscle cells) and 
noncardiovascular tissues (ileum, duodenum, jejunum, caecum, and colon) [54]. ACE2 is 
an integral type I membrane protein [55], but can also be shed from the membrane to a 
still active soluble form [56]. 
Initially, the decapeptide Ang I was considered to be the primary substrate for ACE2, 
generating the biologically active peptide Ang-(1-9) [53]. However, investigations of ACE2 
activity demonstrated that the catalytic activity of the carboxypeptidase for Ang II is 400 
times higher than for Ang I, concluding Ang II as the main substrate of ACE2, which is 
metabolised to the heptapeptide Ang-(1-7) [57, 58] .  
 
4.1.3.2 The protective angiotensin-(1-7) and its receptor Mas 
For a long time, it was assumed that Ang-(1-7) was a peptide without biological activity. 
The first proof of its biological activity was in 1988. Schiavone et al. [59] demonstrated in 
in vitro experiments that the heptapeptide induces the release of vasopressin from the 
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hypothalamic neurohypophyseal explant. At the same time, the formation of Ang-(1-7) 
from Ang I via an ACE-dependent pathway was described [60]. 
Since 1988, Mas was presumed to be a functional angiotensin receptor [61]. As the 
binding of Ang II to Mas could never be shown, this hypothesis was questioned for a long 
time [61]. In 2003, the Walther group described Ang-(1-7) as a ligand for the Mas receptor 
[62]. Santos et al. showed that the knockout of Mas in mice completely abolished the 
vasodilatory effects of Ang-(1-7) in aortic rings isolated from those animals. Furthermore, 
they showed that the transfection of COS cells with the Mas receptor resulted in Ang-(1-
7) mediated release of arachidonic acid (AA) [62].  
However, the results of several studies suggest that the peptide interacts with several 
receptors of the RAS. Beside Mas [62], researchers found that Ang-(1-7) also binds to the 
AT1 receptor, using replacement assays with I125-AngII [63]. However, the affinity of the 
heptapeptide for the AT1 receptor is much lower than for the Mas receptor, since high 
concentrations (≥10-6 M) of Ang-(1-7) has been required in those studies. In addition, Ang-
(1-7) has a low affinity for the AT2 receptor [64]. However, since pharmacological studies 
implicated that many Ang-(1-7) mediated effects are AT2 receptor independent, the 
receptor might be only involved in certain conditions and in certain tissues [64]. 
Furthermore, the peptide might also interact with the Mas-like receptors MrgD and Mrg, 
as the peptide was able to increase the AA release in COS cells overexpressing these 
receptors. [65]. 
Interestingly, most effects mediated by Ang-(1-7) are counteracting the effects caused by 
Ang II activating the AT1 receptor [66]. The signalling of the AT2 receptor will be 
described in detail in Chapter 4.2.4.4. 
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4.1.4 Physiological effects mediated by angiotensin-(1-7)  
The main function of the RAS is the regulation of blood pressure, fluid balance and salt 
homeostasis including thirst. Beside those classical functions, the RAS is also involved in 
other processes.  
 
Figure 4.1.4 Ang-(1-7) tissue specific effects 
Overview of the beneficial effects mediated by Ang-(1-7) in different tissues such as brain, central 
nervous system, heart, blood vessels, fat tissue and liver. Furthermore, Ang-(1-7) plays a role in the 
modulation of the immune response.  
 
The system plays a role in certain diseases, such as Alzheimer’s disease [67, 68], 
Parkinson’s disease [69], epilepsy [70], alcoholism [71, 72], depression and diabetes [73] 
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Ang-(1-7) often counteracts the cardiovascular effects of Ang II/ AT1, but it is also 
involved in other tissue specific processes (Figure 4.1.4). 
 
4.1.4.1 Angiotensin-(1-7) mediated effects in the kidney 
The function of the heptapeptide in the renal system is contradictive. Many studies could 
show positive effects of Ang-(1-7) in renal diseases. The heptapeptide improved 
glumerulosclerosis [76] and had positive effects on general renal parameters 
(microalbuminuria and serum albumin levels) in a murine model of adriamycin-induced 
nephropathy [77]. In a genetic mouse model for diabetes type 2, Ang-(1-7) has been 
renoprotective against diabetic nephropathy. This was associated with lower levels of 
inflammatory markers (reduced macrophage levels in perirenal adipose tissue), less 
oxidative stress (less superoxide production) and less fibrosis in renal tissue [78]. In 
kidney epithelial cells, the heptapeptide modulates the activity of transporters, limiting 
the transcellular sodium flux. The modulation of transporter activity occurs by activation 
of phospholipase A2 (PLA2) [79].  
On the other hand, it seems that Ang-(1-7) has detrimential effects under certain 
conditions. In streptozotocin (STZ) induced diabetic rats, for example, the infusion of the 
heptapetide worsened the renal function and did not improve the renal injury [80]. In 
murine models of renal insufficiency (unilateral ureteral obstruction and 
ischemia/ reperfusion injury), the administration of Ang-(1-7) had pro-inflammatory 
effects, increased fibrosis and apoptosis and worsened the conditions. Furthermore, the 
knockout of the Mas receptor reduced the renal damage, indicating that the Ang-(1-7)/ 
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Mas axis plays an important role in the pathogenesis and progression of subsets of renal 
failure [81]. 
In cells isolated from the proximal tubules of rats, Ang-(1-7) displayed growth inhibitory 
properties by counteracting the Ang II mediated phosphorylation of the mitogen-
activated protein kinase (MAPK) [82]. The pre-incubation of rat mesangial cells with Ang-
(1-7) in addition to Ang II, opposed several Ang II mediated responses, like the production 
of ROS, the activation of the nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB), and MAPK phosphorylation [83]. In contrast, in human mesangial cells the 
heptapeptide stimulated cell growth pathways by increasing AA release and MAPK 
phosphorylation [84]. While Liu et al. showed that the heptapeptide promotes Erk1/2 
(MAPK1/2) phosphorylation [85], Oudit et al. demonstrated that Ang-(1-7) inhibited high 
glucose-stimulated nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) 
via Mas receptor activation [86].  
Animals lacking the Mas receptor showed a reduced volume of urine and sodium 
excretion, and an increase in glomerular filtration. Furthermore, the knockout mice 
showed an increased proteinuria [87]. 
 
4.1.4.2 Angiotensin-(1-7) mediated effects in the heart 
The heptapeptide has been detected in heart areas such as, aortic root, coronary sinus, 
sinus node, right atrium, and in the hermus cells [88, 89].  
Ang-(1-7) activated the sodium pumps, reduced the frequency and duration of ischemia-
reperfusion arrhythmias [90, 91], and improved heart function after ischemia-
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reperfusion-induced cardiac injury in rats [92]. Furthermore, Ang-(1-7) seems to play an 
important role in the regulation of cardiac remodelling and expression of extracellular 
matrix proteins in rat heart [93]. In a rat model of myocardial infarction, the chronic 
infusion of the heptapeptide resulted in many beneficial effects. It increased the coronary 
perfusion, preserved the cardiac function, and reversed the vascular endothelial 
dysfunction in aortic rings [94]. In addition, chronic Ang-(1-7) treatment 
ameliorated cardiac hypertrophy and fibrosis and attenuated the growth-
promoting pathways in the heart of insulin-resistant rats [95]. In hypertensive rats, the 
administration of Ang-(1-7) was also cardio protective. The heptapeptide significantly 
reduced the Ang II induced cardiac remodelling by the upregulation of a MAPK specific 
phosphatase (dual-specificity phosphatase 1, DUSP-1) [96].  The administration of Ang-(1-
7) in models of cardiac fibrosis in Sprague-Dawley rats prevented the Ang II induced 
fibrosis in the rat heart [97]. Also in hypertensive rats, the treatment with Ang-(1-7) 
upregulated Mas and AT2 and resulted in decreased fibrosis [98].  
The deletion of Mas resulted in a marked increase in fibronectin and collagen type I and 
III in the heart compared to wild-type mice, indicating the importance of the Ang-(1-7)/ 
Mas axis in the modulation of the extracellular matrix [99, 100]. In addition, the Mas-
deficient mice showed a gender-specific difference in heart rate variability and blood 
pressure variability compared to wild-type animals, suggesting that Mas has a significant 
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4.1.4.3 Angiotensin-(1-7) mediated effects in endothelium and blood vessels  
Ang-(1-7) has a significant impact on endothelial function. Ang-(1-7) failed to cause 
vasodilation in coronary arteries of dogs where the endothelium was removed [102], 
indicating that the vasodilatory effect of Ang-(1-7) is endothelium dependent. Not only 
are endothelial cells crucial for Ang-(1-7)-mediated vascular effects, they are also 
important for the generation and catabolism of the heptapeptide. Santos et al. could 
demonstrate that the incubation of 125I-Ang I with bovine and human endothelial cells 
resulted in a time-dependent generation of 125I-Ang-(1-7), 125I-Ang II and 125I-Ang-(1-4) 
[103]. In endothelial cells, the heptapeptide induces the release of hyperpolarizing factors 
and vasodilators such as prostanoids and nitric oxide (NO) [104-106] by activating the 
endothelial nitric oxide synthase (eNOS) [107]. 
Most of the Ang-(1-7) mediated vasodilatory effects seem to be Mas receptor-dependent. 
The Ang-(1-7) induced decrease in the perfusion pressure in isolated rat hearts was 
abolished by A779 [108]. Mesenteric microvessels isolated from Mas-deficient mice 
showed no response to Ang-(1-7). Furthermore, in wild-type mesenteric microvessels the 
pre-incubation with the Mas antagonists A779 or D-Pro totally abolished the vasodilatory 
effect of Ang-(1-7), indicating that this effect is Mas dependent [109].  
In addition, the vasodilatory effects are gender specific. Experiments with hypertensive 
rats showed that oestrogen promotes the generation of Ang-(1-7) and potentiates its 
effects [110]. In rats fed on a high salt diet (model for diet-induced hypertension), the 
anti-oxidative effects of the ACE2/Ang-(1−7)/Mas axis helped to maintain and restore 
normal endothelial function in cerebral vessels. The chronic infusion of Ang-(1-7) reduced 
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vascular superoxide levels and restored the NO-dependent dilatation. The administration 
of A779 blocked those effects [111]. 
The knockout of Mas on a mixed FVBN and C57BL/6 background, showed an endothelial 
dysfunction [112, 113]. The Walther group could show that microvessels isolated from 
mice deficient in Mas lose the ability to respond to bradykinin with a vasorelaxation [113]. 
Furthermore, Mas deletion resulted in an imbalance between NO and ROS [114]. 
Interestingly, there is a significant difference in the pronounced phenotype depending on 
the genetic background [115]. Mas-deficiency on a pure C57Bl/6 background showed a 
less prominent endothelial dysfunction compared to a pure FVB/N background. 
Additionally, C57Bl/6Mas-deficient mice remained normotensive, whereas the FVB/N 
developed an elevated blood reassure [115]. 
 
4.1.4.4 Angiotensin-(1-7) mediated effects on the central nervous system 
In the brain, Ang-(1-7) influences processes such as, learning, memory, and 
neuroprotection. Most of these effects are Mas dependent [116].  
The activation of the Mas receptor resulted in the activation of neuronal NOS (nNOS) and 
NO synthesis. The activation of nNOS is important for object recognition memory and 
long-term potentiation in the hippocampus and amygdala [116, 117]. Rats lacking the 
Mas receptor developed a deficiency in object recognition and memory, showing that the 
Ang-(1−7)/ Mas axis plays an important role in learning and memory [118]. 
The ACE2/ Ang-(1−7)/ Mas axis has also neuroprotective effects in ischemic stroke. In rats 
with induced ischemic stroke, the central infusion of the Mas receptor agonist, A779, 
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resulted in larger infarct volumes compared to the control animals. Furthermore, the 
central infusion of an angiotensin-converting enzyme 2 inhibitor (MLN-4760) worsened 
neurological function [119].  
Animals lacking the Mas receptor showed an increased maintenance of long-term 
potentiation in the brain. The hippocampal morphology, basal synaptic transmission, and 
presynaptic function was not changed. Male mice displayed an increased anxiety 
behaviour compared to wild-type animals, which was not observed in female mice, 
indicating a gender-specific effect of Mas expression effects [120]. 
 
4.1.4.5 Angiotensin-(1-7) mediated effects in fat tissue 
Components of the RAS can also be found in adipose tissue [121]. The activation and 
expression is depending on the state of ingestion. For example, in sucrose-fed rats the 
concentration of ACE2 and Ang-(1-7) are elevated in adipose tissue [122].  
In rats, which were fed with high-fructose or high-fat diets, the long-term administration 
of Ang-(1-7) reduced the total fat mass, adipocyte size, adipose inflammation, and 
superoxide production by NADPH [123, 124]. A study in 2010 used the over expression of 
an Ang-(1-7)-releasing fusion protein in rats to increase plasma Ang-(1-7) levels. This 
resulted in a significantly reduced adipose tissue mass and decreased plasma 
triacylglycerides [125]. Besides the beneficial effects on lipid metabolism, Ang-(1-7) also 
influences the glucose homeostasis and insulin resistance in adipose tissue, which will be 
discussed in Chapter 4.3.7.  
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The deletion of Mas in mice resulted in a metabolic syndrome-like state. Mas-knockout 
mice had a normal body weight, but showed dyslipidemia, increased insulin levels and 
leptin, and increased abdominal fat mass. Furthermore, a glucose intolerance and 
reduced insulin sensitivity was observed [126]. In addition, the KOs showed a reduced 
response of adipocytes to the anti-lipolytic effect of insulin [127]. 
 
4.1.4.6 Regulation of inflammation through angiotensin-(1-7) 
Several studies could show that the Ang-(1-7)/ Mas axis plays a role in inflammatory 
responses. Ang-(1-7) reduced leukocyte migration, cytokine expression and release, and 
activation of fibrogenic pathways.  
Using a rat model of autoimmune myocarditis, Sukumaran et al. [128, 129] could 
demonstrate that the ACE2/ Ang-(1-7)/ Mas axis plays an important role in the anti-
inflammatory effects of Telmisartan and Olmesartan (AT1 blockers). The increase of 
myocardial protein levels of ACE2, Ang-(1-7) and Mas was correlated with an increase of 
the anti-inflammatory cytokine, interleukin (IL)-10, and a reduction of pro-inflammatory 
cytokines such as tumour necrosis factor (TNF)-α, interferon (IFN)-γ, IL-1β, IL-6. This was 
associated with less myocardial fibrosis and the down-regulation of phosphatidylinositide 
3-kinases (PI3K), phospho-Akt( pAkt), phospho-p38, phospho- c-Jun n-terminal kinases 
(pJNK), phospho-MAPK1 and phospho-MAPK2 (pErk1/2) [128, 129]. Ang-(1-7) 
counteracted the Ang II induced inflammation in human aortic smooth muscle cells by 
inhibiting the activation of NADPH oxidase and nuclear factor kappa-light-chain-enhancer 
of activated B cells (NFκB), which results in the prevention of inducible NOS (iNOS) 
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generation. Those effects were blocked by A779 and D-Pro, indicating that this is Mas-
dependent [130]. 
Mas-deficient mice showed a reduced concentration of intra-renal NFκB compared to the 
wild-type animals after unilateral ureteral obstruction, indicating that the absence of the 
Mas gene suppresses inflammation in the kidneys. These mice also had a decreased 
matrix deposition, apoptosis and inflammatory cell infiltration [131]. Macrophages from 
C57BL/6 Mas deficient mice showed an increased migratory and pro-inflammatory 
phenotype, which led to an increased immune cell infiltration in the spinal cord or in 
atherosclerotic plaques [132]. 
 
4.1.4.7 Regulation of cell proliferation through angiotensin-(1-7) 
Many studies demonstrated that the Ang-(1-7)/ Mas axis has anti-proliferative effects in 
vascular smooth muscle cells [133, 134], liver tissue [135, 136], cardiomyocytes [134] and 
tumors [137-139].  In VSMC, Ang-(1-7) inhibited the growth via increasing the prostacyclin 
(PGI2) [133]. Using a rat model of hepatic fibrosis (induced by bile duct ligation), it was 
possible to show that Ang-(1–7) and the Mas agonist AVE 0991 improved fibrosis 
significantly [136]. In a mouse model for hepatocellular carcinoma (tumour growth in 
mice was induced by injecting H22 cells), Ang-(1-7) administration reduced the tumour 
growth and inhibited the angiogenesis [137]. In in vitro experiments, Ang-(1-7) abolished 
the AngII-induced migration, invasion, VEGF expression, and MMP-9 activity in breast 
cancer cells (MDA-MB-231 and LM3) [139]. 
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The molecular mechanisms that promote the anti-proliferatory effects of Ang-(1-7) 
include the inhibition of MAPK and the stimulation of prostaglandin synthase and cyclic 
adenosine monophosphate (cAMP) production [133, 140, 141].  
Mas KO mica showed an increased renal expression of transforming growth factor (TGF) 
β1 and extracellular matrix proteins [87] 
 
4.2 The G-protein coupled receptors AT2, Mas and MrgD 
GPCRs, also known as seven transmembrane receptors (7TMR), are the largest group of 
membrane bound receptors, and are only found in eukaryotes and animals [142]. This 
receptor family is a widely used target for the pharmaceutical industry for the treatment 
of diseases such as diabetes, obesity and Alzheimer’s disease [143]. Approximately 34 % 
of all modern drugs target GPCRs [143]. The GPCRs in vertebrates are divided in to six 
categories: Class A (or 1) (Rhodopsin-like), Class B (or 2) (Secretin receptor family), Class C 
(or 3) (Metabotropic glutamate/ pheromone), Class D (or 4) (Fungal mating pheromone 
receptors), Class E (or 5) (cAMP receptors) and Class F (or 6) (Frizzled/ Smoothened) 
[144]. 
 
4.2.1 Signalling pathways of G-protein coupled receptors 
The name, GPCR or 7TMR, comes from their structure (Figure 4.2.1), as they possess 
seven membrane-spanning domains (transmembrane helices) [145]. 
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Figure 4.2.1 G-Protein 
coupled receptor 
Schematic structure 




The binding of an agonist to the GPCR leads to a conformational change and activates 
intracellular responses. The majority of the signalling is G-protein dependent, but G-
protein independent signalling, such as phosphatase activation, also exists [146-148].  
G-proteins are trimers of α, β, and γ subunits (Gα, Gβ, and Gγ) (Figure 4.2.1) [149]. In their 
inactive state, they are bound to guanosine diphosphate (GDP). If the GPCR is activated, 
the guanine exchange factor (GEF) domain activates the G-protein by exchanging GDP for 
guanosine triphosphate (GTP) at the Gα-subunit. This leads to a dissociation of the 
subunits from the receptor. The Gα-GTP-monomer and a Gβγ-dimer, are now able to 
modulate the activity of other intracellular proteins and ion channels [150, 151].  
There are four sub-classes of Gα-proteins distinguished from each other by sequence 
differences and function/ downstream signalling (Gαs, Gαi/o, Gαq/11, and Gα12/13) [149]. 
Gαs and Gαi/o are modulating the  cAMP-generating enzyme adenylate cyclase (AC) [152]. 
AC catalyses the conversion of cytosolic adenosine triphosphate (ATP) to cAMP (Figure 
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Figure 4.2.2 The Gαs and Gαi pathway 
Schematic overview of the Gαs and Gαi mediated intracellular pathways. The generation of cAMP 
activates multiple intra cellular responses, including ion channels, transcription factors, and 
metabolic enzymes (AC: Adenylyl cyclase, B-Raf: Mitogen activated protein kinase kinase kinases, 
cAMP: Cyclic adenosine monophosphate, CREB: cAMP response element–binding protein, EPAC:  
Exchange factor directly activated by cAMP, Gly Phos: Glycogen phosphorylase, Gly Synth: 
Glycogen synthase, MAPK: Mitogen-activated protein kinase, MEK: MAPK/ERK kinase, PDE: 
Phosphodiesterase, PhosK: Phosphorylase kinase, PKA: Protein kinase A, RAP1: Ras-related protein 
1). 
 
Cytosolic cAMP activates the guanine-nucleotide-exchange factor directly activated by 
cAMP (EPAC), but also the serine/ threonine-specific protein kinase A (PKA) [153], and 
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Phosphorylated CREB (pCREB) translocates to the nucleus, binds to the CREB response 
element (CRE) and acts as a transcription factor. CREB plays an important role in neuronal 
plasticity and long-term memory and is important for the survival of neurons. Mouse 
studies showed that the lack of CREB during the embryogenesis leads to the death of the 
mice immediately after birth, indicating a crucial role in developmental processes during 
embryogenesis [154]. Furthermore, EPAC 2 proteins are known to regulate exocytosis in 
different cell types, such as insulin secretion from pancreatic β-cells [155]. Additionally, 
the activation of PKA initiates a cascade, which is responsible either for the breakdown or 
the synthesis of glycogen, as phosphorylase kinase activates both glycogen synthase (Gly 
Synth) and glycogen phosphatase (Gly Phos), indicating the importance of the cAMP 
pathway in the regulation of glucose homeostasis [156]. 
Phospholipase C (PLC) β is the main effector of the Gαq/11 subunit [157]. Briefly, PLCβ 
catalyses the cleavage of membrane-bound phosphatidylinositol 4,5-biphosphate (PIP2) 
into IP3 and  DAG. IP3, as a second messenger, binds to  IP3-receptors found in the 
membrane of the endoplasmic reticulum (ER) to induce Ca2+-release from the ER. The 
increase in Ca2+ activates calmodulins, which in turn activate enzymes such 
as Ca2+/calmodulin-dependent kinases (CAMKs). At the end of this pathway (Figure 4.2.3) 
is the activation of nuclear factor of activated T-cells (NFAT). NFAT plays an important role 
in the immune response and is involved in the expression of a number of immunologically 
important genes [151, 158]. DAG diffuses along the plasma membrane where it activates 
PKC. This results in an activation of the MAPK pathway, which promotes cell growth and 
plays an important role in the regulation of the cell cycle [159]. 
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Figure 4.2.3 The Gαq/11 and Gα12/13 pathway 
Overview of the Gαq/11 and Gα12/13 mediated intracellular pathways (DAG: Diacylglycerol, GEF: 
Guanosine exchange factor, IP3: Inositol trisphosphate, MAPK (Erk): Extracellular signal-regulated 
kinase or mitogen activated protein kinase, MEK: mitogen-activated protein kinase kinase, NFAT: 
Nuclear factor of activated T-cells, PIP2: Phosphatidylinositol 4,5-biphosphate, PKC: Protein kinase 
c, PLC: Phospholipase C, PYK2: Protein tyrosine kinase 2, Rho: Small GTPase, Rock: Rho-associated 
protein kinase, Raf: Serine/threonine-specific protein kinase, Ras: Small GTPase, SRC: Proto-
oncogene tyrosine-protein kinase) 
 
RhoGEFs (p115-RhoGEF, PDZ-RhoGEF, and LARG) are the effectors of the Gα12/13 pathway. 
They activate the cytosolic small GTPase, Rho, which activates the Rho-associated protein 
kinase (ROCK) (Figure 4.2.3) [160]. The activation of ROCK induces the formation of actin 
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actin filaments, leading to the loss of actin monomers and resulting in reduced cell 
migration [161]. Many GPCRs that couple to Gα12/13 also couple to Gαq/11 [151]. 
 
4.2.2 The AT2 receptor 
4.2.2.1 Expression pattern of the AT2 receptor 
AT2 is strongly expressed in foetal tissue. After birth, the expression of the receptor 
decreases significantly, indicating that AT2 plays an important role in development and 
differentiation processes [162, 163]. In addition, the AT2 receptor is involved in the 
regulation of growth, differentiation and regeneration of nervous tissue [164, 165]. In 
adults, AT2 has been found in just a few tissues such as brain, adrenal gland, heart, 
vascular endothelium, kidney, myometrium and ovary [14, 166-169]. However, under 
pathological conditions, such as vascular injury [170, 171], myocardial infarction [172, 
173], congestive heart failure [174], renal failure [175, 176], brain ischemia [177, 178], 
sciatic or optic nerve transection, an increase of AT2 expression has been observed [179-
181].  
 
4.2.2.2 AT2 receptor agonists 
Apart from Ang II, Ang III [44] and Ang-(1-9) have also been reported as ligands for the 
AT2 receptor [47]. In rats, renal cortical interstitial infusion of Ang III has been shown to 
induce natriuresis. The Ang III-induced natriuresis was abolished by co-infusion with 
PD123319 (AT2 antagonist, see also Chapter 4.2.2.3) which indicated that this effect was 
AT2 mediated [182]. In in vivo studies, the Ang-(1-9) mediated effects (anti-hypertensive, 
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anti-fibrotic, anti-hypertrophic) in the hearts of hypertensive rats could also be blocked by 
PD123319 [183].  
The semipeptide CGP42112 is another specific agonist for the AT2 receptor. Studies with 
radio labelled CGP42112 could show that the agonist only bound to human myometrium 
(expressing AT2), but not to vascular smooth muscle cells (no AT2 expression). 
Furthermore, in rat adrenal glomerulosa membranes, expressing AT1 and AT2, only 
binding to AT2 was observed [14, 184]. 
In 2004, Wan et al. developed an orally accessible, nonpeptidic AT2 receptor agonist, 
named Compound 21 (C21) [185]. In in vivo studies, C21 improved post-myocardial 
infarction [186] and provided vasodilatory effects in spontaneously hypertensive rats 
[187]. The ligand also reduced myocardial fibrosis and vascular injury in hypertensive 
stroke-prone rats [188]. From this, the interest in AT2 as a therapeutic target increased. 
Because of its specifity, C21 is widely used to define in vivo function of AT2 in many 
physiologic and pathophysiological states [189].  
 
4.2.2.3 AT2 receptor antagonists 
The two non-peptidic antagonists, PD123319 and PD123177, are widely used tools for 
defining the pharmacology and functions of the AT2 receptor in several cell types, tissues 
and in vivo. PD123319 is approximately 10,000-fold more selective for AT2 than AT1 and 
more selective than PD123177 [190-192].  
More recently, another antagonist has been developed. EMA401 ((S)-2-(diphenylacetyl)-
1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinolinecarboxylic acid) is a 
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highly selective, non-peptidic AT2 receptor antagonist [193]. In a phase-two clinical trial, 
the compound has been found to be efficient against post-herpetic neuralgia [194, 195]. 
The compound might be useful to treat chronic neuropathic pain, as EMA401 inhibited 
capsaicin-evoked calcium influx in human and rodent sensory neuron cultures [196].  
Another antagonist of the AT2 receptor is the small molecule EMA300 (5-[2,2-
di(phenyl)acetyl]-4-[(4-methoxy-3-methylphenyl)methyl]-1,4,6,7-tetrahydroimidazo[4,5-
c]pyridine-6-carboxylic acid). The small molecule eased neuropathic pain in mice with a 
chronic constriction injury of the sciatic nerve, by inhibiting p38 MAPK and p44/p42 
MAPK activation [193]. Recently, EMA200 and EMA300 were tested in a rat model of 
dideoxycytidine-induced anti-retroviral toxic neuropathy. Administration of EMA200 and 
EMA300 induced dose-dependent analgesia in dideoxyxytidine rats [197]. 
 
4.2.2.4 AT2 mediated intracellular signalling 
The signalling mediated by the AT2 receptor is unique among the G-protein coupled 
receptors, as the receptor displays an atypical signal transduction mechanism and 
G-protein coupling [198]. The signalling mechanisms are diverse, and not fully 
understood. AT2 has been reported to couple to Gαi, as the pre-treatment of cultured rat 
neurons with pertussis toxin (PTX), an Gαi  inhibitor, abolished the Ang II mediated 
increase in outward K+ current  [199]. However, focusing on the signalling related to 
growth inhibition, Na+ transport and neuronal activation, the main three pathways 
activated by AT2 include 1) protein phosphatases, 2) NO/ cGMP and 3) phospholipase 
A/ AA-release (Figure 4.2.4).  
 ____________________________________________________ Introduction 
37 | P a g e  
 
 
Figure 4.2.4 AT2 mediated intracellular signalling 
Major AT2 mediated signalling pathways. (AA: arachidonic acid, Akt: Protein kinase B, BCL-2: B-
cell lymphoma 2, cGMP: Cyclic guanosine mono phosphate, JNK: C-Jun n-terminal kinase, MAPK: 
Mitogen activates protein kinase, MKP-1: MAP kinase phosphatase-1, NFκB: Nuclear factor kappa-
light-chain-enhancer of activated B cells, NOS: Nitric oxide synthase, NOX: NADPH oxidase, PGE2: 
Prostaglandin E2, PGI2: Prostaglandin I2, PI3K: Phosphatidylinositol-4,5-bisphosphate 3-kinase, 
PLA2: Phospholipase A2, PP2A: Protein phosphatase 2A, SHP-1: Src homology region 2 domain-
containing phosphatase-1) [200]. 
 
The activation of three main protein phosphatases (PP) has been described: Protein 
phosphatese 2A (PP2A) [201], the Src homology region 2 domain-containing phosphatase-
1 (SHP-1) [202] and the MAP kinase phosphatase-1 (MKP-1) [203]. All three play a role in 
the dephosphorylation, and consequently the activation, of the MAPK [204]. This has a 
negative impact on downstream pathways such as NFκB, BCL-2 phosphorylation and 
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oxidative effects of AT2 [165]. For example, in the neuronal cell line PC12W, AT2-induced 
apoptosis by ERK inactivation and B-cell lymphoma 2 (BCL-2) dephosphorylation through 
MKP-1 [203] and SHP-1 activation [202]. In cultured neurons, the AT2 receptor induces 
apoptosis through PP2A dependent activation of JNK [205]. 
An AT2 mediated increase in NO with a subsequent increase in intracellular cGMP has 
been observed in cultured rat heart endothelial cells [206], dog coronary microvessels or 
large coronary arteries [207] and isolated perfused rat renal arteries [208], where it 
mediates vasorelaxation. Additionally, in the kidney, NO production resulted in natriuresis 
[209]. In PC12W [210] and NG-108-15 [211], neuronal cell lines, NO production via AT2 
stimulation, mediated differentiation and neuronal outgrowth. 
In vivo studies have shown that Ang II activates phospholipase A2 in an AT2 dependent 
manner [212], which leads to AA release and activation of a Na+/HCO3− symporter system, 
an intracellular pH regulator [213]. 
 
4.2.3 The family of the Mas related G-protein coupled receptors 
Mas was the first identified member of the Mas-related G-protein coupled receptors 
(Mrgpr) [214]. Receptors of this family all belong to the class A family. They share a high 
homology of 30 to 41 % with Mas [215]. The Mrgprs have been found in humans and in 
rodents [216-220] and they are divided in 9 subfamilies. Mrgpr (Mrg) A, B, C, and H are 
just found in rodents. The MrgX are specific for primates. Mrg D, E, F and G are expressed 
in different mammalian species, including rodents and primates. Ten subtypes in the 
human and about 50 in rodents have been described for the Mrgpr family. However, the 
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Mrgpr’s found in humans are MAS, MRG, MrgD, MrgE, MrgF, MrgG, and MrgX1-MrgX4 
[216, 218, 220-222].  
 
4.2.4 The Mas receptor 
4.2.4.1 Expression pattern of the Mas receptor 
Discovered in 1986 by Young et al. [214], the Mas receptor was originally isolated from 
DNA of a human epidermoid carcinoma cell line [214]. However, there is one main 
misleading fact about Mas. The term proto-oncogene, which is widely used for the 
receptor, is wrong. Mas was never found to be amplified in primary tumours, but it can 
transform cells when excessively overexpressed. The Mas 5’-region is a hotspot for 
recombination. The rearrangement of the 5’-noncoding sequence, which can occur during 
transfection has been the reason for the oncogenic activity of the receptor and was the 
reason for transformation of NIH-3T3 cells [214, 215]. 
Mas has been found in several tissues. It is highly expressed in the testis [223] and in 
different regions of the brain, such as hippocampus and cerebral cortex, the olfactory 
tubercle, the piriform cortex, and the olfactory bulb, neocortex and frontal lobe [224, 
225]. Low expression levels has been detected in kidney, heart, lung, spleen, liver, tongue 
and skeletal muscle [226-228]. Furthermore, Mas can be found in the endothelial layers 
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4.2.4.2 Mas receptor agonists 
Initially it was believed that Mas is a receptor for Ang II [61]. Jackson et al. [61] used 
transiently transfected Xenopus frog oocytes and a stably transfected mammalian cell line 
to study whether Ang II acts via Mas. Whereas the untransfected oocytes showed a dose-
dependent induction of an inward current in response to the Ang I, II, and III, the Mas-
transfected cells, responded to Ang II and III with mobilization of intracellular Ca2+. This 
led to the conclusion that Mas is a functional Ang II receptor.  
In 2003, studies with Mas-deficient mice were able to demonstrate that Mas is not the 
receptor for Ang II, and Ang-(1-7) was then identified as a agonist for Mas [62]. The 
binding of the heptapeptide was completely abolished in kidneys of mice lacking the Mas 
receptor. Furthermore, no anti-diuretic effect of Ang-(1-7) could be detected in those 
animals after acute dehydration. In addition, the vasorelaxing effect in aortic rings 
isolated from Mas deficient animals was not longer detectable. Contrary, transfection of 
COS cells with the Mas receptor induced AA release after Ang-(1-7) administration [62].  
However, Ang-(1-7) is not the only agonist for Mas. Ang II and Ang IV have been shown to 
activate the Mas receptor. Both peptides induced AA release in Mas transfected COS cells 
[65], implicating that there might be more unknown agonists for this receptor. In 2011, 
angioprotectin was identified in the blood of healthy humans and patients with end-stage 
renal failure [231].  
Angioprotectin is an Ang II-like octapeptide with the sequence Pro-Glu-Val-Tyr-Ile-His-Pro-
Phe. The similarity to the sequence of Ang II raised the hypothesis that angioprotectin 
may be derived from Ang II, but no evidence was found [231]. Angioprotectin alone had 
no vasorelaxant effect on rat aortic rings, but was able to antagonise the vasoconstriction 
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mediated by Ang II. Furthermore, Ang II had no significant effect on the binding of CY3 
labelled angioprotectin to mouse microvascular endothelial cells, indicating AT1 and AT2 
are not the receptors. This study could show that those effects are Mas mediated, as 
angioprotectin had  a significant vasodilatory effect in wild-type mice, but not in Mas 
receptor-deficient mice, [231]. 
Initially AVE0991, a non-peptidic agonist for Mas, was developed to mimic Ang-(1-7) for 
therapeutic applications [232]. AVE0991 has been 10-fold more potent in binding to 
bovine aortic endothelial cell membranes than the heptapeptide, and 5-fold more potent 
in inducing NO release from bovine aortic endothelial cells [232]. A number of  in vivo 
studies could show that AVE0991 prevents diabetes-induced cardiovascular dysfunction 
[233], attenuated cardiac hypertrophy [234], protects against post-ischemic heart failure 
in rats [235], improved inflammation in experimental arthritis [236] and inhibited 
atherogenesis in apoE-knockout mice [237, 238]. Although these results from animal 
studies have been very promising, no clinical trial for AVE0991 is currently registered 
since its development.  
 
4.2.4.3 Mas receptor antagonists 
In 1994, Santos et al. first characterised a Mas specific antagonist, A779 (Asp-Arg-Val-Tyr-
Ile-His-D-Ala), also known as D-Ala7-Ang-(1-7). The blocker differs from Ang-(1-7) in amino 
acid seven. A779 blocked the anti-diuretic effect of Ang-(1-7) in water-loaded rats and 
abolished the Ang-(1-7) mediated changes in blood pressure. In contrast, A779 did not 
block Ang II, vasopressin, Ang III, bradykinin, or substance P [239]. Since its 
characterisation, A779 is a well-accepted and widely used antagonist for Mas.  
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4.2.4.4 Mas mediated intracellular signalling 
The effects mediated by Mas (Chapter 4.1.4) involve a various number of signalling 
pathways as shown in Figure 4.2.5. The main pathways activated by Ang-(1-7) involve AA 
release and Ca2+-independent activation of NOS via PI3K. [62, 65, 232].  
 
Figure 4.2.5 Intracellular signalling pathways of Mas 
Mas mediated signalling pathways. (AA: Arachidonic acid, Akt: Protein Kinase B, IP3: Inositol 
trisphosphate, NOS: Nitric oxide synthase, NOX: NADPH oxidase, PI3K: Phosphatidylinositol-4,5-
bisphosphate 3-kinase, PIP2: Phosphatidylinositol 4,5-biphosphate, PLA2: Phospholipase A2, PLC: 
Phospholipase C,). 
 
In Mas-transfected COS and CHO cells, Ang-(1-7) was able to induce AA release [62, 65]. 
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activation and NO release [232]. Another study has shown that Mas overexpression in 
HEK293 cells activated PLC, indicating that Mas couples to Gɑq/11 [240] (Figure 4.2.5). 
While Ang-(1-7), A779 and AVE0991 failed to initiate the G-protein interaction [232, 241, 
242], other researchers reported that mesangial cells and VSMC showed an increase in 
cAMP and activation of protein kinase A after Ang-(1–7) stimulation [133, 141]. A779 
blocked the increase in cAMP in MC, suggesting Gɑs is involved in the signalling mediated 
by Mas [141]. 
 
4.2.5 The MrgD receptor 
4.2.5.1 Expression pattern of the MrgD receptor 
MrgD (MrgprD), also known as GPCR45 [219] or TGR7 [243], is mainly expressed in dorsal 
root ganglia [222]. The Mas-like receptor seems not to be essential for the development 
and wiring of these neurons, as mice deficient in MrgD showed a normal development 
and functionality [216, 218, 222]. 
MrgD has also been found in other tissues, such as arteries, heart, lung, cerebellum, 
testis, uterus, urinary bladder, skin, trachea, thymus, diaphragm, skeletal muscle, 
prostate, seminal vesicle, and white and brown adipose tissue [220, 222, 243-245].  
MrgD is upregulated in in vivo models of neuropathic pain [243]. Furthermore, increased 
MrgD expression was reported to be associated with inflammatory bowel disease [245], 
atherosclerotic aorta [246], or lung cancer [247]. In NIH-3T3 cells, stably expressing MrgD, 
the receptor promoted cell proliferation and anchorage independent growth, indicating a 
tumour promoting effect [247]. 
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4.2.5.2 MrgD receptor agonists 
The first agonist identified for MrgD was β-alanine [243]. MrgD knockout mice showed 
significantly reduced scratching after drinking β-alanine-infused water, compared to wild-
type mice [248]. In addition, growth promoting effects of β-alanine in MrgD transfected 
NIH-3T3 cells has been reported [247]. 
Recently, Ala1-Ang-(1–7), also known as alamandine, was described as a potent agonist of 
MrgD [42]. The interaction with the receptor seems to be different to the one with β-
alanine, as β-alanine does not inhibit the vasodilatory actions of Ala1-Ang-(1–7) [42]. Ala1-
Ang-(1–7) is a heptapeptide with amino acid sequence Ala–Arg–Val–Tyr–Ile–His–Pro, 
differing from Ang (1–7) only in the N-terminal alanine instead of aspartate. It was 
postulated that Ala1-Ang-(1–7) is generated directly from Ang-(1–7) by the 
decarboxylation of its aspartate residue or by catalytic hydrolysis of Ang A through ACE2 
[42]. Ala1-Ang-(1–7) plasma levels were increased in patients with renal disease [249]. The 
beneficial effects of this heptapeptide are similar to those of Ang-(1-7). In aortic rings 
isolated from mice, Ala1-Ang-(1–7) induced endothelial-dependent vasorelaxation. This 
effect was still detectable when using aortic rings isolated from Mas knockout animals, 
indicating that this effect was Mas independent [42, 250]. Furthermore, Ala1-Ang-(1–7) 
can counteract the vasoconstriction induced by its potential precursor Ang A [246]. 
However, the Ala1 Ang (1–7) mediated effects could not be blocked with the Mas receptor 
antagonist A779, but with D-Pro, which can also block the MrgD receptor [246]. 
Furthermore, Ala1-Ang-(1–7) induced NO-release in MrgD-transfected cells but not in 
Mas-transfected cells, confirming that Ala1-Ang-(1–7) is a natural ligand for MrgD 
receptor [42, 251]. 
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Additional agonists with lower potency than β-alanine or Ala1-Ang-(1-7) for MrgD have 
been described. One compound is the inhibitory neurotransmitter gamma-aminobutyric 
acid (GABA). GABA weakly stimulates the calcium flux in HEK293 cells expressing human 
and rat MrgD [243, 252, 253]. β-aminoisobutyric acid, and diethylstilbestrol, a synthetic 
estrogen hormone, were also reported as novel agonists for MrgD, as they increased 
calcium flux in MrgD transfected HEK293 cells [253].  
 
4.2.5.3 MrgD receptor antagonists 
In 2003, Santos et al. initially described the heptapeptide Asp-Arg-Val-Tyr-Ile-His-D-Pro 
(D-Pro) as a potent Ang-(1–7) antagonist. They demonstrated that the specific binding of 
125I–labeled Ang-(1–7) to mouse kidney slices was completely abolished by D-Pro. This 
heptapeptide analog did not block the binding of 125I-labeled Ang II to AT1 in receptor-
transfected CHO cells or to adrenal medulla, further indicating its specifity as an Ang-(1–
7) antagonist [254]. Additionally, they found that D-Pro blocked the vasorelaxation and 
the anti-diuresis produced by Ang-(1–7) [254]. However, Lautner et al. demonstrated that 
the binding of Ala1-Ang-(1-7) to MrgD-transfected COS cells was competed by D-Pro, but 
not by A779. This indicated that D-Pro is not Mas specific but also blocks the MrgD 
receptor [42]. 
A more specific antagonist of MrgD is MU-6840. This molecule was obtained as an MrgD 
antagonist through a high-throughput-screening of a large small chemical library and is a 
possible anti-cancer compound. It inhibits the spheroid formation in cells expressing 
MrgD [253]. However, the compound can also be described as inverse agonist. It inhibits 
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the constitutive and β-alanine-induced activity of MrgD-transfected cells, as it was 
demonstrated using IP assays [253].  
 
4.2.5.4 MrgD mediated intracellular signalling  
As shown in Figure 4.2.6, the signalling of MrgD involves different pathways.   
 
Figure 4.2.6 Intracellular MrgD signaling pathways 
MrgD mediated signalling pathways. (AA: arachidonic acid, AC: Adenylate cyclase, IP3: Inositol 
trisphosphate, p38 MAPK: Mitogen activated protein kinase p38, NOS: Nitric oxide synthase, NOX: 
NADPH oxidase, PI3K: Phosphatidylinositol-4,5-bisphosphate 3-kinase, PIP2: 
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In HEK293 cells transfected with MrgD, a constitutive coupling to Gɑq and Gɑi proteins has 
been reported, as an increased luciferase signal for NFAT and Elk1 was detected [253]. 
Consequently, the activation of Gɑq and Gɑi led to changes of intracellular Ca2+ and cAMP 
levels [243, 249].  In MrgD-transfected COS cells, Ang-(1-7) was able to induce AA release 
[65]. In isolated adipocytes from rats, Ala1-Ang-(1-7) activated iNOS expression and NO 
production via activation of MrgD and p38 MAPK, and decreased the leptin expression 
and secretion [255]. 
 
4.2.6 The constitutive activity of Mas and MrgD 
Certain GPCRs, including members of the Mrgpr family, exhibit agonist-independent 
signal transduction, known as constitutive activity. Constitutive activity of a receptor is 
the ability to spontaneously produce elevated basal cellular activity, in the absence of a 
ligand [256]. Previously, Canals et al. demonstrated that in HEK293 transfected cells, the 
Mas receptor exhibits constitutive activity, activating Gαq/11 followed by PKC signalling 
without ligand stimulation [240]. Uno et al. could demonstrate a constitutive coupling to 
Gɑq and Gɑi proteins using a reporter assay for MrgD receptor transfected HEK293 cells 
[252, 253]. This inherent activity of the receptor can be manipulated by certain ligands, 
known as inverse agonists. As already mentioned, the synthetic chemical compound MU-
6840 was the first proposed inverse agonist of MrgD, as the compound inhibited spheroid 
proliferation of MrgD-transfected NIH3T3, which was dependent on basal activity of the 
receptor [253]. AR244555 and AR305352 were described as inverse agonists of Mas. 
Using HTRF IP1 assays as readout for Gαq/11 coupling of Mas, Zhang et al demonstrated 
that both compounds were able to decrease the IP1 concentrations in HEK cells stably 
expressing Mas, indicating their function as inverse agonists [257]. 
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4.3 Diabetes mellitus: a pandemic disease 
4.3.1 What is diabetes mellitus? 
Diabetes mellitus (DM) is a chronic metabolic disease, which is caused by the insufficiency 
of secretion or action (insulin resistance, see also chapter 4.3.4) of endogenous insulin. 
Diabetes is a severe public health problem as both the number of cases and the 
prevalence of diabetes have been increasing over the past few decades [258]. 
According to the World Health Organization in 2016, about 422 million people suffer from 
DM worldwide, which equals 8.5 % of the world’s population. The number of cases have 
dramatically increased since 1980, when about 108 million cases were reported (4.7 % of 
the world’s population) [259]. About 90 % of all diagnosed diabetic cases are type 2 
(T2DM) [258, 259]. In 2015, about 1.6 million deaths were directly caused by diabetes, 
which makes DM to the eighth leading cause of death [246]. It is predicted that the 
number of DM cases will raise to over 600 million cases by 2045, showing that DM is a 
huge problem in the modern world [260, 261]. 
Over time, diabetes causes damage to the heart, blood vessels, eyes, kidneys, and nerves. 
Diabetes is the leading cause of kidney failure [262]. Diabetes increases the risk of stroke 
and heart attack [263, 264]. The reduced blood flow and nerve damage in the feet 
increases the chance of foot ulcers, infections, and might lead to limb amputation [265, 
266]. Long-term accumulated damage to the small blood vessels in the retina causes 
diabetic retinopathy, which can result in blindness [267]. 
Symptoms of hyperglycaemia are frequent urination (polyuria), increased thirst 
(polydipsia), increased hunger (polyphagia), fatigue, and weight loss. DM can be 
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associated with other symptoms such as blurred vision, itchiness, peripheral neuropathy, 
recurrent vaginal infections, and fatigue [268] 
 
4.3.2 Diabetes type 1 
In diabetes mellitus type 1 (T1DM), not enough insulin is produced due to the loss of β-
cell function. This results in high blood glucose (BG) levels in the body. This form of 
diabetes normally develops in children and young adults.  
About 5–10 % of all diabetes cases are T1DM. The exact number of people affected 
globally is unknown, but it is estimated that about 80,000 children develop the disease 
each year [269].  
It has to be noted, that T1DM can be associated with depression (12% of the patients) 
[270]. Coeliac disease affects about 6 % of T1DM [271, 272].  
 
4.3.2.1 What causes type 1 diabetes and how can it be prevented? 
The causes of T1DM are not fully understood. Genetic predisposition, environmental 
triggers or certain chemicals or drugs might be reasons for this type of diabetes [273]. 
There are more than 50 genes which are associated with T1DM [274]. They can be 
dominant or recessive, depending on the locus position and combination. For instance, 
certain variants of the gene IDDM1 (Insulin-dependent (type I)  diabetes mellitus) 
increase the risk for DMT1 [275]. In families with no history of T1DM, the risk of 
developing this type of diabetes is approximately 0.4%.  In the case, that one parent is 
affected, the risk increases depending if the mother or the father is affected. If the 
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mother is affected, the risk is about 1% - 4%, and if the father is affected the risk is about 
3% to 8%. If both parents are affected the likelihood of the offspring to develop T1DM is 
about 30% [276].  
Thus, studies showed that 50–70 % of identical twins, where one has the disease, the 
other will not develop it, indicating that genetic factors alone are not a risk factor [277]. In 
addition to genetic factors, environmental factors can influence the frequency for this 
type of diabetes. This is also supported by the observation of the different appearance of 
T1DM among Caucasians, which are living in different areas of Europe [278, 279]. 
However, further research is required to fully understand possible environmental triggers 
and also protective factors, such as dietary agents [280], gut microbiota [281] and viral 
infections [282]. 
Pancreatitis or tumours (either malignant or benign) can also cause a loss of insulin 
production [269]. Furthermore, drugs, which selectively destroy β-cells, can also cause 
T1DM. One of those drugs is the anti-neoplastic agent Streptozotocin (STZ, Zanosar). STZ 
is used to treat metastatic pancreatic cancer if the cancer cannot be removed by surgery 
[283]. STZ is widely used in research for inducing a preclinical model of DMT1 in rodents 
[284]. Currently DMT1 cannot be prevented, as the factors relevant for the development 
of the disease have not been finally determined [269]. 
 
4.3.3 Diabetes type 2 
T2DM is characterised by insufficient insulin production as a result of insulin resistance. 
The inability or reduced response to insulin, mainly in muscles, liver, and fat tissue is 
called insulin resistance [268]. The glucose uptake is disrupted and blood glucose levels 
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elevate. Insulin normally suppresses glucose release and increases the glucose uptake. 
However, in the case of insulin resistance, the liver releases glucose into the blood. An 
increased breakdown of lipids within fat cells is also associated with T2DM [285]. 
Furthermore, high blood glucagon levels, increased salt and water retention by the 
kidneys, and dysregulation of the metabolism by the central nervous system are 
characteristics of T2DM [268]. As a long term consequence of insulin resistance, patient 
develop a disturbance of insulin secretion by pancreatic β-cells [268]. 
 
4.3.3.1 What causes type 2 diabetes and how can it be prevented? 
T2DM is caused by a combination of different factors. An unhealthy lifestyle can 
significantly increase the risk of developing T2DM. Factors include an unhealthy diet 
resulting in obesity [286, 287], lack of physical activity, smoking [288, 289], stress, and 
lack of sleep [290].  
The main cause of T2DM is obesity. Excess body fat is associated with 60–80 % of T2DM 
cases in European countries [287]. Sugar-sweetened drinks [291, 292], saturated fats and 
trans fatty acids are also increasing the risk of T2DM [293]. Only 7 % of T2DM cases seem 
to be caused by a lacking exercise [294]. 
More than 36 genes were identified which may contribute to the risk of T2DM. Most of 
the genes are linked to β-cell function. However, only 10 % of the T2DM cases can be 
linked to genetic predisposition [295]. 
In addition, some medications like glucocorticoids, thiazides, beta-blockers, atypical 
antipsychotics, and statins, can lead to a predisposition to T2DM [296, 297]. Other factors 
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like gestational diabetes [23], Cushing's syndrome, hyperthyroidism, pheochromocytoma, 
certain cancers (such as glucagonomas) [298] and testosterone deficiency are also 
associated with the development of T2DM [299]. 
The best way to prevent T2DM is a healthy lifestyle, a healthy diet, regular exercise and 
weight reduction lowers the risk of developing a T2DM [300, 301]. 
 
4.3.4 Insulin resistance and hyperinsulinemia  
Insulin resistance is a pathological condition in which cells (e.g muscle cells) fail to 
respond normally to the insulin. The most common type of insulin resistance is associated 
with being overweight or obese, a condition known as the metabolic syndrome [302]. As 
the cells do not respond to insulin anymore, blood sugar levels keep increasing [303]. 
Under normal conditions, insulin triggers the transport of glucose into body cells, where it 
is used for energy production, causing the decrease of blood sugar levels. Furthermore, it 
inhibits the lipolysis (using fat as energy source). However, during the state of insulin 
resistance, even in the presence of insulin, excess glucose is not sufficiently transported 
into the cells, causing an increase in the level of blood sugar [303]. Insulin resistance is 
often associated with T2DM [302]. 
As a compensation, β-cells in the pancreas subsequently increase their production of 
insulin, which contributes to an increase of plasma insulin levels resulting in 
hyperinsulinemia [304]. The constant exposure to high insulin levels further triggers  
insulin resistance, resulting in an endless circle of both conditions. High levels of insulin 
lead to an increase in inflammation and are associated with hypertension and a higher 
risk for cancer [304, 305].  
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Therefore, it is important to reduce insulin resistance in T2DM patients rather than further 
increase hyperinsulinemia by just using insulin therapy. 
 
4.3.5 Complications associated with hyperglycaemia   
In general, the harmful effects of hyperglycaemia can be distinguished into macrovascular 
complications (such as coronary artery disease, peripheral arterial disease, and stroke) 
and microvascular complications (such as diabetic nephropathy, neuropathy, and 
retinopathy) [306]. 
4.3.5.1 Macrovascular complications 
The main reason for macrovascular complications is atherosclerosis [306]. In the 
peripheral or coronary vascular system, atherosclerosis is caused by chronic inflammation 
and injury of the arterial walls. Briefly, oxidized lipids from low-density lipoprotein (LDL) 
particles accumulate in the endothelial wall of arteries, causing  chronic inflammation, 
resulting in smooth muscle cell proliferation and collagen accumulation in the arterial 
walls. The end result is a lipid-rich atherosclerotic lesion with a fibrotic cap, which causes 
a narrowing of the arterial walls. It should be mentioned that Ang II may promote the 
oxidation of LDL [307].  
Other macrovascular events include increased coagulability (due to impaired NO 
generation, increased free radical formation in platelets, and altered calcium regulation) 
and impaired fibrinolysis (increase of plasminogen activator inhibitor type 1), which 
further increases the risk of vascular occlusion and cardiovascular events and diseases in 
patients with diabetes [308].  
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4.3.5.2 Microvascular complications 
Microvascular complications include diabetic retinopathy, nephropathy and neuropathy 
[306]. 
Diabetic retinopathy occurs due to the damage of small blood vessels and neurons in the 
retina, which results in impaired visual function and dysfunction of the blood-retinal 
barrier (endothelial dysfunction) [309]. Briefly, the narrowing of the retinal arteries 
(reduced retinal blood flow), leads to a dysfunction of the neurons of the inner retina, this 
is later followed by changes in the function of the outer retina [310]. In late stages, the 
capillaries degenerate, which causes a loss of blood flow, progressive ischemia, and 
microscopic aneurysms, leading to further dysfunction and degeneration of the neurons 
and glial cells of the retina [309, 310]. 
The mechanisms causing diabetic nephropathy are the same as in diabetic retinopathy. 
The damage to the small blood vessels due to high blood sugar levels, results in impaired 
blood flow and endothelial dysfunction. As a result, the glomeruli, which are responsible 
for selective filtration of blood entering the kidney, are damaged and allows proteins in 
the blood leaking through, leading to proteinuria and chronic loss of kidney function [306, 
311]. 
Diabetic neuropathy also occurs as a result of the damage of small blood vessels resulting 
in neuronal ischemia. This nerve damage cause several symptoms, as it can affect all 
organs and systems in the body  [306]. 
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4.3.6 Treatment of diabetes type 1 and 2 
In general, the treatment of diabetes focuses on lowering BG levels, near to the normal 
range (80–140 mg/dl (4.4–7.8 mmol/l), and keeping HbA1c (amount of glycated 
haemoglobin) at around 7 % [312, 313]. 
 
4.3.6.1 Management of type 1 diabetes 
The administration of insulin, either via subcutaneous injection or via insulin pump, is 
necessary for all patients. Thus, a healthy diet and exercise do not help to normalise the 
blood glucose levels, but they are still an important part of the therapy [314]. In some 
cases, a pancreas transplant can restore proper glucose regulation. However, the surgery 
and accompanying immunosuppression required may be more dangerous than continued 
insulin replacement therapy [315]. Furthermore, an islet (β-cell) transplantation may be 
an option for some people with T1DM that is not well controlled with insulin [316]. 
Difficulties include finding compatible donors, survival of the islets, and the side effects 
from the medications used to prevent rejection [317]. The limited options for the 
management of T1DM clarifies the need for alternative treatment options, which are less 
invasive and have more beneficial long-term effects. One possibility would be to restore 
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4.3.6.2 Managing type 2 diabetes 
A long-term change in life style and diet is the main way to manage T2DM in the early 
stage. A proper diet and exercise decrease HbA1c and improve insulin sensitivity and can 
completely reverse the hyperglycaemic status [286, 318]. 
Before the administration of insulin becomes necessary, there are various oral drugs 
available. Metformin is the first line treatment for T2DM which mainly is used in 
overweight patients. It should not be used in patients with severe kidney or liver 
problems [319]. Other classes of medications are sulfonylureas, thiazolidinediones, 
dipeptidyl peptidase-4 inhibitors, sodium–glucose cotransporter 2 (SGLT2) inhibitors, and 
glucagon-like peptide-1 analogues [320].  
Also, the treatment of cardiovascular risk factors such as hypertension, high cholesterol, 
and microalbuminuria, improves the long term perspective of a patients with T2DM [321]. 
Interestingly, in a large-scale clinical trial (EMPA-REG OUTCOME trial), SGLT2 inhibitors 
significantly reduced the mortality of T2DM patients with high risk of cardiovascular 
events, indicating a significant connection between DM and the cardiovascular system 
[322]. Furthermore, blood pressure lowering medications such as ACE inhibitors and 
angiotensin receptor blockers (ARBs) appear to be renoprotective, probably by decreasing 
intraglomerular pressure. These drugs are highly recommended as a pharmacological 
first-line treatment of microalbuminuria, even in patients without hypertension [323]. 
Additionally, the blockade of the RAS using either an ACE inhibitor or ARBs reduced 
cardiovascular events in patients with diabetes more effective, compared to other 
antihypertensive agents [306]. 
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4.3.7 The connection between diabetes mellitus and the renin-
angiotensin system 
The association of DM with retinopathy, nephropathy, hypertension and cardiovascular 
diseases, strongly implicates that the RAS plays an important role in the progression and 
development of DM, as it is also a well-known driver of such diseases [324].  
The increased blood glucose levels in DM can activate the RAS through several 
mechanisms. Hyperglycaemia induces the formation of Nepsilon-(carboxymethyl)-lysine 
(CML) [325, 326]. Studies have found that CML leads to the activation of iNOS, which then 
induces NO production in rat glomerular mesangial cells [327]. The released NO leads to a 
release of renin through the upregulation of cGMP/cAMP-mediated renin exocytosis, 
which results in an over activation of the RAS [328]. In addition, the accumulation of 
succinate as a result of high blood glucose levels seems to activate the RAS. Succinate 
initiates an intracellular signalling pathway in cells from the macula or endothelial cells of 
the afferent arteriole, resulting in the elevation of intracellular calcium levels, production 
of No and activation of prostaglandin E2 (PGE2). This induces renin secretion via the 
pathway shown in Figure 4.3.1 [329-331].  
Studies in diabetic rats found that high blood glucose levels increase the expression of 
pro-renin receptors on cellular surfaces.  This also results in activating RAS [332]. The 
activation of the RAS then results in an upregulation of Ang II, which leads to various 
physiological pathways. Ang II induces oxidative stress [333, 334], endothelial 
dysfunction, inflammation and proliferation [335], which may lead to cardiac problems 
[336], diabetic retinopathy [337] and nephropathy [338].  
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Figure 4.3.1 Mechanism of renin release by high levels of blood glucose 
This diagram shows the pathways involved in the release of renin caused by hyperglycaemic 
conditions. (AC: Adenylate cyclase, cAMP: Cyclic adenosine monophosphate, cGMP: Cyclic 
guanosine monophosphate, CML: Nepsilon-(carboxymethyl)-lysine, eNOS: Endothelial nitric oxide 
synthase, GC: Guanylate cyclase, iNOS: Inducible nitric oxide synthase, IP3: Inositol trisphosphate, 
NO: Nitric oxide, PDE-3: Phosphodiesterase 3, PGE-2: Prostaglandin E2, PIP2: Phosphatidylinositol 
4,5-bisphosphate, PLCβ: Phospholipase C beta,) 
 
Furthermore, by interfering with the insulin receptor signalling, Ang II causes insulin 
resistance [339]. In in vivo studies, using rat heart, Ang II was able to stimulate the 
tyrosine phosphorylation of the insulin receptor substrates (IRS) 1 and 2, which resulted 
in an inhibition of PI3K, instead of activation, preventing normal insulin signalling [339]. 
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Consequently, the blockage of the ACE/Ang II/ AT1 axis in DM patients showed beneficial 
and protective effects [340]. ACE inhibitors or AT1 blockers are used to treat 
hypertension, in DM patients. The use of those inhibitors and blockers significantly reduce 
the number of patients with vascular complications [341, 342]. They seem to increase the 
insulin sensitivity [343], and improve the glucose transport [344]. Furthermore, protective 
effects on pancreatic islets were observed. It could be shown that ACE inhibitors 
protected islets against glucotoxicity and decreased oxidative stress [345]. Additionally, 
they seem to be very useful in the prevention and treatment of diabetic retinopathy and 
nephropathy [346, 347].  
The ACE2/Ang-(1-7)/Mas axis counteracts Ang II mediated effects, this part of the RAS 
also is a useful tool and target for the treatment of DM and associated symptoms. Recent 
studies in rat and mice models reported beneficial effects of Ang-(1–7) on glucose 
homoeostasis. These effects were associated with the improvement of insulin sensitivity 
and glucose uptake in peripheral tissues (muscle, fat) [73, 125, 348, 349]. In a study using 
a rat model of inducible T2DM, the oral administration of Ang-(1–7) reduced the 
hyperglycemia [348]. Another study showed that the chronic administration of Ang-(1–7) 
in rats with metabolic syndrome resulted in the normalisation of insulin sensitivity and 
insulin mediated signal transduction of skeletal muscle, liver, and adipose tissue. 
Furthermore, a normalisation of blood glucose levels and serum triglyceride levels was 
reported [73]. A third study demonstrated that Ang-(1–7) administration to primary 
epididymal adipocytes of mice and to 3T3-L1 adipocytes resulted in an improved glucose 
uptake. This was associated with reduced production of ROS due to a reduction in the 
expression of a NOX subunit, mediated by Ang-(1-7) [349]. In transgenic rats with Ang-(1-
7) overexpression, an increased glucose uptake in adipocytes, an improved insulin 
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sensitivity and a reduction of cholesterol and triglycerides in plasma has been observed 
[125]. Furthermore, Ang-(1–7) was able protect the β-cell function of rats with STZ-
induced diabetes mellitus. The heptapeptide prevented the shrinkage of the cytoplasm 
and condensation of nuclear chromatin and significantly improved the insulin production 
of pancreatic β-cells [350].  
In vivo studies in diabetic mice and rats demonstrated that the intraocular administration 
of ACE2 or Ang-(1-7) significantly reduced the diabetes-induced retinal vascular leakage, 
acellular capillaries, infiltrating inflammatory cells and oxidative damage in both [351]. 
Furthermore, Ang-(1-7) ameliorated diabetic renal injury in STZ-induced DM in rats by 
reducing oxidative stress and inhibiting TGFβ1 and vascular endothelial growth factor 
(VEGF)-mediated pathways [352]. 
Taken together, in addition to the blockage of the ACE/ Ang II/ AT1 axis, the stimulation of 
the ACE2/ Ang-(1-7)/ Mas axis might play an important role in the treatment of DM 
related symptoms, such as diabetic nephropathy, hypertension and retinopathy.  
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5 Aim of the study 
Over the past years, the number of publications on Ang-(1-7) and its beneficial effects 
significantly increased. Despite this, the underlying intracellular mechanisms remain 
unclear. Studies have shown that Mas is associated with Ang-(1-7)-stimulated 
signalling [62]. Whereas Ala1-Ang-(1-7), a peptide very similar to Ang-(1-7), has been 
associated with MrgD [42].  Furthermore, the Mas and MrgD receptors showed a 
significant increase in AA release in response to the Ang-(1-7) [65], indicating that other 
receptors might be involved in the Ang-(1-7) mediated signalling. Therefore, the first 
aims of the first study were: 
1) Identification of intracellular pathways activated by Ang-(1-7)  
2) Confirmation of Mas as a functional receptor for the heptapeptide 
3) Identification of other receptors involved in Ang-(1-7)-mediated signalling 
4) Investigation of the receptor fingerprint of Ala1-Ang-(1-7) 
Over the past decades, there has been an increasing interest in the association between 
the RAS and certain diseases like diabetes mellitus, neurodegenerative diseases and. With 
that, the interest in Ang-(1-7) as therapeutic target is now huge. Diabetes Mellitus is just 
one example. Initial work could show that Ang-(1-7) had beneficial effects on glucose 
metabolism and islet function [125, 348, 350].  
In order to evaluate whether Ang-(1-7) is a promising tool for the treatment of 
Diabetes Mellitus, ex vivo and in vivo experiments will be used for: 
1) Identification of intracellular pathways activated by Ang-(1-7) in β-cells 
2) Identification of receptors involved in Ang-(1-7)-mediated signalling 
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3) In vivo investigation of the Ang-(1-7) mediated effect on blood glucose in STZ 
induced diabetic animals 
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Hypothesis 
Ang-(1-7) does not stimulate AT2, but acts through the Mas receptor. Furthermore, other 
receptors from the Mas-like family might be a target for the heptapeptide. 
 
Aim of the study  
The aim of the study was to identify a second messenger stimulated by Ang-(1-7) and to 
use this as a readout to proof that Mas is a functional receptor for the heptapeptide. 
Additionally, the new method was used to identify other receptors for Ang-(1-7) by 
working with primary and receptor-transfected cells.  
 
Author contributions 
Anja Tetzner performed experiments for Figure 1-5, developed the images for the figures 
and worked on the manuscript. 
Kinga Gebolys performed experiments for Figure 1-5 and worked on the manuscript. 
Christian Meinert performed the experiments for Figure 1C and 1D. 
Sabine Klein performed the experiment for Figure 5E 
Anja Uhlich performed part of the experiments for Figure 1D 
Óscar Villacañas analysed the ligand-protein interactions and supervised the modelling 
part. 
Thomas Walther initiated the work, coordinated the experiments, advised, drafted the 
main text body, and finalized the manuscript. 
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Abstract 
Angiotensin (Ang)-(1-7) has cardiovascular protective effects and is the opponent of the 
often detrimental Ang II within the renin-angiotensin system. Although it is well-accepted 
that the G-protein coupled receptor Mas is a receptor for the heptapeptide, the lack in 
knowing initial signalling molecules stimulated by Ang-(1-7) prevented definitive 
characterisation of ligand/receptor pharmacology as well as identification of further 
hypothesized receptors for the heptapeptide. The study aimed to identify a second 
messenger stimulated by Ang-(1-7) allowing confirmation as well as discovery of the 
heptapeptide’s receptors. 
Ang-(1-7) elevates cAMP concentration in primary cells such as endothelial or mesangial 
cells. Using cAMP as readout in receptor-transfected HEK293 cells, we provided 
pharmacological proof that Mas is a functional receptor for Ang-(1-7). Moreover, we 
identified the G-protein coupled receptor MrgD as a second receptor for Ang-(1-7). 
Consequently, the heptapeptide failed to increase cAMP concentration in primary 
mesangial cells with genetic deficiency in both Mas and MrgD. Mice deficient in MrgD 
showed an impaired hemodynamic response following Ang-(1-7) administration. 
Furthermore, we excluded the Ang II type 2 receptor AT2 as a receptor for the 
heptapeptide but discovered that the AT2 blocker PD123319 can also block Mas and 
MrgD receptors.  
Our results lead to an expansion and partial revision of the renin-angiotensin system, by 
identifying a second receptor for Ang-(1-7), by excluding AT2 as a receptor for the 
heptapeptide, and by enforcing the revisit of such publications which concluded AT2 
function by only using PD123319. 
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Keywords: Angiotensin-(1-7), AT2 receptor, Mas receptor, MrgD receptor, renin-
angiotensin system  
 
Introduction  
The renin-angiotensin system (RAS) is an important regulator of arterial blood 
pressure, electrolyte homeostasis, and water and sodium intake [353], but is also 
involved in other processes like tissue regeneration  [354]. The RAS is a complex cascade 
in which precursor peptides are processed by specific enzymes to their active forms. 
Angiotensinogen is metabolised by renin to the biologically inactive decapeptide 
angiotensin (Ang) I that is then cleaved by the Ang converting enzyme (ACE) to Ang II, 
the primary active peptide of the RAS.  
A homologue of ACE, termed ACE2, cleaves a single amino acid from the octapeptide Ang 
II, which produces Ang-(1-7) [58]. Since Ang-(1-7) can counter-regulate adverse effects of 
AngII, [58] the interest in this peptide significantly increased over the last decade [355]. 
In previous work, we identified the G protein-coupled receptor Mas to be associated 
with Ang-(1-7)-induced signalling, since e.g. genetic deletion of Mas abolishes the 
binding of Ang-(1-7) to mouse kidney [62]. This binding could be also blocked by co-
treatment with D-Ala7-Ang-(1-7), also named A779, a specific Ang-(1-7) antagonist [62]. 
There is still intense discussion about the interaction of Ang-(1-7) with the Ang II type 
2 (AT2) receptor. For example, Walters and colleagues described the vaso-depressing 
effect of Ang-(1-7) in AT1 blocker-treated rats can be markedly blocked by PD123319, 
an AT2 blocker, suggesting that Ang-(1-7) acts via the AT2 receptor [356]. 
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Furthermore, we and others described that D-Pro7-Ang-(1-7) (D-Pro) blocks Ang-(1-7) 
effects [254, 357]. Interestingly, the two distinct Ang-(1-7) receptor blockers, A779 
and D-Pro, reversed the normalising effects of Ang-(1-7) on systemic and pulmonary 
hemodynamics in a model of acute lung injury, but only D-Pro blocked the protection 
from lung oedema and protein leak, whereas A779 restored the infiltration of 
neutrophils indicating that Ang-(1-7) may act via distinct receptors [357]. 
Therefore, we aimed to identify and quantify a second messenger stimulated by Ang-
(1-7) allowing pharmacological confirmation of Mas as a functional heptapeptide 
receptor, to understand the postulated interaction between AT2 and Ang-(1-7), and to 
discover the hypothetical second receptor, by working with primary and receptor-
transfected cells and in vivo approaches.  
 
Methods 
Most of the techniques have been previously described in detail by our group including 
culture of primary cells [358] and culture and transfection of HEK-293 cells [65]. A 
detailed description of techniques, where there is no reference by our group, is provided 
including cAMP measurement, quantification of PKA activity and CREB phosphorylation, 
and measurement of acute hemodynamic effects. 
Mice deficient in Mas and MrgD (double knockout) have been generated through 
breeding of single Mas [120] and MrgD [359] (strain #36050, B6.129S1-
Mrgprdtm5Mjz/Mmnc, The Mutant Mouse Regional Resource Center 8U42OD010924-13, 
Chapel Hill, NC, USA) knockouts in the animal facilities at UCC, Ireland. 
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Chemicals and reagents 
Angiotensin (Ang)-(1-7), D-Ala7-Ang-(1-7), D-Pro7-Ang-(1-7) were from Biosynthan (Berlin, 
Germany). Adrenaline, Forskolin, HOE 140 (Icatibant), IBMX, isoproterenol, RPMI1640, 
trypsin/EDTA, PMSF, protease inhibitor cocktail, phosphatase inhibitor cocktail were 
purchased from Sigma Aldrich (St. Louise, Missouri, USA). DMEM was purchased from 
BioScience (Dun Laoghaire, Dublin, Ireland). Fetal Bovine Serum (FBS) was purchased 
from GIBCO (Life Technologies, Carlsbad, California, USA). L-NAME was from Cayman 
Chemical Company (Ann Arbor, Michigan, USA). PD123319 was from Parke-Davis 
Pharmaceutical Research (Detroit, Michigan, USA). Transfection reagent was purchased 
from Qiagen (Venlo, Limburg, Netherlands).  
 
Cell culture conditions, transfection and stimulation 
Human embryonic kidney (HEK-293) cells were cultured in DMEM medium supplemented 
with FBS (10%), HEPES buffer (1%), sodium pyruvate (1%), and L-glutamine (1%) and 
maintained under standard conditions (5% CO2, 95% humidity and 37°C). Cells were 
cultured in 75 cm2-tissue culture flasks and seeded in 48-well plates at density of 75,000 
cells per well. The next day, HEK-293 cells were transfected using transient transfection 
procedure following manufacturer’s instructions. Briefly, 150ng of pcDNA3.1 or a 
combination of 50ng of pcDNA3.1 and 100ng of Mas, MrgD, AT2, or Mrg [65] were mixed 
with serum-free medium and PolyFect transfection reagent. After 10min incubation at 
room temperature which allowed the complex formation, the medium containing serum 
and other supplements was added and the total volume was transferred into appropriate 
wells of 48-well plate. The cells were incubated for 16-20h. The next day, the medium 
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was replaced by serum-free medium 1h before stimulation. After stimulated with A779, 
D-Pro, IBMX, HOE 140, L-NAME, PD123319, forskolin or IBMX (all 10-6M) for 10min, the 
solvent, Ang-(1-7) or isoproterenol (all 10−7M) were added for 15min. Then, the cells were 
lysed by adding 180μl/well 0.1N hydrochloric acid with 0.1% Triton X-100, and the lysates 
were stored at −80°C until further use. The protein concentration was determined using 
Pierce BCA Protein Assay Kit according to the manufacturer’s protocol (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA).  
 
Isolation and culture of primary cells and their stimulation 
Primary aortic smooth muscle cells (VSMC) were isolated from the thoracic aortas of 6 to 
8-week old male C57/BL6 mice and cultured as described previously [358]. Kidney 
mesangial cells (MC) were isolated from 10 to 12-week old female mice deficient in Mas 
[120], MrgD [359] (strain #36050, B6.129S1-Mrgprdtm5Mjz/Mmnc, The Mutant Mouse 
Regional Resource Center 8U42OD010924-13, MMRRC, Chapel Hill, North Caroline, USA) 
or in both (generated through cross-breeding of both single knocks in the animal facilities 
at UCC, Cork, Ireland) and from their age- and gender-matched C57/BL6 control according 
to the protocol previously described.[358] VSMC were used between passage 2 and 3 
whereas MC were used at passage 2. Cardiac fibroblasts (CFB) were isolated from 
ventricles of adult male C57/BL6 mice as described previously [360]. Primary human 
dermal microvascular endothelial cells (HDMEC) were purchased from European 
Collection of Cell Cultures (Salisbury, UK). Primary human umbilical vein endothelial cells 
(HUVEC) were purchased from LONZA BioResearch (Basel, Switzerland). Mouse 
endothelial cells from cerebral cortex, bEnd.3, were a gift from Dr. Siems from FMP 
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(Forschungsinstitut fuer Molekulare Pharmakologie, Berlin, Germany). All primary cells 
were cultured in 75cm2 tissue culture flasks and seeded for cAMP assay in 24-well plates 
at density of 75,000 cells per well. For protein isolation, cells where cultured in 50mm 
dishes until 80% confluence. The stimulation with Ang-(1-7) or blockers was carried out as 
described above. For the test of the adenylyl cyclase inhibitor (SQ22536), cells where pre-
stimulated with 2x10-6M for 15min, followed by stimulation with Ang-(1-7) at 10-7M for 
15min. 
 
Measurement of cAMP in cell lysates 
cAMP concentration in cell lysates was determined using Direct cAMP ELISA kit (Enzo Life 
Sciences Ltd., Exeter, United Kingdom). Briefly, wells of 96-well plate (Goat Anti-Rabbit 
IgG pre-coated) were neutralized with 50µl of Neutralizing Reagent. Next, 100μl of 
acetylated cAMP standard or cell lysate was added, followed by 50µl of blue cAMP-
Alkaline Phosphatase Conjugate and 50µl of yellow EIA Rabbit Anti-cAMP antibody. The 
plate was then incubated on a shaker (~ 400rpm) at room temperature for 2h. Next, the 
wells were aspirated and rinsed three times with Wash Buffer (1:10, Tris buffered saline 
containing detergents and sodium azide in deionized water). After the final wash, the 
plate was tapped against clean paper towel to remove any remaining Wash Buffer. To 
each well 200µl p-Nitrophenyl Phosphate Substrate Solution was added, and the plate 
was incubated for 1h at room temperature. The enzymatic reaction was stopped by 
adding 50µl of Stop Solution, and the absorbance at 405nm was measured immediately. 
The cAMP concentration was determined from non-linear standard curve using GraphPad 
Prism 5.0 software.  
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Western blot analyses 
Cells were lysed in RIPA buffer containing protease and phosphatase inhibitor cocktails 
(Sigma, St. Louis, MO, USA). Protein quantification was measured with Pierce BCA Protein 
Assay Kit according to the manufacturer’s protocol. Twenty five µg protein were 
separated on 10% SDS-polyacrylamide gels and transferred to Immobilon®-P PVDF 
membrane (Merck KGaA Darmstadt, Germany) using a Semi Dry Blotter PEGASUS (PHASE 
Gesell. für Phorese, Analytik und Separation mbH, Luebeck, Germany). After blocking with 
5% dry milk powder in TBS-T buffer for 1h, the PVDF membrane was incubated with the 
primary antibodies: CREB, pCREB, (1:1000 dilution in 5% BSA/TBS-T) purchased from Cell 
Signaling Technology (Danvers, MA, USA) or the anti-GAPDH (1:5000 in 5% milk/TBS-T) 
from Sigma Aldrich (St. Louise, Missouri, USA), at 4°C overnight. After three washing steps 
with TBS-T buffer, blots were incubated with the appropriate horseradish peroxidase 
(HRP)-conjugated secondary antibodies: anti-rabbit IgG in the dilution of 1:2000 in 5% 
milk/TBS-T (Cell Signaling Technology) or 1:1000 in 5% milk/TBS-T (Sigma Aldrich) at room 
temperature for 2h. The membranes were developed employing the enhanced 
chemiluminescence (ECL)-based system (Roche Holding AG, Basel, Switzerland). 
Densitometric evaluation was performed with ImageJ software (National Institute of 
Health, USA). 
 
Protein Kinase A activity assay 
The measurement of Protein Kinase A (PKA) activity was performed using the PKA 
Colorimetric Activity Kit (Arbor Assays Headquarters, Ann Arbor, Michigan, USA) following 
manufacturer’s instruction. Briefly, HEK293 cells (75,000 per well) were seeded into 48-
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well plates. On the next day, cells were transiently transfected using PolyFect reagent as 
described above. For HUVEC cells, 24-well plates (75,000 per well) were used and plated 
overnight. Sixteen to 20h later, the medium containing serum and other supplements was 
replaced by serum-free medium 1h before stimulation. Then, cells were stimulated with 
Ang-(1-7) (10-7M, 10-8M or 10-9M) for 15min. For experiments with the adenylyl cyclase 
inhibitor (SQ22536), the cells where pre-stimulated for 15min with 2x10-6M, followed by 
stimulation with Ang-(1-7) at 10-7M for 15min. Cells were lysed in 50µL (HEK293) or 100µL 
(HUVEC) activated cell Lysis Buffer provided by the kit, containing 1mM PMSF, 1µl/ml 
protease and phosphatase inhibitor cocktail (Sigma) and incubated for 30min on ice. The 
lysates were transferred to 1.5ml reaction tubes and centrifuged at 10,000rpm at 4°C for 
10min. The supernatant was directly used for analysis or stored at -80°C till 
measurement.  
For measurement, all samples were diluted 1:10 in Kinase Assay Buffer provided by the 
Kit. For the measurement 40µL of the sample (in triplicates) or standard (in duplicates) 
were pipetted in to each well. Afterwards, 10µl of ATP was added to each well and 
incubated for 1.5h at 30°C on a shaker. Next, the wells were aspirated and rinsed four 
times with Wash Buffer (1:20 in deionized water). After the final wash, the plate was 
tapped against clean paper towel to remove any remaining Wash Buffer. Twenty-five μL 
of the Goat anti-rabbit IgG HRP and 25μL of the Rabbit Phospho PKA Substrate antibody 
were added to each well and incubated at room temperature for 60min with shaking. The 
wells were aspirated again and rinsed four times with Wash Buffer (1:20 in deionized 
water). After the final wash, the plate was tapped against clean paper towel to remove 
any remaining Wash Buffer. Next, 100μL of the TMB Substrate Solution were added to 
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each well and incubated for 30min at room temperature. Afterwards, 50µL of stop 
solution was added to each well and the optical density was measured in a plate reader at 
450nm. The PKA activity (U/ml) was determined from linear standard curve using linear 
regression from Excel. 
 
Dual-luciferase reporter assay 
For Dual-Luciferase reporter assays, HEK293 cells were seeded into 48-well plates (75,000 
cells/well). About 24h later, cells were transiently transfected with 100ng eukaryotic 
expression vectors of AT1 [65], AT2 or Mrg together with 25ng pNFAT-TA-Luc-, (BD 
Biosciences; Heidelberg; Germany) or pELK-Luc Reporter Vector (Signosis, Santa Clara, 
California, USA) luciferase reporter plasmids and 25ng pRL-TK (Promega GmbH, 
Mannheim, Germany) using the protocol described above. Next day, the medium was 
replaced by serum-free medium 1h before stimulation. After 6 hours of stimulation with 
Ang-(1-7) or Ang II (10−7M and 10−6M), cells were lysed with 65µL/well passive lysis buffer 
provided with the Dual Luciferase Reporter Assay kit (Promega GmbH, Mannheim, 
Germany) and incubated on a shaker for 15min at room temperature. The activity for 
Firefly and Renilla Luciferase was measured with Orion L Microplate Luminometer 
(Berthold Detection Systems GmbH, Pforzheim, Germany) according to the manufactures 
protocol. Briefly, 30µL of lysed cells where transferred into a white 96-MicroWell plate 
(Thermo Fisher Scientific, Waltham, Massachusetts, USA), and 100µL of Luciferase Assay 
Reagent II was added. After quantifying the firefly luminescence, the reaction was 
quenched by adding 100µL of Stop&Glo reagent and renilla activity was measured. For 
calculations, the ratio of firefly and renilla luciferase was used. 
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mRNA isolation and Real-time PCR 
Total cellular RNA was isolated using the NucleoSpin RNA isolation kit (MACHEREY-
NAGEL, Düren, Germany) according to the manufacturer’s protocol. After isolation, 
2,000ng total RNA was transcribed into cDNA using the RevertAid H Minus First Strand 
cDNA Synthesis kit (MBI Fermentas, Hanover, MD, USA) and oligo(dT)18 primer. After 
synthesis, RNAse free water was added to the single cDNA to a final volume of 100µl. 
Quantification of gene expression was performed by real-time quantitative PCR (RT-PCR) 
on the StepOne™ Real-Time PCR System (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA) employing the Platinum SYBR Green qPCR SuperMix-UDG 
(Invitrogen) and specific primers: Mas forward: CCTCCCATTCTTCGAAGCTGTA, Mas 
reverse: GCCTGGGTTGC-ATTTCATCTTT, MrgD forward: TCTACTGGGTGGATGTGAAACG, 
MrgD reverse: TCATTAGTACACGTGGATGGCG, AT2 forward: 
GAATTACCCGTGACCAAGTCCT, AT2 reverse: GGAACTCTAAACACACTGCGGA. Real time 
quantitative PCR amplifications were performed in a final volume of 20µl at 95°C for 
15min followed by 40 cycles with denaturation at 95°C for 30sec, annealing at 58°C for 
30sec and elongation at 72°C for 30sec. PCR products were finally subjected to a melting 
curve analysis. The mRNA levels were quantified with the StepOne™ analysis software in 
comparative quantitation mode and normalized to beta-Actin expression levels. All 
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Measurement of arterial pressure and heart rate 
The acute mean arterial pressure response to Ang-(1-7) injection was measured by direct 
cannulation in anesthetized 10 to 14-week old male mice of wild-type and MrgD-deficient 
genotype [361]. The mice were anesthetized with a combination of ketamine (78mg/kg 
body weight) and Xylacine (17.1mg/kg body weight) given intraperitoneal. Body 
temperature was maintained at 37°C. The right caroid artery was cannulated with PE-10 
tubing and connected to a physiological pressure transducer (MEMSCAP, Skoppum, 
Norway), and the mean arterial pressure was continuously recorded with a digital data 
recorder (Lab Chart, ADInstruments Ltd, Oxford, United Kingdom). The heart rate was 
recorded using mouse needle electrodes (ADInstruments Ltd). After stabilization, 
Ang-(1-7) (30µg/kg body weight) was injected in the tail vein. The mean arterial pressure 
and heart rate were monitored continuously for 30min. 
 
In silico modelling 
The 3D structure of Ang-(1-7) was prepared by minimising their NMR experimental 
structures (PDB:2JP8) with AMBER* force field and in water solvent using Schrödinger's 
Macromodel (MacroModel, version 9.7, Schrödinger, LLC, New York, NY, 2009). It was 
further docked (keeping the backbone rigid) with Autodock 4.2.3 [362] into a modelled 
structure of Mas receptor [363], in which the F112 side chain conformation was modified 
to create a larger binding site and to expose specific binding residue [364, 365]. The 
complex was minimized as before. The resulting conformation of Ang-(1-7) was 
considered the bioactive conformation. Hercules software (Intelligent Pharma S.L., 
Barcelona, Spain) was applied to superpose PD123319 over Ang-(1-7). PD123319 non-ring 
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bonds were treated as flexible (amide bonds set to either 0º or 180º) while flexible ring 
conformations were computed with Corina (Corina_Linux2 3.46, Molecular Networks 
GmbH, Erlangen, Germany) using an energy window value of 20kJ/mol. Ionization states 
were estimated with Schrödinger's Epik (Epik version 2.8017, Schrödinger, LLC, 2009, New 
York, NY, USA), and Gasteiger's charges were assigned to atoms in both molecules as 
implemented in Openbabel [366]. 
 
Statistical Analyses 
Data presented are mean ± SEM. Data were analysed by Student’s t-test or 1-way and 2-
way ANOVA tests accompanied by Bonferroni post hoc test using GraphPad Prism 6.0 
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Results 
Angiotensin-(1-7) increases intracellular cAMP in different cell-types 
Tallant and Clark described an increase in cAMP in VSMC stimulated by Ang-(1-7) [133]. 
Furthermore, Liu et al. described the stimulation of intracellular signalling by Ang-(1-7) in 
glomerular mesangial cells. Their data indicated that the heptapeptide can increase 
intracellular cAMP [141]. As we aimed to identify the receptors associated with Ang-(1-7) 
signalling, we initially examined whether cAMP would be an efficient readout to quantify 
changes in intracellular signalling following Ang-(1-7) stimulation. Ang-(1-7) increased 
cAMP in a dose-dependent manner in primary mesangial cells with highest efficacy at 
10-7M and an EC50 value of 6.2nM (Figure 6.1.1 A). This increase was blocked by the two 
Ang-(1-7) antagonists, A779 and D-Pro, but also by the AT2 receptor blocker PD123319 
(Figure 6.1.1 B). As a variety of papers described the blocking effect of the bradykinin B2 
receptor blocker, Icatibant, as well as the inhibitory effect of the NO synthase inhibitor 
L-NAME, on Ang-(1-7) mediated signalling [367], we tested both substances in our 
primary-cell assay. While Icatibant failed to block an Ang-(1-7)-mediated increase in 
cAMP, L-NAME inhibited the effects of Ang-(1-7). The heptapeptide could not add to the 
increased concentration of cAMP reached by L-NAME treatment alone (Figure 6.1.1 B).  
To test the ability of Ang-(1-7) to increase cAMP in other cell types, we stimulated 
primary cardiac fibroblasts (CFB) and vascular smooth muscle cells (VSMC) with the 
heptapeptide. While CFBs did not respond to Ang-(1-7) (Figure 6.1.1 C), it increased cAMP 
in VSMC, and the same compounds blocked the effect as described for primary mesangial 
cells (Figure 6.1.1 D). 
 ________________________________________________________ Results 
78 | P a g e  
 
  
Figure 6.1.1 Intracellular cAMP is increased in angiotensin-(1-7) in various cell types 
 (A) concentration-dependent increase in cAMP level in primary mesangial cells, (B) effect of A779, 
D-Pro7-Ang-(1-7) (D-Pro), PD123319, Icatibant, and L-NAME (all 10-6M) on Ang-(1-7) (10-7M)-
mediated increase in cAMP in mesangial cells, (C) lack of increase in intracellular cAMP in cardiac 
fibroblasts, (D) effect of the receptor blockers and L-NAME on Ang-(1-7)-mediated increase in 
cAMP in primary vascular smooth muscle cells. Data are presented as mean ± SEM. ***P<0.001 vs. 
PBS, ###P<0.001 vs. Ang-(1-7), n=3x3. 
 
Angiotensin-(1-7) stimulates the generation of intracellular cAMP in endothelial cells 
Since Ang-(1-7) relaxes vessels in an endothelium-dependent manner [368], we tested the 
most commonly used endothelial cell-line, human umbilical vein endothelial cells 
(HUVEC), for its response to Ang-(1-7). As described before for other cell-lines, the 
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PD123319, and inhibited by L-NAME (Figure 6.1.2 A). As shown in Figure 6.1.2 B, the 
increase in cAMP was concentration-dependent, whereby the EC50 was reached at 13nM. 
As the concentration of cAMP depends on its generation as well as its degradation, we 
tested whether the Ang-(1-7)-mediated raise in cAMP is the consequence of increased 
stimulation of adenylyl cyclase (AC) or decreased activity of phosphodiesterases (PDE). 
We used Forskolin, an activator of AC, which directly stimulates cAMP level and IBMX, a 
nonselective PDE inhibitor which inhibits cAMP degradation. As expected, both Forskolin 
and IBMX led to an increase in intracellular cAMP (Figure 6.1.2 C). However, Ang-(1-7) 
could increase cAMP levels stimulated by IBMX but did not further increase the levels 
reached by Forskolin alone. The additive effect of Ang-(1-7) and IBMX excludes the Ang-
(1-7)-mediated raise in cAMP to be a result of PDE inhibition.  
To finally confirm that Ang-(1-7)-mediated increase in cAMP is AC-dependent we used the 
specific enzyme inhibitor SQ22536. As shown in Figure 2D, the SQ22536 alone had no 
effect on cAMP concentration but the inhibitor blunted the Ang-(1-7)-mediated raise in 
cAMP linking Ang-(1-7) signalling to Gs/AC/cAMP axis.  
As cAMP initiates a variety of downstream signalling pathways including PKA activation, 
we tested whether the Ang-(1-7)-mediated increase in cAMP leads to an increased PKA 
activity. Stimulation of HUVEC with Ang-(1-7) for 15min resulted in a significant increase 
in PKA activity (Figure 6.1.2 E). 
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Figure 6.1.2 Ang-(1-7) increases cAMP and PKA activity in human umbilical vein 
endothelial cells (HUVEC).  
(A) Effect of A779, D-Pro7-(Ang-(1-7) (D-Pro), PD123319, Icatibant, and L-NAME (all 10-6M) on Ang-
(1-7) (10-7M)-mediated increase in cAMP, (B) concentration-dependent increase in cAMP level, (C) 
cAMP level stimulated with Forskolin, IBMX, Ang-(1-7) alone, or in combinations, (D) effect of the 
adenylyl cyclase inhibitor SQ22536 alone or in combination with Ang-(1-7) on cAMP level (E) 
activation of PKA by Ang-(1-7). Data are presented as mean ± SEM. ***P<0.001 vs. PBS, 
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Angiotensin-(1-7) stimulates the generation of intracellular cAMP in HEK293 cells 
expressing either Mas or MrgD 
In order to test for receptors involved in the Ang-(1-7)-mediated increase in cAMP levels, 
we used HEK293 cells. First, we tested untransfected cells to exclude that these cells 
already respond to the heptapeptide. As shown in the left panel of Figure 6.1.3 A, the 
heptapeptide had no effect on cAMP levels, confirming HEK293 cells as an ideal tool to 
measure cAMP in response to Ang-(1-7) in receptor-transfected cells.  
We chose four different receptors for further tests. Firstly, we tested Mas as Ang-(1-7) 
has previously shown to be an endogenous ligand for this receptor [62]. Secondly, Mrg 
and MrgD receptors have been selected, as we showed a significant AA release in 
response to the heptapeptide in Mrg- and MrgD-transfected cells but not in other 
receptors of the Mas-like family [65]. Finally, we also tested the AT2 receptor, since 
PD123319 is believed to be a specific AT2 receptor blocker, and we showed that it blocks 
the Ang-(1-7)-mediated increase in cAMP (Figure 6.1.1 B and D, Figure 6.1.2 A). When 
HEK293 cells were transfected with plasmids for those four receptors, Ang-(1-7) 
stimulation caused a significant increase in intracellular cAMP levels in cells 
overexpressing Mas or MrgD but not Mrg and AT2 (Figure 6.1.3, right panel).  
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Figure 6.1.3 Ang-(1-7)-induced signalling is mediated by Mas and MrgD.  
(A) cAMP concentration in untransfected HEK293 cells stimulated with either Ang-(1-7) (10-7M), 
A779, D-Pro7-(Ang-(1-7) (D-Pro) and PD123319 (all 10-6M) (left panel) and cAMP level in Mas, Mrg, 
MrgD and AT2 transfected HEK293 cells stimulated with Ang-(1-7) (right panel), (B) luciferase 
production in HEK293 cells transiently co-transfected with pcDNA3.1, AT1, AT2 or Mrg, and 
pNFAT-Luc after stimulation with PBS, Ang-(1-7), or Ang II (C) luciferase production in HEK293 cells 
transiently co-transfected with pcDNA3.1, AT1, AT2 or Mrg, and pElk1-Luc after stimulation with 
PBS, Ang-(1-7), or Ang II. Data are presented as mean ± SEM. ***P<0.001, **P<0.01 vs. related 
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To exclude other main signalling pathways for AT2 and Mrg to be activated by Ang-(1-7) 
involving other G proteins such as Gαq/11 and Gαi, we tested activation of these two G 
proteins by measuring activation of transcription factors specifically activated by them. 
We have chosen nuclear factor for activated T-cells (NFAT), which is known to be coupled 
to Gαq/11  [65] and Elk1 as indicator for Gαi activation [253]. Since AT1 receptor is known to 
signal through Gαq/11 and Gαi after stimulation with Ang II [369], we used this receptor as 
the positive control. As expected, Ang II increased luciferase production in AT1 receptor 
expressing cells co-transfected with either NFAT or Elk1 (Figure 6.1.3 B and C, right 
panels). In contrast, Ang-(1-7) failed to stimulate any of the transcription factors in AT2- 
and Mrg-expressing HEK293 cells (Figure 6.1.3 B and C, left panel). Notably, Ang-(1-7) has 
been also unable to stimulate the two G proteins in AT1-transfected cells. 
We used both Mas and MrgD receptors to investigate in detail their involvement in Ang-
(1-7)-mediated signalling. The efficiency of the transfection in HEK293 cells was proofed 
by using qPCR and fluorescence microscopy (shown in Figure 10.1.1, Appendix part1). As 
shown on Figure 6.1.4 A, Ang-(1-7) stimulation caused a dose-dependent increase in the 
intracellular cAMP level in Mas-transfected cells with an EC50 of 5.5nM. Then, we selected 
the concentration of highest efficacy (10-7M) for further tests with the previously effective 
blockers. Figure 6.1.4 B shows that none of the 3 blockers had an effect on cAMP levels in 
pcDNA3.1- or Mas-transfected cells. However, the increase in cAMP concentration 
generated by Ang-(1-7) in Mas-transfected cells was blocked by all three blockers (Figure 
6.1.4 B).  
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Figure 6.1.4 Ang-(1-7)-induced signalling is mediated by Mas and MrgD. 
(A) concentration-dependent increase in cAMP level in Mas-transfected cells, (B) increased cAMP 
concentration by Ang-(1-7) is blocked by A779, D-Pro and PD123319 in Mas-transfected cells, (C) 
concentration-dependent increase in cAMP level in MrgD-transfected cells, (D) increased cAMP 
concentration by Ang-(1-7) is blocked by tested blockers in MrgD-transfected cells, (E) activation of 
PKA by Ang-(1-7) in Mas- or MrgD-transfected cells and the effect of the adenylyl cyclase inhibitor 
SQ22536. Data are presented as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 vs. PBS, #P<0.05, 
##P<0.01, ###P<0.001 vs. Ang-(1-7), n=3x3 (A,C), n=8x3 (B,D), n=2x3 (E). 
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Independent experiments were carried out on HEK293 cells transfected with MrgD where 
Ang-(1-7) also caused a dose-dependent increase in cAMP concentration with an EC50 
value of 6.6nM (Figure 6.1.4 C). In contrast to Mas-transfected cells, only D-Pro and 
PD123319 blocked the Ang-(1-7)-mediated increase in cAMP level, while A779 had no 
significant effect (Figure 6.1.4 D).  
To confirm that the increase in PKA activity seen in HUVEC (Figure 6.1.2 E) can be 
associated to Mas and MrgD signalling, we measured activity in response to Ang-(1-7) in 
Mas- and MrgD-transfected cells. In both receptor-overexpressing cells, the heptapeptide 
significantly increased PKA activity. This increase was blunted by the adenylyl cyclase 
inhibitor SQ22536 (Figure 6.1.4 E) confirming cAMP generation as the trigger for PKA 
activation. 
 
Angiotensin-(1-7)-mediated cAMP generation is absent in mesangial cells derived from 
Mas/MrgD knockout animals 
In order to confirm that Mas and MrgD are the two receptors used by Ang-(1-7) to 
generate cAMP in primary cells, we used mesangial cells derived from double knockout 
mice deficient in both receptors. These mice are fertile and without obvious 
morphological abnormalities. Initially, we examined whether the measured increase in 
cAMP in mesangial cells is above the threshold to initiate downstream signalling (Figure 
6.1.5 A). Because one of the consequences of cAMP increase can be the activation of the 
transcription factor cAMP response element-binding protein (CREB) [370],we evaluated 
whether the Ang-(1-7) mediated increase in cAMP can also induce CREB phosphorylation. 
Figure 6.1.5 A and B show that CREB phosphorylation occurred 5min following Ang-(1-7) 
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stimulation and reached control levels within 30min. This induction was blunted by 
pre-treatment with SQ22536 confirming cAMP generation as initial signal for CREB 
phosphorylation. 
 
Figure 6.1.5 Ang-(1-7) induced signalling is absent in mesangial cells derived from 
Mas/MrgD knockout animals.   
(A) Western blot of phosphorylated CREB (pCREB) and CREB and the house-keeping protein 
GAPDH. (B) Calculation of time-dependent CREB phosphorylation in comparison to absolute CREB 
protein after Ang-(1-7) stimulation and/or treatment with adenylyl cyclase inhibitor SQ22536 
(15min Ang-(1-7)). (C) Effect of Ang-(1-7) in Mas knockout (KO), MrgD KO and Mas/MrgD double 
KO cells (PBS values of each genotype set as 100%). (D) mRNA of Mas, MrgD, and AT2 in wild-type 
(WT) and double KO cells. Data are presented as mean ± SEM. *P<0.05, **P<0.01 ***P<0.001 vs. 
PBS/WT, ##P<0.01, ###P<0.001 vs. Ang-(1-7) in WT. n=2 (A, B), n=3x3(C, D). 
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Next, we tested whether Ang-(1-7)-mediated increase in cAMP observed in wild-type 
mesangial cells could be abolished in Mas or MrgD deficient cells or cells isolated from 
Mas/MrgD double knockouts. Deficiency in one of the receptors reduced the Ang-(1-7) 
signal generated in wild-type cells, while the double knockout completely blunted it 
(Figure 6.1.5 C).  
In order to exclude upregulation of the remaining receptor and also to confirm that both 
Mas and MrgD receptors are absent in knockout cells, we investigated the mRNA levels in 
mesangial cells derived from double knockouts. Figure 6.1.5 D shows that Mas and MrgD 
mRNA levels were barely detected in cells from double knockouts. Notably, deficiency in 
both receptors did not significantly alter AT2 mRNA levels.  
 
Angiotensin-(1-7)-mediated acute hemodynamic effects are blunted in MrgD-deficient 
mice 
As we and others showed that vasorelaxant effects of Ang-(1-7) are Mas dependent [254, 
368], we finally tested whether the genetic deficiency in MrgD would also have an in vivo 
effect on the hemodynamic properties of Ang-(1-7). Acute bolus infusion of the 
heptapeptide led to a significant drop in mean arterial blood pressure, while no decrease 
was observed in MrgD knockouts (Figure 6.1.6 A). 
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Figure 6.1.6 Ang-(1-7) induced signalling is absent in mesangial cells derived from 
Mas/MrgD knockout animals.   
(A) Effect of Ang-(1-7) on mean arterial pressure (MAP) in wild-type mice and MrgD knockouts. (B) 
in silico modelling of Ang-(1-7) (mesh) and PD123119 (sticks) with the following mesh color code: 
blue stands for hydrogen donor chemical groups, red for hydrogen acceptor chemical groups, and 
green for carbon atoms. Data are presented as mean ± SEM. ***P<0.001 vs. PBS/WT, n=5/5(E). 
 
Discussion 
The lack in knowing a second messenger for Ang-(1-7) prevented not only the 
pharmacological confirmation of assumed receptors and the identification of further 
hypothesized receptors, but also the determination of efficacy and potency of a potential 
receptor/ligand interaction. The need of such second messenger is also illustrated by the 
fact that two publications over the last years intensively investigated phosphorylation of 
intracellular molecules [371] and quantities of intracellular proteins [372], respectively, in 
response to Ang-(1-7). Although aimed to identify useful molecules for receptor 
pharmacology, the data published failed to add useful tools to this approach.  
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Here, we demonstrate that a second messenger, cAMP, is an ideal tool to quantify 
changes in intracellular signalling mediated by Ang-(1-7). This allowed us to provide final 
pharmacological evidence that Mas is a functional receptor for Ang-(1-7). More 
importantly, the use of cAMP as a readout enabled us to screen for other receptors 
associated with Ang-(1-7) signalling in a hypothesis-based manner. Consequently, these 
results provide the first experimental proof that MrgD is a second receptor for Ang-(1-7) 
that has been confirmed under in vivo conditions. The hypothesis that MrgD acts as a 
receptor for the heptapeptide has been based on different findings including (1) high 
sequence homology between Mas and MrgD; (2) a description from a Brazilian group that 
Ala1-Ang-(1-7) but not Ang-(1-7) is a ligand for MrgD [42], because unpublished modelling 
of both peptides excludes a decisive effect of the first amino acid on the Gs activation 
and thus made it likely that a receptor for Ala1-Ang-(1-7) is also a receptor for Ang-(1-7); 
and (3) our data that Ang-(1-7) can stimulate AA release in MrgD-transfected cells [65]. 
However, the experiments with Mrg might seed doubts on the latter point, as the 
relatively moderate AA release was not paralleled by an increase in cAMP in Mrg-
transfected cells; but association between cAMP and AA release warrants further 
investigation. 
We are the first group to establish cAMP as a readout for Ang-(1-7) receptor 
pharmacology, although there have been indications in the literature for such an 
association. Beside the work by Tallant and Clark [133] and by Liu et al. [141] in primary 
cells, a paper from 2012 showed indirect cAMP involvement in Ang-(1-7) signalling as its 
modulation of sympathetic activity in the paraventricular nucleus was abolished by an 
adenylyl cyclase inhibitor and a PKA inhibitor [373]. 
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Furthermore, physiological effects of the heptapeptide and effects in preclinical models 
also implicate the involvement of cAMP. For example, we demonstrated the dominant 
effect of Ang-(1-7) on hematopoietic stem cells/progenitors [374], and there is significant 
evidence that cAMP stimulates such processes [375]. 
Although Mas-deficient animals showed significant effects in preclinical disease models, 
they do not show a strong phenotype (healthy, fertile, normal growth, normal 
development, and normal plasma Ang II levels) [120], except endothelial dysfunction 
[368]. Based on our present data, one could argue that the lack in phenotype is a result of 
the heptapeptide’s ability to shunt the lack of Mas by using the sequence and signalling-
like receptor MrgD. However, although not intensively phenotyped yet, the double-
knockouts look normal, are fertile, and show no increased mortality within 12 months. 
This further supports the hypothesis that Ang-(1-7) is affective especially under disease 
conditions. 
One of the key findings of this study is the exclusion of AT2 as a functional Ang-(1-7) 
receptor. Our experiments excluded not only activation of Gs by the heptapeptide in 
AT2-transfected cells and thus an increase in cAMP concentration, but also coupling to 
two other major G proteins activated by G protein-coupled receptors (GPCRs).  
Furthermore, our data also provides the identification of the reason for the controversial 
discussion on Ang-(1-7)/AT2 over the last years. There are only few published 
experiments using AT2 knockouts for the evaluation of an AT2-mediated part of Ang-(1-7) 
action showing either no effect or only partial effects [376]. However, there are many 
papers concluding that Ang-(1-7) acts via AT2, because of the blocking effect of 
PD123319. Based on our findings that PD123319 can also block Mas and MrgD, such a 
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conclusion could be wrong as the blocking effect of PD123319 is not based on AT2 but on 
both Ang-(1-7) receptors.  
This unspecific receptor profile of PD123319 might not be surprising, if we compare its 
structure with Ang-(1-7). PD123319 structure can be embedded in the molecular volume 
of the predicted bioactive conformation of Ang-(1-7) bound to Mas and displays chemical 
similarities to Ang-(1-7), implicating that both molecules fit into the two Ang-(1-7) 
receptors, whereby PD123319 may fail to stimulate intracellular signalling (Figure 6.1.6 
B). 
However, identifying PD123319 as a non-specific AT2 receptor blocker, also requires a 
careful re-evaluation of papers, which conclude that the effects blocked by PD123319 are 
mediated via AT2, as we now know that it could also relate to Mas and MrgD. 
 
Taken together, our results correct the view on the RAS (AT2 is not an Ang-(1-7) 
receptor), expand our understanding of the beneficial ACE2/Ang-(1-7)/Mas axis to a two-
receptor axis (Mas and MrgD), identify the primary intracellular signalling cascade for the 
heptapeptide when interacting with its receptors (Gs/AC/cAMP leading to an increase in 
PKA activity and CREB phosphorylation), and force a re-evaluation of more than thousand 
publications concluding that effects blocked by PD123319 are AT2-specific. 
 
Perspectives 
As Ang-(1-7) has been identified as a protective peptide in cardiovascular diseases, the 
identification of a second receptor for the peptide allows for the development of tailored 
drugs (non-peptidic agonists) stimulating either Mas or MrgD or both receptors 
depending on their expression/importance in diseases of different aetiology.  
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Novelty and Significance 
What is new? 
We discovered MrgD as the second receptor for Ang-(1-7) an. Both Mas and MrgD 
activate adenylyl cyclase initiating an increase in cAMP, consequently activating PKA, and 
leading to CREB phosphorylation. We also generated double knockout mice deficient in 
both Ang-(1-7) receptors, Mas and MrgD. We describe them as not having an obvious 
anatomical/morphological phenotype, being fertile, and not showing increased mortality 
until one year of age. 
By identifying PD123319 as a non-specific AT2 receptor blocker which also blocks Mas 
and MrgD, we now know that effects of the blocker assigned to its interaction with the 
AT2 receptor could also relate to the two Ang-(1-7) receptors Mas and MrgD. 
 
What is relevant? 
We demonstrate the in vivo relevance of our findings by showing that the lack in Ang-(1-
7)/MrgD interaction leads to a much less pronounced vasorelaxant response to Ang-(1-7) 
in mice deficient in MrgD. 
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Summary 
Our results lead to an expansion and partial revision of the renin-angiotensin system, by 
identifying a second receptor for Ang-(1-7). We also solved the decade-long controversial 
discussion of whether AT2 is a receptor for Ang-(1-7) by excluding this with our 
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Hypothesis 
Ala1-Ang-(1-7) does not just stimulate MrgD, but also the Mas receptor. Additionally, the 
lack of the carboxylate group at position one might result in a change of 
pharmacodynamics compared to Ang-(1-7). 
 
Aim of the study: 
The aim of the study was not just to proof that MrgD, but also Mas is a functional 
receptor for Ala1-Ang-(1-7). Furthermore, using various cell types (receptor-transfected 
HEK293 cells, human endothelial cells, receptor-deficient primary mesangial cells), and a 
variety of receptor blockers and enzyme inhibitors together with the recent identified 
cAMP assay as a readout, the ligand/receptor pharmacology for Ala1-Ang-(1-7) was aimed 
to be examined. 
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main text body, and finalized the manuscript. 
 
Abstract 
Within the renin-angiotensin system, angiotensin (Ang)-(1-7) is cardiovascular protective, 
stimulates regeneration, and opposes the often detrimental effects of Ang II. We 
identified two receptors for the heptapeptide; the G protein-coupled receptors Mas and 
MrgD. Recently, a decarboxylated form of Ang-(1-7), Ala1-Ang-(1-7) (Alamandine), has 
been described as having similar vasorelaxant effects as Ang-(1-7), but distinctively 
stimulating the MrgD receptor. The aim of this study was to elucidate the consequences 
of the lack of the carboxyl group in amino acid one on intracellular signalling, to discover 
the receptor fingerprint for Ala1-Ang-(1-7), and to characterize the consequences for 
pharmacodynamics. Ala1-Ang-(1-7) elevated cAMP concentrations in primary endothelial 
and mesangial cells. However, the dose-response curves clearly discriminated from the 
curves generated with Ang-(1-7), with a much lower EC50 and a bell-shape curve for 
Ala1-Ang-(1-7). We provided pharmacological proof that both, Mas and MrgD, are 
functional receptors for Ala1-Ang-(1-7). Consequently, the heptapeptide failed to increase 
cAMP concentration in primary mesangial cells with genetic deficiency in both receptors. 
As previously described for Ang-(1-7), the Ala1-Ang-(1-7) effects on Mas/MrgD-
transfected HEK293 cells and on primary cells were blocked by the AT2 receptor blocker, 
PD123319. The very distinct dose-response curves for both heptapeptides could be 
explained by in silico modelling, electrostatic potential calculations, and an involvement 
of Galpha i for higher concentrations of Ala1-Ang-(1-7). Our results identify Ala1-Ang-(1-7) as 
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a peptide with specific pharmacodynamic properties and build the basis for the design of 
more potent and efficient Ang-(1-7) analogues for therapeutic interventions in a rapidly 
growing number of diseases. 
 
Keywords : Ala1-Angiotensin-(1-7), dose-response curve, G-proteins, Mas receptor, MrgD 
receptor, renin-angiotensin system 
 
Introduction 
The renin-angiotensin system consists of an increasing number of angiotensin (Ang) 
peptides which play an important role in the regulation of arterial blood pressure, 
electrolyte homeostasis, and water and sodium intake [353], as well as in processes like 
tissue regeneration [354, 377]. The renin-angiotensin system is a complex cascade in 
which precursor peptides are processed by specific enzymes to their active forms. In the 
past few years especially, Ang-(1-7) has become a peptide of interest, because of its 
beneficial actions in cardiovascular and renal diseases, counter-regulating the adverse 
effects of AngII [58]. Ang-(1-7) is mainly produced from AngII by Ang converting enzyme 2 
(ACE2) [58]. 
In previous work, we identified the G protein-coupled receptor Mas to be associated 
with Ang-(1-7)-induced signalling which could be blocked by D-Ala7-Ang-(1-7), also 
named A779, a specific Ang-(1-7) antagonist [62]. Very recently, we also discovered a 
second receptor for the heptapeptide, the Mas-related G protein-coupled receptor 
MrgD [378]. In that study, we also showed that the primary intracellular pathway 
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activated by Ang-(1-7) interactions with either Mas or MrgD involves adenylyl cyclase, 
cAMP and phosphokinase A [378].  
A decade ago, Jankowski et al. identified a modified analogue of AngII in human 
plasma [40]. This Ala1-AngII, the authors named AngA, can be generated by the 
decarboxylation of the amino acid aspartate on position one to alanine. AngA 
interacts with the AT1 receptor [379] and its physiological effects can be blocked by 
the AT1 receptor blocker candesartan [380]. Based on such findings, an international 
team hypothesized the existence of Ala1-Ang-(1-7) as a product of Ala1-AngII through 
conversion by ACE2 [42]. Indeed, Ala1-Ang-(1-7) has been identified and named 
alamandine. As Kupchan et al. used  similar terminology, Allamandin, for a completely 
different molecule, we will use the original term, Ala1-Ang-(1-7), describing the amino 
acid change in Ang-(1-7), to prevent confusion [381]. Lautner et al. characterized Ala1-
Ang-(1-7) as the target peptide for the MrgD receptor but not for the Mas receptor 
[42]. However, as we could show that Ang-(1-7) can stimulate both Mas and MrgD, we 
aimed to test whether Ala1-Ang-(1-7) targets the same receptors as Ang-(1-7), or 
shows a distinct receptor fingerprint. In particular, we focused on the characterisation 
of the ligand/receptor pharmacology, by determining efficiency and potency using 
receptor-transfected HEK293 cells, human endothelial cells, receptor-deficient 
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Materials and Methods 
Materials 
Angiotensin (Ang)-(1-7), Ala1-Ang-(1-7), D-Ala7-Ang-(1-7), and D-Pro7-Ang-(1-7) were 
synthetized from Biosyntan (Berlin, Germany). HEK293, Forskolin, RPMI-1640, HEPES 
solution, Sodium pyruvate, Trtiton X-100 and trypsin/EDTA were purchased from Sigma 
Aldrich (St. Louise, Missouri, USA). DMEM, Fetal Bovine Serum (FBS) and l-glutamine were 
purchased from GIBCO (Life Technologies, Carlsbad, California, USA). PD123319 was from 
Parke-Davis Pharmaceutical Research (Detroit, Michigan, USA), PTX was from EMD 
Millipore (Billerica, MA, USA), Polyfect transfection reagent from Qiagen (Venlo, Limburg, 
Netherlands), and Pierce BCA Protein Assay Kit from Thermo Fisher Scientific (Waltham, 
Massachusetts, USA). Direct cAMP ELISA kit was from Enzo Life Sciences Ltd. (Exeter, 
United Kingdom). HUVEC were purchased from LONZA (Basel, Switzerland). 
 
Animals 
Mice deficient in Mas [120, 359] and both Mas and MrgD (double knockout) [378] have 
been bred and housed in the animal facilities at UCC, Cork, Ireland. Animal studies are 
reported in compliance with the ARRIVE guidelines [382, 383]. Experiments performed 
conformed with the guidelines from Directive 2010/63/EU of the European Parliament on 
the protection of animals used for scientific purposes. Experiments involving animals have 
been approved by the Irish HPRA and also by the Animal Experimentation Ethics 
Committee (AEEC) in UCC. 
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Cell culture conditions, transfection and stimulation 
Human embryonic kidney (HEK-293) cells were cultured in DMEM medium supplemented 
with FBS (10%), HEPES buffer (1%), sodium pyruvate (1%), and L-glutamine (1%) and 
maintained under standard conditions (5% CO2, 95% humidity and 37°C). Cells were 
cultured in 100mm cell culture dishes and seeded in 48-well plates at a density of 75,000 
cells per well. The next day, HEK-293 cells were transfected using a transient transfection 
procedure following the manufacturer’s instructions. Briefly, 150ng of control plasmid 
pcDNA3.1 or a combination of 50ng of pcDNA3.1 and 100ng of expression vectors 
containing the cDNA for Mas or MrgD were mixed with serum-free medium and PolyFect 
transfection reagent. After 10min incubation at room temperature, which allowed the 
complex formation, complete medium was added and the total volume was transferred 
into appropriate wells of the 48-well plate. The cells were incubated for 16-20hrs. The 
next day, the medium was replaced by serum-free medium 1hr before stimulation. After 
stimulation with A779, D-Pro, PD123319, forskolin (all 10-6M), or PTX (50ng/ml) for 
15min, the solvent, Ala1-Ang-(1-7) or Ang-(1-7) (all in the mentioned concentrations) were 
added for 15min. Then, the cells were lysed by adding 180 µl/well of 0.1M hydrochloric 
acid with 0.1% TritonX-100, and the lysates were stored at −80°C until cAMP 
measurement. The protein concentration was determined using Pierce BCA Protein Assay 
Kit according to the manufacturer’s protocol (Thermo Fisher Scientific, Waltham, 
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Isolation and culture of primary cells and their stimulation 
Kidney mesangial cells (MC) were isolated from 10-12-week old mice deficient in Mas and 
MrgD, and from their age- and gender-matched C57/BL6 control, according to the 
protocol previously described [384]. MC were cultured in 75cm2 tissue culture flasks and 
seeded at passage 2 for stimulation in 24-well plates at a density of 100,000 cells per well.  
Primary human umbilical vein endothelial cells (HUVEC) were purchased from LONZA 
(Basel, Switzerland). HUVEC were cultured in 100mm cell culture dishes and were seeded 
at 75,000 per well in 24-well plates at passage 5-7, for stimulation. Stimulation with 
Ala1-Ang-(1-7) and the blockers was carried out as described above. 
 
Measurement of cAMP in cell lysates  
cAMP concentration in cell lysates was determined using Direct cAMP ELISA kit (Enzo Life 
Sciences Ltd., Exeter, United Kingdom). Briefly, wells of 96-well plate (Goat Anti-Rabbit 
IgG pre-coated) were neutralized with 50µl of Neutralizing Reagent. Next, 100μl of 
acetylated cAMP standard or cell lysate was added, followed by 50µl of blue cAMP-
Alkaline Phosphatase Conjugate and 50µl of yellow EIA Rabbit Anti-cAMP antibody. The 
plate was then incubated on a shaker (~ 400rpm) at room temperature for 2h. Next, the 
wells were aspirated and rinsed three times with Wash Buffer (1:10, Tris buffered saline 
containing detergents and sodium azide in deionized water). After the final wash, the 
plate was tapped against clean paper towel to remove any remaining Wash Buffer. To 
each well, 200µl p-Nitrophenyl Phosphate Substrate Solution was added, and the plate 
was incubated for 1h at room temperature. The enzymatic reaction was stopped by 
adding 50µl of Stop Solution, and the absorbance at 405nm was measured immediately. 
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The cAMP concentration was determined from non-linear standard curve using GraphPad 
Prism 6.0 software.  
 
mRNA isolation and Real-time PCR 
Total cellular RNA was isolated using the NucleoSpin RNA isolation kit (MACHEREY-
NAGEL, Düren, Germany) according to the manufacturer’s protocol. After isolation, 
2,000ng total RNA was transcribed into cDNA using the RevertAid H Minus First Strand 
cDNA Synthesis kit (MBI Fermentas, Hanover, MD, USA) and oligo(dT)18 primer according 
to the manufacturer’s guidelines. After synthesis, RNAse free water was added to the 
single cDNA to a final volume of 100µl. Quantification of mRNA levels was performed by 
real-time quantitative PCR (RT-PCR) on the StepOne™ Real-Time PCR System (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA) employing the Platinum SYBR Green 
qPCR SuperMix-UDG (Invitrogen) and gene specific primers (Mas forward: 
TTTATAGCCATCCTGAGCTTCC, Mas reverse: AATGTGGTGTAGGTTCCCAAAG, MrgD 
forward: AAACTATTCCAGAGGGAGCACA, MrgD reverse: TGGACCTTGTCAGTGGTATTGA). 
The amplifications were performed in a final volume of 20µl using the following PCR 
cycle: 95°C for 15min followed by 40 cycles with denaturation at 95°C for 30sec, annealing 
at 58°C for 30sec and elongation at 72°C for 30sec. PCR products were finally subjected to 
a melting curve analysis. The mRNA levels were quantified with the StepOne™ analysis 
software in comparative quantitation mode and normalized to beta-Actin expression 
levels. All quantitative RT-PCRs were done at least three times in duplicate using RNA 
from independent experiments. 
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In silico modelling 
The 3-dimensional structure of Ang-(1–7) was prepared by minimizing their nuclear 
magnetic resonance experimental structures (PDB:2JP8) with Schrödinger Macromodel 
(MacroModel, version 9.7, Schrödinger, LLC, New York, NY), using AMBER94 force field and water 
solvent. It was further docked (keeping the backbone rigid) with Autodock 4.2.3 [362] into 
a modeled structure of the Mas receptor [385], in which the F112 side chain 
conformation was further modified to create a larger binding site and to expose specific 
binding residues [364, 365]. The complex was minimized as before. Surface areas and 
electrostatic potentials were computed with Schrödinger Maestro (Maestro, version 
11.3.016, Release 2017-3, Platform Linux-x86_64, Schrödinger, LLC, New York, NY). 
 
Statistical Analyses 
To ensure reproducibility of the results and to minimize bias, HEK293 cells, MC, and 
HUVECs were used at comparable passage numbers. The same kits and reagents were 
used for the experiments wherever possible. Data presented are mean ± SEM where n 
denotes the number of experiments in triplicates. A P-value of <0.05 was considered 
statistically significant.  Data were analysed using GraphPad Prism 6.0 (GraphPad 
Software Inc., San Diego, CA, USA). Statistical tests preformed were a Student’s t-test or a 
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Results 
Ala1-Angiotensin-(1-7) stimulates the generation of intracellular cAMP in endothelial 
cells 
As we previously demonstrated that Ang-(1-7) can increase intracellular cAMP in a dose-
dependent manner [378], we first tested whether Ala1-Ang-(1-7) can act in a 
similarmanner using the most commonly characterized endothelial cell-line, human 
umbilical vein endothelial cells (HUVEC). Although Ala1-Ang-(1-7) was comparably as 
efficient as Ang-(1-7), the dose-response curve showed a completely different 
appearance (Figure 6.2.1 A). Not only is the curve bell-shaped in contrast to the one 
generated by Ang-(1-7) which runs into a plateau with increasing concentrations, the 
increase in cAMP occurs much earlier with a leftward shift of almost 3 magnitudes of 
order (EC50 was reached at 3.6 x 10-11M with Ala1-Ang-(1-7) and at 1.1 x 10-8M with Ang-
(1-7)).  
To investigate whether this effect on cAMP is mediated by receptors that are sensitive to 
the two Ang-(1-7) antagonists, A779 and D-Pro, and to the unspecific AT2 receptor 
blocker PD123319, which we identified as also blocking the Ang-(1-7) receptors Mas and 
MrgD [378], we used Ala1-Ang-(1-7) in the concentration of highest efficacy (10-9M) 
without and with the 3 receptor blockers. As shown in Figure 6.2.1 B, the three 
compounds did not affect base-line cAMP concentrations, but all three blockers 
significantly reduced the increase in intracellular cAMP in response to Ala1-Ang-(1-7). 
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Figure 6.2.1 Intracellular cAMP is increased by Ala1-Angiotensin-(1-7) in human 
umbilical vein endothelial cells (HUVEC).  
 (A) HUVEC were stimulated for 15min with a range of concentrations (10-6 to 10-13M) of Ala1-Ang-
(1-7) before analysis of cAMP concentration. (B) HUVEC were stimulated for 15min with blockers 
(A779, D-Pro7-Ang-(1-7) (D-Pro) and PD123319 (all 10-6M)), followed by 15min stimulation with 
Ala1-Ang-(1-7) (10-9M). Results are expressed as mean ± SEM; (A) n=3, (B) n=4. Data was reported 
as a fold change or percentage of the untreated control mean. ***P<0.001, significantly different 
from control; ###P<0.001, ##P<0.01 or #P<0.05, significantly different from Ala1-Ang-(1-7); 
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Ala1-Angiotensin-(1-7) stimulates the generation of intracellular cAMP in HEK293 cells 
expressing MrgD 
Based on our work with Ang-(1-7) [378] and the results published by Lautner et al.,[42], 
we then tested Mas- and MrgD-transfected cells. As shown in Figure 6.2.2 A, Ala1-Ang-(1-
7) stimulation caused a dose-dependent increase in the intracellular cAMP level in MrgD-
transfected cells with an EC50 of 3.98 x 10-13M. Since in HUVEC the dose-response curve 
peaked at 10-9M of Ala1-Ang-(1-7) but in MrgD-transfected cells at 10-11M, we selected 
10-11M for further tests with the previously effective blockers. Figure 6.2.2 B shows that 
none of the 3 blockers had a baseline effect on cAMP levels in the pcDNA3.1 control or in 
MrgD-transfected cells. However, the increase in cAMP concentration generated by 
Ala1-Ang-(1-7) in MrgD-transfected cells was blocked by D-Pro and PD123319, but not by 
A779 (Figure 6.2.2 B).  
 
Ala1-Ang-(1-7) in higher concentrations activates Gαi reducing the generation of cAMP 
As cAMP is generated by the enzyme adenylyl cyclase which can be activated by Gαs but 
also inhibited by Gαi signalling, we hypothesised that the bell-shaped curve could be the 
result of a Gαi activation due to higher concentrations of Ala1-Ang-(1-7). We used MrgD 
receptor-transfected cells and generated dose-response curves for Ala1-Ang-(1-7) with 
and without pre-treatment with pertussis toxin (PTX), a Gαi inhibitor, which prevents the 
Gαi proteins from interacting with the receptor. Since the Gαi subunits remain locked in 
their inactive state, they are unable to inhibit adenylate cyclase activity. As shown in 
Figure 6.2.2 C, the parallel treatment with PTX prevented the decline in intracellular 
cAMP concentrations with increasing concentrations of Ala1-Ang-(1-7). 
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Figure 6.2.2 Ala1-Ang-(1-7) signals through the MrgD receptor.  
(A) MrgD-transfected HEK293 cells were stimulated for 15min with a range of concentrations (10-6 
to 10-18M) of Ala1-Ang-(1-7) before analysis of cAMP concentration. (B) Cells were stimulated for 
15min with blockers (A779, D-Pro7-Ang-(1-7) (D-Pro) and PD123319 (all 10-6M)), followed by 
15min stimulation with Ala1-Ang-(1-7) (10-11M). (C) Cells were stimulated for 15min with PTX 
(50ng/ml) followed by stimulation with Ala1-Ang-(1-7) (10-11M) for a further 15min. Results are 
expressed as mean ± SEM; (A) n=5, (B) n=4 and (C) n=3. Data was reported as a fold change or 
percentage of the untreated control mean.  ***P<0.001, significantly different from the MrgD 
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Ala1-Angiotensin-(1-7) stimulates the generation of intracellular cAMP in HEK293 cells 
expressing Mas 
 
Figure 6.2.3 Ala1-Ang-(1-7) can also signal via the Mas receptor.  
(A) Mas-transfected HEK293 cells were stimulated for 15min with a range of concentrations (10-6 
to 10-18M) of Ala1-Ang-(1-7) before analysis of cAMP concentration, (B) Cells were stimulated for 
15min with blockers (A779, D-Pro7-Ang-(1-7) (D-Pro) and PD123319 (all 10-6M)), followed by 
15min stimulation with Ala1-Ang-(1-7) (10-11M). (C) mRNA of Mas and MrgD-transfected HEK293 
cells (pcDNA3.1 values are set as 1). Results are expressed as mean ± SEM; (A) n=4, (B) n=3 and (C) 
n=8. Data was reported as a fold change or percentage of the untreated control. ***P<0.001, 
**P<0.01, significantly different from the Mas control; ###P<0.001, significantly different from 
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In experiments with HEK293 cells transfected with the Mas receptor, Ala1-Ang-(1-7) also 
caused a dose-dependent increase in cAMP concentration with an EC50 value of 6.3pM 
reaching highest efficacy at 5 x 10-11M (Figure 6.2.3 A). In contrast to MrgD-transfected 
cells, D-Pro, PD123319 and A779 all blocked the Ala1-Ang-(1-7)-mediated increase in 
cAMP level in Mas-transfected cells (Figure 6.2.3 B).  
To confirm specific overexpression of mRNA for both receptors, we measured expression 
of receptor mRNA in MrgD and Mas-transfected cells to confirm transfection efficacy. As 
shown in Figure 6.2.3 C, transfection with Mas- or MrgD- plasmids led to a significant 
overexpression of the receptor mRNA.  
To visualise the transfection efficacy on protein level, HEK293 cells were transfected with 
Mas-mCherry or MrgD-GFP. As shown in Figure 10.1.1 B (Appendix part 1), transfected 
cells carrying not just the receptor cDNA, but both receptors are expressed in the 
cytoplasmic membranes of these cells. 
 
Absence of Ala1-Angiotensin-(1-7)-mediated cAMP generation in mesangial cells derived 
from Mas/MrgD knockout animals 
To test whether the lack of Mas and MrgD blunts the ability of Ala1-Ang-(1-7) to generate 
cAMP in primary mesangial cells, as previously examined in Ang-(1-7), we used mesangial 
cells derived from double knockout mice deficient in both receptors, a strain introduced 
recently [378]. Ala1-Ang-(1-7) increased cAMP dose-dependently in wild-type mesangial 
cells, with a typical bell-shape curve as shown before in endothelial cells and Mas or 
MrgD-transfected HEK cells. (Figure 6.2.4 A).  
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Figure 6.2.4 Ala1-Ang-(1-7) induced signalling is absent in mesangial cells derived from 
Mas/MrgD double-knockout animals.  
(A) WT C57BL/6 mesangial cells were stimulated for 15min with a range of concentrations (10-6 to 
10-14M) of Ala1-Ang-(1-7) before analysis of cAMP concentration. (B) WT C57BL/6 mesangial cells 
were stimulated for 15min with blockers (A779, D-Pro7-Ang-(1-7) (D-Pro) and PD123319 (all 
10-6M)), followed by 15min stimulation with Ala1-Ang-(1-7) (10-11M). (C) Mas/MrgD knockout 
(DKO) mesangial cells were stimulated for 15min with blockers (A779, D-Pro7-Ang-(1-7) (D-Pro) 
and PD123319 (all 10-6M)), followed by 15min stimulation with Ala1-Ang-(1-7) (10-11M). Results are 
expressed as mean ± SEM; (A) n=6, (B) n=5 & (C) n=2. Untreated control values of each genotype is 
set as 100%.  ***P<0.001, *P<0.05, significantly different from WT control mean; ###P<0.001, 
#P<0.05, significantly different from Ala1-Ang-(1-7); ANOVA with Bonferoni post-hoc test. 
 
While D-Pro, PD123319 and A779 did not affect base-line cAMP concentrations in 
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cAMP level in these wild-type cells (Figure 6.2.4 B). This cAMP increase observed in wild-
type mesangial cells was completely blunted in mesangial cells isolated from double-
knockout mice (Figure 6.2.4 C), but still remainaing in the single knockouts (see appendix 
Figure 10.2.1). In addition, Forskolin, a direct adenylyl cyclase activator, increased cAMP 
concentration in DKO mesangial cells, illustrating that the lack of stimulation by Ala1-Ang-




Here, we demonstrate that Ala1-Ang-(1-7), like Ang-(1-7), stimulates the generation of the 
second messenger, cAMP, and cAMP is thus an ideal tool to quantify changes in 
intracellular signalling mediated by Ala1-Ang-(1-7). Using this readout allowed us to 
provide final pharmacological evidence that MrgD is a functional receptor for Ala1-Ang-(1-
7). More importantly, the use of cAMP as a readout enabled us to generate results 
providing the first experimental proof that Mas is the second receptor for Ala1-Ang-(1-7). 
Furthermore, our data confirm findings with Ang-(1-7) [378], that A779 fails to 
significantly reduce the stimulation of cAMP production by Ala1-Ang-(1-7) in MrgD-
transfected cells. This may be due to the D-orientation of alanine in position 7, which 
might prevent the peptide fitting into the MrgD receptor, while it still fits into Mas and 
thus, can block the agonist effects there. 
Previous work by other groups implicated that the two Ang peptides, Ang-(1-7) and 
Ala1-Ang-(1-7) target different receptors, with Ala1-Ang-(1-7) stimulating MrgD but not 
Mas [42]. Our data shows that not only can Ang-(1-7) can signal via Mas and MrgD, but 
 ________________________________________________________ Results 
112 | P a g e  
 
also the decarboxylated version of the heptapeptide, Ala1-Ang-(1-7). One of the reasons 
for this discrepancy might be due to our finding that Ala1-Ang-(1-7) generates a bell-
shaped dose response curve and is much more potent than Ang-(1-7). Consequently, at 
concentrations where Ang-(1-7) is most efficient, Ala1-Ang-(1-7) might have little effect as 
it is back to base-line levels of cAMP. However, since we measured cAMP, while others 
looked at NO release, it would be interesting to see whether increasing concentrations of 
Ala1-Ang-(1-7) would also generate a dose-response curve for NO, with highest efficiency 
similar to the EC50 described here for receptor-transfected cells and primary kidney and 
endothelial cells. Nevertheless, our findings are also supported by modelling of Ang-(1-7) 
in the Mas receptor binding site, in which the decarboxylation of the first residue could 
lead to a more favorable electrostatic complementary with the receptor surface and thus, 
making it likely that the Mas receptor could also be a receptor for Ala1-Ang-(1-7).  
While our data excludes a receptor fingerprint discriminating between both peptides, one 
of the key findings of our experiments is that Ala1-Ang-(1-7) is much more potent than 
Ang-(1-7), although the difference between both peptides seems marginal, with only a 
lack of the carboxylate group in Ala1-Ang-(1-7).  
To better understand the reason for improved potency, we investigated the potential 
binding mode of the N-terminal segment of Ang-(1-7), as well as the electrostatic 
potential of the binding site and its complementarity to both Ang-(1-7) and Ala1-Ang-(1-
7). The proposed binding mode of Ang-(1-7) places Arg2 establishing a salt bridge with 
Glu167 and a cation-π interaction with Tyr248 of the Mas receptor. These interactions 
constrain the mobility of the N-terminal part of Ang-(1-7) and prevent the negatively 
charged carboxylate in Asp1 side chain from interacting with a positive chemical group in 
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the protein (see Figure 6.2.5). Actually, the surface of the binding site is estimated with a 
positive surface area value of 5 Å2 and a much greater negative surface area value of 109 
Å2 (considering residues within 5 Å of Ang-(1-7)). This predominance of a negatively 
charged protein surface is more stressed on the extracellular side (where the N-terminal 
Ang-(1-7) is predicted to bind), as seen in Figure 6.2.5. Thus, the Asp1 side chain may not 
be stabilised according to the proposed model due to charge repulsion, although the 
water accessibility of this area could screen this effect.  
 
Figure 6.2.5 Electrostatic potential of Mas receptor model in the predicted Ang-(1-7) 
binding site (considering residues within 10 Å of Ang-(1-7)).  
Red areas are favourable to interact with positively charged groups and blue with negatively 
charged groups. Predicted binding pose of Ang-(1-7) is depicted in green-coloured carbon atoms. 
These predictions are in agreement with the increased potency observed for Ala1-Ang-(1-
7) because: i) it does not have the carboxylate group in the first residue, thus avoiding a 
charge repulsion with the predominant negatively charged area; and ii) this same absence 
may favour a salt bridge between the N-terminal amino group and the Mas receptor, 
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particularly with Asp173. Thus, the interactions extracted from this model might build the 
base for a screening program to identify agonists stimulating Mas and MrgD. 
Another very dominant pharmacodynamic difference between the two peptides is the 
bell-shaped dose-response curve for Ala1-Ang-(1-7). There are hints in the literature, 
which might explain this bell-shaped dose-response curve. Since the late nineties, 
different groups have shown the ß2-adrenergic receptor to couple not only to Gαs, but 
also to Gαi proteins in the heart [386, 387] and in receptor-transfected HEK293 cells [388], 
whereby the degreeof activation of the two G proteins would define the agonist effect on 
intracellular cAMP concentrations. Interestingly, it has been also shown that this dual 
activation is not specific for the ß2-adrenergic receptor but has also been seen in 
histamine, serotonin, and glucagon receptors [389]. 
A decade ago, Beyermann et al. [390] confirmed this model by using the corticotropin-
releasing factor receptor type 1. They demonstrated that native ligands stimulated Gαi 
and Gαs proteins, whereby in all cases, Gαi.has been activated approx. two magnitudes of 
order to the right. Therefore, we tested whether Ala1-Ang-(1-7) could also lead to an Gαi 
activation in higher concentrations, reducing the Gαs-mediated increase in cAMP. By using 
PTX, a substance that prevents Gαi-associated inhibition of adenylyl synthase leading to a 
reduction in intracellular cAMP, the decline in the dose response curve observed with 
Ala1-Ang-(1-7) alone, disappeared. The curve runs in a plateau following PTX treatment 
and looked similar to the Ang-(1-7) curve, although with a significant leftward shift. Thus, 
it looks like Ala1-Ang-(1-7), but not Ang-(1-7) can activate two G proteins, and thus, similar 
to a car, by pressing the gas and brake pedal, it brings the speed (an increase in cAMP) to 
zero. 
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The authors are aware that limitations of our study include the lack of knowledge in 
whether the decarboxylation of Ang-(1-7) to Ala1-Ang-(1-7) results in any loss or gain of 
funcion in vivo, which can only be evaluated by animal and human studies. However, the 
enzyme being responsible for the reaction is still unidentified and thus, its inhibition / 
knockout in vivo can still not be experimentally realized. 
Taken together, our results change the view on Ala1-Ang-(1-7) as a peptide exclusively 
activating MrgD but not Mas, illustrate that minor changes in Ang-(1-7) (decarboxylation 
on amino acid 1) can lead to major changes in the pharmacodynamics of both receptors 
and provide a mechanistic explanation for such differences. Thus, our data lays the 
foundation for the development of new Ang-(1-7) analogues which may generate a more 
potent stimulation of the receptors and hence, leading to safer and more efficient 
treatment options for a growing number of diseases in which Ang-(1-7) might be 
beneficial, based on its success in preclinical disease models.  
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 Hypothesis: 
C21 is not an AT2 specific agonist, but also interacts with other receptors such as Mas and 
MrgD. 
 
Aim of the study: 
Previous experiments indicated that PD123319 is not an AT2 specific antagonist, 
therfore the aim of the study was to test whether the AT2 receptor agonist, C21, is 
specific.  Using receptor-transfected HEK293 cells, human endothelial cells, receptor-
deficient primary mesangial cells, isolated mesenteric microvessels, and a variety of 
receptor blockers the interaction with the two Ang-(1-7) receptors, Mas and MrgD 
(ligand/receptor pharmacology), was determined. 
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Abstract 
Compound 21 (C21) is a highly selective non-peptidic AT2 receptor agonist. C21, like 
angiotensin (Ang)-(1-7), has cardiovascular protective effects. Since the chemical 
structure of C21 is similar to the Mas receptor-specific non-peptidic agonist AVE0991, and 
we recently showed that the AT2 blocker, PD123319, can also block the effects of Ang-(1-
7) at its natural receptors, Mas and MrgD, we tested whether C21 is really AT2-specific or 
can also stimulate the Ang-(1-7) receptors. 
Using cAMP as a readout in receptor-transfected HEK293 cells, we generated 
pharmacological proof that Mas (EC50=1.99 x 10-12mol/L) and MrgD 
(EC50=2.96 x 10-9mol/L) are functional receptors for C21, whereby the three receptor 
blockers, A779, D-Pro7-Ang-(1-7), and PD123319 showed receptor-specific effects towards 
C21. Furthermore, C21 elevated the cAMP concentration in primary mesangial cells 
(EC50=1.12 x 10-6mol/L). However, increases in cAMP levels and in CREB phosphorylation 
were still detectable in cells isolated from AT2-deficient mice, but completely blunted in 
Mas/MrgD-double knockouts. In addition, C21-stimulated relaxation of isolated 
mesenteric arteries was abolished by Mas/MrgD blockers. Finally, in silico modelling 
illustrated the structural similarities and differences between C21, AVE0991, and 
Ang-(1-7).  
Our results identify C21 as not being a specific AT2 receptor agonist but also interacting 
with the two Ang-(1-7) receptors, Mas and MrgD. Therefore, the overlap in beneficial 
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effects of Ang-(1-7) and C21 might be based on the stimulation of the same receptors 
under specific pathophysiological circumstances. This also enforces the revisit of 
publications, which concluded on AT2 function by only using C21.  
 




The renin-angiotensin system (RAS) is an important regulator of arterial blood 
pressure, electrolyte homeostasis, and water and sodium intake [353], but is also 
involved in other processes like tissue regeneration [354]. Activation of the detrimental 
angiotensin (Ang) II type 1 (AT1) receptor leads to the pathogenesis of hypertension via 
vasoconstriction and sodium retention [14]. It is now widely known that the RAS includes 
further receptor subtypes opposing the actions of the AT1 receptor [14]. The Ang II type 
2 (AT2) receptor and the Mas receptor are the best characterised protective receptors in 
the RAS, whereby they mediate tissue protective and regenerative actions, such as anti-
fibrotic and anti-inflammatory actions [355].  
AT2 or Mas receptor deficiency does not lead to a critical phenotype, however, if 
knockout animals are exposed to myocardial infarction [391], stroke [392], chronic kidney 
disease [393], or atherosclerosis [394], symptoms are substantially more severe than in 
healthy controls, indicating both receptors are protective in cardiovascular diseases.  
It is well accepted that Compound 21 (C21) is a highly selective non-peptide AT2 receptor 
agonist [185], which has been shown to reduce blood pressure [187], and improve cardiac 
function following myocardial infarction [186]. As the AT2 receptor mediates beneficial 
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effects, C21 has been and is currently being studied in a variety of disease models, such as 
stroke [395], and heart failure [396]. 
During the past few years, also Ang-(1-7) has become a key peptide within the RAS due to 
its cardiovascular and renal protective effects, which often counteract the adverse actions 
of AngII [42]. Previously, we identified the G protein-coupled receptor Mas to be 
associated with Ang-(1-7)-induced signalling, which was found to be blocked by 
D-Ala7-Ang-(1-7), named A779, a specific Ang-(1-7) antagonist [397]. We also very 
recently discovered a second receptor for Ang-(1-7), the Mas-related G protein-
coupled receptor MrgD [378]. Furthermore, we showed in that study that the primary 
intracellular pathway which is activated by Ang-(1-7) upon interaction with Mas or 
MrgD, involves adenylyl cyclase, cAMP, and phosphokinase A [378]. 
The interaction of Ang-(1-7) with the AT2 receptor has been intensively discussed for 
almost two decades, mainly based on pharmacological studies using AT2 blockers 
[355]. However, we recently showed that the AT2 receptor blocker, PD123319, can also 
block the effects of Ang-(1-7) at its natural receptors, Mas and MrgD [378]. 
Furthermore, since other studies have shown that the Mas receptor blocker A779 can 
prevent the protective C21 effects in an ischemic stroke model [398], and the chemical 
structures of C21 and the Mas-specific agonist AVE0991 are very similar, interaction of 
C21 with Mas seems likely.  
Therefore, we aimed to test whether the AT2 receptor agonist C21 is, similar to the 
AT2 blocker PD123319, not specific and can interact with the two Ang-(1-7) receptors 
Mas and MrgD. In particular, we focused on the characterisation of the 
ligand/receptor pharmacology, by determining efficiency and potency using receptor-
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transfected HEK293 cells, human endothelial cells, receptor-deficient primary 
mesangial cells, isolated mesenteric microvessels, and a variety of receptor blockers. 
 
Methods 
Chemicals and reagents 
Ang-(1-7), D-Ala7-Ang-(1-7) and D-Pro7-Ang-(1-7) were synthetized by Biosyntan (Berlin, 
Germany). HEK-293, Forskolin, RPMI-1640, trypsin/EDTA, Irbesartan, SQ22536, HEPES 
solution, penicillin-streptomycin, noradrenaline and sodium pyruvate were purchased 
from Sigma Aldrich (St. Louise, Missouri, USA). C21 was purchased from AXON Medchem 
B.V. (Groningen, The Netherlands). DMEM, GlutaMax and Fetal Bovine Serum (FBS) were 
purchased from BioScience (Dun Laoghaire, Dublin, Ireland). PD123319 was from Parke-
Davis Pharmaceutical Research (Detroit, Michigan, USA). PTX was bought from EMD 
Millipore (Billerica, MA, USA). Polyfect transfection reagent was purchased from Qiagen 




Mice deficient in both Mas and MrgD (double knockout) [378] or deficient in AT2 [399, 
400] have been bred and housed in the animal facilities at UCC, Cork, Ireland. Animal 
studies are reported in compliance with the ARRIVE guidelines.[382] Experiments 
performed conformed with the guidelines from Directive 2010/63/EU of the European 
Parliament on the protection of animals used for scientific purposes. 
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Cell culture conditions, transfection and stimulation 
Human embryonic kidney (HEK293) and Balb/c-3T3 cells were cultured in DMEM medium 
supplemented with FBS (10%), HEPES buffer (1%), sodium pyruvate (1%), and L-glutamine 
(1 %) and maintained under standard conditions (5% CO2, 95% humidity and 37°C). Cells 
were cultured and transfected as described previously [378]. After pre-incubation with 
A779, D-Pro or PD123319 (10−6mol/L) or PTX (50ng/ml) for 15min, the solvent, C21 
(10−7mol/L) was added for 15min and cells were lysed immediately after [378].  
 
Isolation and culture of primary cells and their stimulation 
Kidney mesangial cells (MC) were isolated from 9-11 week old mice deficient in Mas and 
MrgD (double knockout) [378], or deficient in AT2 [399, 400] and also from their age- and 
gender-matched C57/BL6 controls, according to the protocol previously described [384]. 
Primary human umbilical vein endothelial cells (HUVEC) were purchased from PromoCell 
(Heidelberg, Germany). Primary cells were cultured and stimulated as described by 
Tetzner & Gebolys et al [378]. For the test of the adenylyl cyclase inhibitor (SQ22536), 
cells were pre-stimulated with 2x10-6mol/L for 15min, followed by stimulation with C21 at 
10-7mol/L for another 15min.  
 
Measurement of cAMP in cell lysates 
cAMP concentration in cell lysates was determined using Direct cAMP ELISA kit (Enzo Life 
Sciences Ltd., Exeter, United Kingdom), as previously described [378]. The cAMP 
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concentration of the samples was determined from the non-linear standard curve using 
GraphPad Prism 6.0 software.  
 
Dual luciferase assay (DLR) 
The protocol for Dual-Luciferase reporter assays has been described in detail previously 
[65]. In brief, HEK293 cells were seeded in 48-well plates (75,000 cells/well). About 24h 
later, cells were transiently transfected with 100 ng eukaryotic expression vectors of AT1 
or Mas, together with 25ng pELK-Luc Reporter Vector (Signosis, Santa Clara, California, 
USA) luciferase reporter plasmids and 25ng pRL-TK (Promega GmbH, Mannheim, 
Germany). After 6h of stimulation with C21 (10-14mol/L to 10-6mol/L or AngII (10−6mol /L), 
cells were lysed and incubated on a shaker for 15min at RT [378].  
 
 
Western blot analyses 
The protocol has been described in detail previously [378]. In short, twenty five µg 
protein were separated on 10 % SDS-polyacrylamide gels. PVDF membrane was incubated 
with the primary antibodies: CREB, pCREB, (1:1,000 dilution in 5% BSA/TBS-T) purchased 
from Cell Signalling Technology (Danvers, MA, USA) or the anti-GAPDH antibody (1:5,000 
in 5% milk/TBS-T) from Sigma Aldrich (St. Louise, Missouri, USA), at 4°C overnight. Blots 
were incubated with the appropriate horseradish peroxidase (HRP)-conjugated secondary 
antibodies: anti-rabbit IgG in the dilution of 1:2,000 in 5% milk/ TBS-T (Cell Signalling 
Technology) or 1:1,000 in 5% milk/TBS-T (Sigma Aldrich) at room temperature for 2h. The 
membranes were developed using the enhanced chemiluminescence (ECL)-based system 
 ________________________________________________________ Results 
124 | P a g e  
 
(Roche Holding AG, Basel, Switzerland). Densitometric evaluation was performed with 
ImageJ software (National Institute of Health, USA). 
 
Vascular reactivity in mesenteric microvessels 
Three-month-old male C57BL6 mice were used for analysing vascular reactivity. Prior to 
the experiments, the animals were briefly exposed to carbon dioxide in a chamber until 
they fell unconscious and were then immediately culled by cervical dislocation. Third-
branch mesenteric arteries (mean internal diameter ranging between 150 and 200μm) 
were mounted as ring preparations on a small-vessel myograph to measure isometric 
tension as described before [109]. Arteries were contracted with 10μmol l−1 
noradrenaline, and then the vasoactive response to C21 (1pmol l−1 to 1μmol l−1) was 
tested by adding increasing concentrations of the drug. In some cases, the mesenteric 
segments were preincubated for 15min with the D-Pro-Ang-(1-7) (1μmol l−1) or  
PD123319 (1μmol l−1), before addition of NA.  
 
In silico modelling 
Ang-(1-7)-Mas complex was modelled as described previously [378]. The resulting Mas 
structure was used in the docking calculation. Docking of C21 was performed with Glide 
version 74011 (Schrödinger LCC, New York, NY), setting the center of the grid box to the 
centroid of Ang-(1-7) as modelled and scaling the vdW radii of ligand atoms with a charge 
value lower than 0.15 with a factor of 0.80. C21 was prepared with LigPrep version 41011 
coupled with Epik version 39011 (Schrödinger LCC, New York, NY), setting pH to 7.4 ± 2. 
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AVE0991 was prepared equivalently with LigPrep and superposed to the resulting docked 




Data presented are mean ± SEM, where n denotes the number of experiments in 
triplicates. A P-value of <0.05 was considered statistically significant. To ensure 
reproducibility and to minimize bias, HEK293 cells, MC, and HUVECs were used at 
comparable passage numbers throughout the repeated experiments. The same kits and 
reagents were used for the experiments wherever possible. Data were analysed by 
Student’s t-test or one-way analysis of variance (ANOVA) tests accompanied by 











 ________________________________________________________ Results 




C21 stimulates the generation of intracellular cAMP in HEK293 cells expressing Mas 
Since C21 has structural similarities to the Masagonist AVE0991 [398], we first tested in 
experiments with Mas-transfected HEK293 cells, whether C21 can also stimulate the 
Ang-(1-7) receptor. The succesful overexpression of Mas was demostrated using qPCR 
analysis and flourescensmicroscopy as shown in Figure 10.1.1 of the supplemental data 
provided in Appendix part 1. As shown in  6.3.1A, C21 caused a dose-dependent increase 
in cAMP concentration with an EC50 value of 1.995 pmol/L reaching highest efficacy at 10-
10 mol/L. Using the concentration of highest efficacy, we investigated the effect of 
blockers which have been shown to target the Mas receptor, D-Pro, PD123319, and A779 
[378]. None of the 3 blockers had a baseline effect on cAMP levels in cells transfected 
with the control plasmid, pcDNA3.1, or in Mas-transfected cells. However, the increase in 
cAMP concentration generated by C21 in Mas-transfected cells was fully blocked by D-Pro 
and PD123319, but only partially by A779 (Figure 6.3.1 B).  
We then tested whether the increase in cAMP was adenylyl cyclase dependent. SQ22536 
blunted the C21 effect but had no significant effect on baseline cAMP levels (Figure 6.3.1 
C). To exclude that the C21 induced increase of cAMP is mediated by less Gαi activity and 
thus higher adenylyl cyclase activity, Mas-transfected HEK cells were stimulated with C21 
and co-treated with PTX, a Gαi inhibitor, whereby PTX failed to reduce the C21-mediated 
increase in intracellular cAMP (Figure 6.3.1 D).  
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Figure 6.3.1 C21 signals via the Mas receptor.  
(A) Mas or pcDNA-transfected HEK293 cells     were stimulated for 15min with a range of 
concentrations of C21 before analysis of cAMP concentration. (B) Effect of blockers A779, D- D-Pro 
and PD123319, (all 10-6mol/L) on C21 (10-10mol/L)-mediated increase in cAMP.  
(C) Effect of adenylyl cyclase inhibitor SQ22536, alone or in combination C21 (10-10mol/L), on cAMP 
level. (D) Effect of Galphai inhibitor PTX, alone or in combination with C21 (10-10mol/L), on cAMP 
level. (E) Luciferase production in HEK293 cells transiently co-transfected with pcDNA3.1, AT1, or 
Mas, and pElk1-Luc after stimulation with PBS, C21 or Ang II. Results are expressed as mean ± 
SEM. Data was reported as a fold change or percentage of the untreated control. *P<0.05, 
**P<0.01 ***P<0.001 vs. Mas control mean, #P<0.05, ##P<0.01, ###P<0.001 vs. C21; ONE WAY 














































































































































































 ________________________________________________________ Results 
128 | P a g e  
 
 
C21 effects were Gαi independent, which was further confirmed by investigating the 
activation of the Gαi-dependent transcription factor, Elk1. While the positive control AngII 
induced a significant increase in Elk1-stimulated transcription in AT1(a Gαq/11 and Gαi 
coupled receptor)-transfected cells, C21 did not stimulate Elk1 in Mas-transfected cells 
(Figure 6.3.1 E).  
 
C21 stimulates the generation of intracellular cAMP in HEK293 cells expressing MrgD 
Based on our work with Ang-(1-7) showing that the heptapeptide stimulates not only 
Mas, but also the sequence-similar receptor MrgD [378]. we then tested for effects of C21 
in MrgD-transfected cells. Like for Mas, the succesful overexpression of MrgD was 
demostrated using qPCR analysis and flourescensmicroscopy as shown in Figure 10.1.1 of 
the supplemental data provided in Appendix part 1. As shown in Figure 6.3.2 A, C21 
stimulation caused a dose-dependent increase in the intracellular cAMP level in MrgD-
transfected cells with an EC50 of 2.96 x 10-9mol/L. In contrast to Mas-transfected cells, D-
Pro, PD123319, and A779 all blocked the C21 (10-7mol/L)-mediated increase in 
intracellular cAMP in MrgD-transfected cells (Figure 6.3.2 B). 
To exclude that the receptor-mediated effects are only cell-type specific for HEK293, we 
transfected another cell type, Balb/c-3T3 cells with Mas (Figure 6.3.2 C) and MrgD (Figure 
6.3.2 D). Also, in this fully independent cell type, C21 generated a dose-dependent 
increase in intracellular cAMP. 
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Figure 6.3.2 C21 can also signal through the MrgD receptor.  
(A) MrgD or pcDNA-transfected HEK293 cells were stimulated for 15min with a range of 
concentrations (10-14 to 10-6mol/L) of C21 before analysis of cAMP concentration. (B) Effect of 
blockers A779, D-Pro7-(Ang-(1-7) (D-Pro) and PD123319, (all 10-6mol/L) on C21 (10-7mol/L)-
mediated increase in cAMP. (C) Mas-transfected Balb/c-3T3  cells were stimulated for 15min with 
a range of concentrations (10-14 to 10-6mol/L) of C21 before analysis of cAMP concentration. (D) 
Effect of C21 in MrgD-transfected Balb/c-3T3 cells on cAMP level. Results are expressed as mean ± 
SEM. Data was reported as a fold change or percentage of the untreated control mean. *P<0.05, 
**P<0.01 ***P<0.001 vs. MrgD control mean, #P<0.05, ##P<0.01, ###P<0.001 vs. C21; ONE WAY 
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Absence of C21-mediated cAMP generation in mesangial cells derived from Mas/MrgD 
knockout animals 
To test whether the lack of Mas and MrgD blunts the ability of C21 to generate cAMP in 
primary MC, we used mesangial cells derived from double knockout mice deficient in 
both receptors, a transgenic strain introduced very recently [378]. C21 increased cAMP 
dose-dependently in wild-type MC with an EC50 of 1.12 x 10-10mol/L (Figure 6.3.3 A). 
While D-Pro, PD123319, and A779 did not affect base-line cAMP concentrations in 
mesangial cells, all three compounds blocked the C21-mediated increase in intracellular 
cAMP in these wild-type cells (Figure 6.3.3 B). Importantly, the cAMP increase observed in 
wild-type mesangial cells was completely blunted in mesangial cells isolated from double-
knockout mice (Figure 6.3.3 C). These cells still had a functional adenylyl cyclase and 
downstream signalling, as shown by normal responsivelness to the positive control 
Forskolin.   
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Figure 6.3.3 C21 induced signalling is absent in mesangial cells derived from Mas/MrgD 
double-knockout animals.  
(A) WT C57BL/6 mesangial cells were stimulated for 15min with a range of concentrations 
(10-12 to 10-6mol/L) of C21 before analysis of cAMP concentration. (B) Effect of blockers A779, D-
Pro7-(Ang-(1-7) (D-Pro) and PD123319, (all 10-6mol/L) on C21 (10-7mol/L)-mediated increase in 
cAMP in WT C57BL/6 mesangial cells. (C) Mas/MrgD knockout (DKO) or AT2 knockout mesangial 
cells  were stimulated for 15min with C21 (10-7mol/L). Results are expressed as mean ± SEM. 
Untreated control values of each genotype is set as 100%.  **P<0.01 ***P<0.001 vs. WT control 
mean, #P<0.05, ##P<0.01, ###P<0.001 vs. C21; ANOVA with Bonferoni post-hoc test. n=6 (A), n=4 













































































































Mesangial Cells Mesangial Cells
 ________________________________________________________ Results 
132 | P a g e  
 
C21 still mediates cAMP generation in mesangial cells derived from AT2 knockout mice 
As C21 is advertised as a specific AT2 receptor agonist, we investigated the remaining C21 
effects in mesangial cells deficient in AT2. As illustrated in Figure 6.3.3 C, the efficacy in 
stimulating an increase in intracellular cAMP was reduced, but not blunted.
 
Figure 6.3.4 C21 induced signalling is absent in mesangial cells derived from Mas/MrgD 
double-knockout animals. 
(A) Western blot of phosphorylated CREB (pCREB) and CREB and the housekeeping protein GAPDH 
and calculation of time-dependent CREB phosphorylation in comparison to absolute CREB protein 
after C21 stimulation in wildtype (WT) mesangial cells. (B) Western blot of phosphorylated CREB 
(pCREB) and CREB after C21 stimulation in AT2 knockout mesangial cells Results are expressed as 
mean ± SEM. Untreated control values of each genotype is set as 100%.  *P<0.05, **P<0.01 
***P<0.001 vs. WT control mean; ONE WAY ANOVA with Bonferoni post-hoc test. n=2 (A), n=3 (B). 
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Since cAMP leads to an increase in pCREB phosphorylation downstream, we measured 
whether the remaining increase in cAMP after stimulation with C21 in AT2-deficient 
mesangial cells was still sufficient in phosphorylating CREB. C21 increased pCREB in wild-
type MC in a time-dependent manner (Figure 6.3.4 A), and was still able to promote such 
phosphorylation at the timepoint of highest efficacy (15min) in AT2-deficient cells (Figure 
6.3.4 B). 
 
C21 stimulates the generation of intracellular cAMP in endothelial cells via Mas/MrgD 
but not AT2 
Next, we tested whether C21 can also increase intracellular cAMP, comparable to 
Ang-(1-7), in endothelial cells, using the most commonly characterized endothelial cell-
line, human umbilical vein endothelial cells (HUVEC). C21 nicely stimulated cAMP 
generation as shown in Figure 6.3.5 A. Notably, the increase in cAMP occurs much earlier 
with a leftward shift of almost 3 magnitudes of order with C21, in comparison to Ang-(1-
7) where we have previously reported an EC50 of 1.2 x 10-8mol/L [378].  
To investigate whether the effect on cAMP is mediated by receptors that are sensitive to 
the two Ang-(1-7) antagonists, A779 and D-Pro, and to the unspecific receptor blocker 
PD123319 (blocks Mas/MrgD, and AT2), we used C21 in the concentration of highest 
efficacy (10-7mol/L) without and with the 3 receptor blockers. As shown in Figure 6.3.5 B, 
the three compounds did not affect base-line cAMP concentrations, but all three blockers 
significantly reduced the increase in intracellular cAMP in response to C21. 
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As shown in receptor-transfected cells for C21 in Figure 6.3.1 C, the increase in 
intracellular cAMP mediated by C21 could be inhibited by SQ22536. The increase 
mediated by our positive control Ang-(1-7)  could also be inhibited, as shown before 
[378].  
Since Ang-(1-7) and C21 behave similarily in HUVEC, this implies that both agonists 
stimulate Mas and MrgD but not AT2. To confirm that HUVEC do not have functional AT2 
receptors, we stimulated the cells with Ang II, with and without the AT1 receptor blocker 
Irbesartan (Figure 6.3.5 D). While C21 stimulated the increase in intracellular cAMP, AngII 
failed to do so, even when blocking the AT1 receptor and thus, allowing Ang II only to 
interact with AT2 (Figure 6.3.5 D).  
To confirm our cell culture findings under ex vivo conditions, precontracted isolated 
mesenteric arteries responded with a significant vasorelaxation to increasing 
concentrations of C21. However, this relaxation could not only be blocked by PD123319, 
but also the Mas/MrgD-specific antagonist, D-Pro, to levels of the spontanous relaxation 
over time, illustrating that the relaxation is Mas/MrgD- but not AT2-dependent (Figure 
6.3.5 E). 
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Figure 6.3.5 Intracellular cAMP is increased by C21 in human umbilical vein endothelial 
cells (HUVEC).  
(A) HUVEC were stimulated for 15min with a range of concentrations (10-13 to 10-6mol/L) of C21 
before analysis of cAMP concentration. (B) Effect of blockers A779, D-Pro7-(Ang-(1-7) (D-Pro) and 
PD123319, (all 10-6mol/L) on C21 (10-7mol/L)-mediated increase in cAMP in HUVEC. (C) Effect of 
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(10-7mol/L), on cAMP level. (D) Effect of Ang II (10-7mol/L), with and without the AT1 receptor 
blocker Irbesartan (10-6mol/L), on cAMP level. (E) Effect of D-Pro and PD123319 (1µM) on the 
endothelium-dependent relaxations induced by C21 (0.1nmol/L to 10μmol/L) in isolated 
mesenteric arteries from control C57BL/6 mice. Data are expressed (mean ± SEM) as the 
percentage of the previous contraction induced with 3μmol/L noradrenaline (NA). The number of 
segments used for every curve, which were obtained from 4 to 6 animals, are in parenthesis. 
Results are expressed as mean ± SEM. Data was reported as a fold change or percentage of the 
untreated control mean. *P<0.05, **P<0.01 ***P<0.001 vs. control mean, #P<0.05, ##P<0.01, 
###P<0.001 vs. C21; ONE WAY ANOVA with Bonferoni post-hoc test. n=4 (A, D), n=5 (B), n=6 (C,E). 
 
In silico modelling shows the structures of C21 and AVE0991 are similar 
Figure 6.3.6 A shows the very similar structures of C21 and AVE0991. The superposition of 
both structures also shows high three-dimensional resemblance, although some 
differences stand out (Figure 6.3.6 B). In addition to having a sulfonylurea instead of a 
sulfonylcarbamate, AVE0991 is a larger compound with three chemical groups, which fall 
outside the volume of C21, all of them attached to the imidazole ring (phenyl, methoxy 
and formyl groups). Finally and interestingly, the estimation of the ionisation states gives 
a protonated imidazole ring in C21, while it is neutral in the case of AVE0991. 
Docking of C21 into the Mas receptor (Figure 6.3.6 C) displays a hydrogen bond, cation-π 
and π-π directional interactions in the imidazol-1-ylmethylphenyl group. No other polar 
groups are observed in direct interaction with the receptor, although water-mediated 
interactions could be possible. In addition, the isobutyl group is observed to establish 
favourable contacts with Leu80, Leu81 and Ile84.  
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Figure 6.3.6 In silico modelling and structure of AVE0991 and C21 compounds 
(A) 2D structure of AVE0991 and C21, (B) 3D superposition of AVE0991 (purple-coloured carbon 
atoms) over C21 (yellow-coloured carbon atoms), (C) Docking pose of C21 compound in the 




Recently, we provided experimental proof that PD123319, which served as a specific AT2 
receptor blocker for two decades, also prevents the beneficial effects of Ang-(1-7) by 
blocking the two heptapeptide receptors, Mas and MrgD. Here we identify C21, the most 
popular AT2 receptor agonist, which has been shown to be beneficial in preclinical 
models of cardiovascular diseases [185, 401], as an agonist for Mas and MrgD. 
This supports our hypothesis that AT2, although without significant sequence homology 
to Mas/MrgD, except within the transmembrane domains where all GPCRs share a 
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common sequence pattern, has very similar properties in its ligand-binding site to the two 
receptors of the Mas-like family. 
Our in silico modelling illustrates both similarities and differences between C21 and 
AVE0991, the first non-peptidic agonist for the Mas receptor [232]. The main common 
features between C21 and AVE0991 include the imidazole ring, the isobutyl chain and the 
sulfonamide group, which are all attached to a 3-phenylthiophene bicyclic scaffold. On 
the other hand, C21 presents a protonated imidazole, a sulfonylurea and three extra 
fragments attached to the imidazole ring with no equivalence in the AVE0991 structure. 
The differences between C21 and AVE0991 could lead to distinct differences in their 
affinity and intrinsic activity [398]. Therefore, it was important to generate the 
experimental proof that C21, like AVE0991, can stimulate the Mas receptor. It might be 
interesting to investigate in follow-up experiments, whether AVE0991 is not Mas-specific, 
but can, similar to C21 also stimulate MrgD and AT2. 
From a perspective of drug development for cardiovascular diseases, it might be 
important to merge the information on C21/AVE0991 and Ang-(1-7) to develop a 
pharmacophore. A pharmacophore is a model of molecular features which are necessary 
for molecular recognition of a ligand by a receptor [402]. This can explain how structurally 
diverse ligands can bind to a common receptor site and it can also be used to identify 
novel agonists through de novo design or virtual screening. This can be used to distinguish 
between the three receptors, leading to the discovery of agonists with specific receptor 
fingerprints, (stimulating either all three, or only one or two of the receptors), allowing 
for use depending on the receptor profile in various cardiovascular and 
neurodegenerative diseases. 
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Our data also illustrates that the use of Mas/MrgD blockers or animals with Mas/MrgD or 
AT2 deficiency, will make it possible in upcoming preclinical experiments to distinguish 
the receptor which C21 acts through, in specific pathophysiological circumstances. Using 
this approach in primary mesenteric arteries, we established first data indicating an 
undiscovered receptor stimulated by C21. Since the lack of Mas and MrgD does not only 
blunt the C21 effect observed in wild-type cells, but even attenuates the intracellular 
cAMP levels (Figure 6.3.3 C, middle panel), this may be explained by a 4th receptor 
stimulated by C21, which is Gαi coupled and thus, reduces adenylyl cyclase activity and 
consequently, cAMP generation. This drop in Mas/MrgD-deficient cells allows us to 
correctly read the data in AT2-deficient mesangial cells. The increase by C21, which is 
slightly above the control level, is in reality much higher, starting from a negative value 
based on the cAMP-lowering effect of the hypothetical Gαi coupled receptor also 
stimulated by C21. Final proof of this hypothesis could be generated with cells deficient in 
Mas/MrgD and AT2, where any drop in intracellular cAMP after C21 stimulation would 
relate to such a postulated receptor. 
C21 stimulates different receptors in primary cells, which is also illustrated in the second 
cell type we used, HUVEC. Figure 6.3.5 A shows a biphasic dose-response curve, whereby 
its two peaks nicely correspond to the peaks in Mas and MrgD-transfected cells. 
There is a significant overlap of cardiovascular protective effects of C21 and Ang-(1-7), 
which we and others have explained previously with two beneficial arms of the RAS: the 
AngII/AT2 axis and the Ang-(1-7)/Mas & MrgD axis. While this might still be correct, our 
results provide a new explanation, by showing that both compounds share, at least in 
part, the same receptors.  
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It will be interesting to identify diseases, where C21 is beneficial, independent of 
Mas/MrgD stimulation, as these diseases would benefit from an AT2-specific agonist.  
Taken together, our results provide the groundwork for a better understanding of the 
function of the AT2 receptor under physiological and pathophysiological circumstances, 
as we demonstrate that conclusions based on only C21s effects might be incorrect. This 
also forces the revisit of such publications, which conclude on AT2 receptor effects using 
only C21. Furthermore, the identification of the second messenger, cAMP, being 
regulated by C21, will allow for the focused identification of intracellular networks in 
response to C21 treatment and the prediction of potential applications of this drug by 
identifying diseases where elevation of cAMP is assumed to be beneficial, and where 
target organs express either Mas, MrgD or AT2.  
 
Perspectives  
While Ang-(1-7) only stimulates Mas and MrgD, C21 also acts through the AT2 receptor. 
The molecular understanding of the common structural pattern required to stimulate all 
three receptors, or only one or two of them, opens the avenue for the development of 
tailored drugs (non-peptidic agonists) for cardiovascular and neurodegenerative diseases, 
based on the specific receptor fingerprint in target organs associated with the treatment 
of such diseases. 
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Novelty and Significance 
What is new? 
We demonstrate that C21 is not an AT2-specific agonist, as it also interacts with both Ang-
(1-7) receptors, Mas and MrgD. Consequently, C21 still has biological effects in AT2-
deficient tissue, as long as it expresses one of the heptapeptide receptors. 
 
What is relevant? 
The understanding of structural similarities of receptor agonists will lay the ground for the 
design of tailored non-peptidic agonists stimulating all three, two or only one of the 
receptors. 
Summary 
C21 can stimulate both Mas and MrgD, explaining similar beneficial effects as Ang-(1-7), 
also enforcing the revisit of such publications, which concluded on AT2 function by only 
using C21. 
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6.4 The Angiotensin-(1-7)/Mas axis improves pancreatic β-
cell function in vitro and in vivo 
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Hypothesis: 
Ang-(1-7)/Mas axis is a potential therapeutic target for diabetic disorders (type 1 and type 
2 diabetes). 
Aim of the study: 
The aim of the study was to investigate the positive effects of Ang-(1-7) on the regulation 
of insulin secretion in pancreatic β-cells. Therefore, in vitro, ex vivo, and in vivo 
experiments were used to examine the responsible processes and mechanisms of the 
Ang-(1-7) related effects on insulin secretion. 
 
Disclosure statement: The authors have nothing to disclose. 
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Abbreviations 
ACE2  angiotensin-converting enzyme 2 
Ang  angiotensin 
AT1  Ang II type 1 receptor  
[Ca2+]c cytosolic calcium concentration 
cAMP  cyclic adenosine monophosphate 
EPAC 2  exchange protein directly activated by cAMP 2  
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GLP-1  glucagon-like peptide-1 
GSIS  glucose-stimulated insulin secretion 
KO  knockout 
Mas  receptor Mas 
NEP  neprilysin 
PKA  cAMP-dependent protein kinase 
RAS  renin-angiotensin system 
RT-qPCR reverse transcription and quantitative polymerase chain reaction 
WT  wild-type  
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Abstract 
The ACE2/angiotensin (Ang)-(1-7)/Mas axis of the renin-angiotensin system (RAS) often 
opposes the detrimental effects of the ACE/AngII/AT1 axis and has been associated with 
beneficial effects on glucose homeostasis, while underlying mechanisms are mostly 
unknown. Here, we investigate the effects of Ang-(1-7) and its receptor Mas on β-cell 
function.  
Isolated islets from Mas-deficient and wild-type mice were stimulated with Ang-(1-7) or 
its antagonists and effects on insulin secretion determined. Islets’ cytoplasmic calcium 
and cAMP concentrations, mRNA amounts of Ins1, Ins2, Pdx1, and Mafa, and effects of 
inhibitors of cAMP downstream signaling were determined. Ang-(1-7) was also applied to 
mice by osmotic pumps for 14 days and effects on glucose tolerance and on insulin 
secretion were assessed.  
Ang-(1-7) increased insulin secretion from wild-type islets whereas antagonists and 
genetic Mas-deficiency led to reduced insulin secretion. The Mas-dependent effects of 
Ang-(1-7) on insulin secretion did not result from changes in insulin gene expression or 
changes in the excitation-secretion coupling, but from increased intracellular cAMP 
involving exchange protein activated directly by cyclic AMP (EPAC). Administration of 
Ang-(1-7) in vivo had only marginal effects on glucose-tolerance in wild-type mice, but still 
resulted in improved insulin secretion from islets isolated of these mice. Interestingly, 
although less pronounced than in wild-types, Ang-(1-7) still affected insulin secretion in 
Mas-deficient islets.  
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The data indicates a significant function of Ang-(1-7) in regulation of insulin secretion 
from mouse islets in vitro and in vivo, mainly, but not exclusively, by Mas-dependent 
signaling, modulating the accessory pathway of insulin secretion via increased cAMP.  
 
Introduction 
The renin-angiotensin system (RAS) is an important regulator of blood pressure and is 
activated in a number of pathophysiological conditions (such as hypertension, 
hyperglycaemia, and cardiac insufficiency) triggering pathogenesis and progression of 
these diseases. In addition to inducing insulin resistance, the activation of RAS and in 
particular the effect of increased angiotensin (Ang) II levels hyper-stimulating the Ang II 
type 1 receptor (AT1) are also associated with the deterioration of β-cell function and 
thus the adequate production and secretion of insulin [403].  
The angiotensin-converting enzyme 2 (ACE2, EC 3.4.17.23) metabolises Ang II into Ang-(1-
7) by splitting off the C-terminal amino acid. This enzyme has a protective role in general 
and for the cardiovascular system in particular [404]. These positive effects are 
attributable both to the fact that ACE2 reduces Ang II concentration, which in turn 
reduces the activation of AT1, and that more beneficial Ang-(1-7) can stimulate its 
receptor Mas [62], counteracting the AT1 signalling [51].  
The beneficial effects of Ang-(1-7) with respect to glucose homoeostasis have been 
described, but mainly concern the improvement of insulin sensitivity and thus the glucose 
uptake in peripheral tissues (muscle, fat). Exemplarily, in a rat model of metabolic 
syndrome, chronic infusion of Ang-(1-7) resulted in the normalization of insulin 
sensitivity/signal transduction of skeletal muscle, liver, and adipose tissue and of 
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hyperglycaemia, hyperinsulinaemia, and hypertriglyceridaemia [73]. In primary 
epididymal adipocytes of mice and in 3T3-L1 adipocytes, Ang-(1-7) resulted in an increase 
in glucose uptake, coupled with reduced production of reactive oxygen species due to an 
Ang-(1-7)-mediated inhibition of NADPH oxidase subunit expression [349]. An increase in 
glucose uptake in the adipocytes of transgenic rats with Ang-(1-7) overexpression was 
also observed, with improved insulin sensitivity and glucose tolerance and reduced 
triglyceride and cholesterol serum levels [125]. Furthermore, it has been shown that the 
oral administration of Ang-(1-7) counteracts hyperglycaemia in a rat model of inducible 
diabetes mellitus type 2 [348].  
Initial work on the role of the ACE2/Ang-(1-7)/Mas axis and in particular the effect of Ang-
(1-7) on insulin production and secretion showed that Ang-(1-7) can prevent the marked 
shrinkage of the cytoplasm and condensation of nuclear chromatin and significantly 
facilitated insulin production in pancreatic β-cells of rats with streptozotocin (STZ)-
induced diabetes mellitus [350]. Thus, it was the aim of the study to explore the 
processes and mechanisms that result in the positive effects of Ang-(1-7) on the 
regulation of insulin secretion in pancreatic β-cells. Moreover, it was intended to conduct 
in vitro, ex vivo, and in vivo experiments designed to lay the foundations that will 
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Materials and Methods 
Mice  
The protocol of the study was approved by the Veterinary and Food Control Office, State 
Department of Agriculture, Food Safety and Fisheries Mecklenburg-Vorpommern, 
Germany (Permit Number: 7221.3-1.1-097/12). Animals were housed at 21˚C, exposed to 
a 12-h light and darkness cycle with access to food and water, ad libitum. For all 
experiments, 11- to 14-week old mice deficient in the receptor Mas (Mas-/-; -/-) [120] and 
their age- and sex-matched wild-type (WT; +/+) controls were used (all on C57Bl/6J 
background) whereby knockouts and wild-types have been generated from heterozygous 
mice and housed under identical conditions. 
 
Immunofluorescence microscopy 
Formalin-fixed paraffin sections (5 µm) of mice pancreases were deparaffinised and 
rehydrated using standard methods. Antigen retrieval and immunostaining were 
performed as previously described [405] using primary and Alexa 488- and Cy3-
conjugated secondary antibodies (listed in the Antibody table). Sections were covered 
with Roti®-Mount FluorCare DAPI (Roth, Karlsruhe, Germany) and images acquired using 
a Leica TCS SP5 confocal microscope (Leica Microsystems, Wetzlar, Germany).  
 
Histochemistry, immunohistochemistry, and determination of beta cell volume fraction 
Pancreatic tissue was fixed in 4% neutral buffered formalin, dehydrated and embedded in 
paraffin. Staining of slides (2µm) with either hematoxylin and eosin or by 
immunohistochemistry was performed as followed: Slides were deparaffinised and 
treated with primary antibodies against insulin (Santa Cruz Biotechnology, Dallas, USA) or 
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CD34 (Dako, Glostrup, Denmark) (for details see Antibody table). Stainings were 
performed on automated immunohistochemistry stainers: insulin on Leica Bond using 
Bond Polymer Refine Detection kit (Leica Biosystems, Newcastle, UK, no. DS9800); CD34 
on Roche Ventana using OptiView DAB IHC Detection kit (Ventana Medical Systems, Oro 
Valley, USA, no. 760-700). Volume fractions of insulin positive islet cells were estimated 
by the stereological point counting method described by Weibel  [406] using Nikon NIS 
Elements software 4.30. 585 points were counted per animal. 
 
Isolation of mouse islets of Langerhans 
One ml collagenase P (2mg/ml) (Roche) was injected into the mouse pancreas through 
the common bile duct. After resection, the whole pancreas was digested in 2ml 
collagenase P solution for 6min at 37°C with gentle shaking. Ice-cold islet isolation buffer 
(135mmol/l NaCl, 5.6mmol/l KCl, 1.28mmol/l CaCl2, 1.2mmol/l MgCl2, 10mmol/l HEPES, 
0.1% BSA, 100U/ml penicillin, 100µg/ml streptomycin, 3mmol/l glucose, pH7.4) was 
added, samples were shaken vigorously for 15s and centrifuged (500×g, 2min, 4°C). 
Pellets were resuspended in islet isolation buffer and islets hand-picked and collected in 
RPMI 1640 (PAN Biotech, Aidenbach, Germany) supplemented with 10% FBS (Thermo 
Fisher Scientific, Waltham, USA), 100 U/ml penicillin and 100µg/ml streptomycin (PAN 
Biotech). Unless otherwise stated, islets pooled from at least 5 animals (250 islets per 
mouse, approximately) were used for each set of experiments, and this was regarded as 
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Glucose-stimulated insulin secretion (GSIS) 
Five islets per well were cultured in 12-well plates (Greiner bio-one cell star®, 
Frickenhausen, Germany) with 500µl RPMI 1640 (supplemented as described above) at 
37°C with 5% CO2. After 24h, islets were incubated in KRB (123mmol/l NaCl, 4.7mmol/l 
KCl, 1.2mmol/l KH2PO4, 2.6mmol/l CaCl2, 1.2mmol/l MgSO4, 10mmol/l HEPES, 20mmol/l 
NaHCO3, 0.5% BSA, pH7.4) with 2.8mmol/l glucose for 90 min, with buffer exchanged 
once after 30min. Islets were exposed to either 2.8mmol/l glucose, 2.8mmol/l glucose + 
40mmol/l KCl, or 20mmol/l glucose, for 2h. For the treatments, Ang-(1-7) (0.2µmol/l), 
A779 (1µmol/l), D-Pro7-Ang-(1-7) (1µmol/l) (all from Bachem, Bubendorf, Switzerland), 
HJC 0350 (50µmol/l; Tocris Bioscience, Avonmouth, Bristol, UK), or H89 (20µmol/l; Cell 
Signaling, Frankfurt aM, Germany) were added. Supernatants were collected, centrifuged 
at 100×g for 2min at 4°C and insulin concentrations in the supernatants determined by 
ELISA (Mercodia, Uppsala, Sweden).  
 
Intra-islet insulin content  
Single islets were collected in 50µl lysis buffer (50mmol/l Tris-HCl (pH8.0), 5mmol/l EDTA, 
150mmol/l NaCl, 10% glycerol, 0.5% NP-40, 2mmol/l Na3VO4, 1mmol/l NaF, 0.1mmol/l 
PMSF, and cOmplete™ protease inhibitor cocktail (Roche)). After 30min incubation on ice, 
samples were shock-frozen in liquid nitrogen and the intra-islet insulin contents 
determined by ELISA. 
 
RNA isolation and quality control. Total RNA was extracted from isolated islets by 
performing a modified phenol extraction [407]. RNA integrity was validated by means of 
the lab-on-chip capillary electrophoresis technology (Bioanalyzer 2100, Agilent 
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Technologies, Santa Clara, USA). Only RNA samples with a RNA Integrity Number (RIN) > 
7.5  [408] and absorption quotients of A260nm/A280nm ≥ 1.8, A260nm/A230nm ≥ 1.9 
were used for subsequent experiments. 
 
Reverse transcription and quantitative PCR (RT-qPCR) 
Five hundred ng of total islet RNA were reverse-transcribed into cDNA using a RevertAid 
First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). qPCR was performed in a CFX96 
thermocycler (Bio-Rad, Munich, Germany). The 20 μl reaction mixture consisted of 
1×SensiMix ™ SYBR Hi-ROX Mastermix (Bioline, Luckenwalde, Germany), 0.25μmol/l of 
specific primers (Life Technologies GmbH, Darmstadt, Germany; detailed primer 
information is shown Table 1) and 1μl cDNA. Initial denaturation at 95°C for 10min was 
followed by 40 cycles at 95°C for 15s, annealing at 58 - 64°C for 15s and elongation at 
72°C for 20sec. Data were normalised to Rplp0. PCR products were separated in agarose 
gels and visualised by RedSafe (iNtRON Biotechnology, Summit, USA), using Quick-
Load® 100 bp DNA ladder (New England Biolabs, Frankfurt, Germany) as molecular weight 
marker. 
 
Determination of cytosolic calcium concentrations [Ca2+]c 
[Ca2+]c was measured in β-cell clusters in a bath-solution (140mmol/l NaCl, 5mmol/l KCl, 
1.2mmol/l MgCl2, 2.5mmol/l CaCl2, 10mmol/l HEPES, pH7.4, and glucose as indicated). 
Ang-(1-7) (1µmol/l) and A779 (1µmol/l) were present during the pre-incubation (24h) and 
the whole measurement. Control experiments were performed without compounds. 
[Ca2+]c was measured by the fura-2 method according to Grynkiewicz et al. [409] using 
equipment and software from TILL photonics (Gräfelfing, Germany). Cells were loaded 
 ________________________________________________________ Results 
152 | P a g e  
 
with fura-2-AM (5µmol/l) (Biotrend, Köln, Germany) for 35min at 37°C. Intracellular fura-2 
was excited alternately at 340 or 380nm by means of an oscillating diffraction grating. The 
emitted light was filtered (LP515nm) and measured by a digital camera. The ratio of the 
emitted light intensity at 340nm/380nm excitation was used to calculate [Ca2+]c according 
to an in vitro calibration with fura-2 K+-salt. 
 
Determination of cyclic AMP (cAMP) concentrations 
Twenty islets per well isolated from wild-type or Mas-deficient mice were cultured for 
24h and incubated in KRB as described for the GSIS. Islets were stimulated with or 
without 0.1µmol/l Ang-(1-7) and/or the two antagonists, D-Ala7-Ang-(1-7) (A779) and D-
Pro7-Ang-(1-7) (D-Pro) for 15min and lysed in 150 µl lysis buffer (0.1mol/l HCl, 0.1% 
Tween-20). Concentrations of cAMP were determined using the Direct cAMP ELISA kit 
(Enzo Life Sciences Ltd., Exeter, United Kingdom) following manufacturer’s instructions.  
 
Immunoblot analysis  
300-400 islets were treated with Ang-(1-7) (0.2µmol/l) or A779 (1µmol/l) for 24h, washed 
twice with ice-cold PBS and lysed in 30µl lysis buffer (as shown for intra-islet insulin). 
After centrifugation (17,000×g, 30min, 4°C) the supernatant was used. For each condition 
10µg of total islet protein was separated in Mini-PROTEAN® TGX Stain-Free™ Precast Gels 
(Bio-Rad, Munich, Germany) using Tris/glycine/SDS running buffer (25mmol/l Tris-HCl, 
129mmol/l glycine, 0.1% SDS) under standard conditions according to the manufacturer’s 
instructions. Proteins were transferred to polyvinylidene fluoride (PVDF) membranes 
using the Trans-Blot® Turbo™ RTA Mini PVDF Transfer Kit and the Trans-Blot® Turbo™ 
System (Bio-Rad). Membranes were blocked in TBST (138mmol/l NaCl, 20mmol/l Tris, 
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0.1% Tween 20, pH7.6) with 5% low fat powdered milk and incubated with p-PKA and 
total PKA primary antibodies (Cell signaling; for details see Antibody table). Using a HRP-
linked secondary antibody and SuperSignal™ West Dura Extended Duration Substrate 
(Thermo Fisher Scientific) the signals were detected in a ChemiDoc™ Imaging System (Bio-
Rad). Signal intesities were analysed using ImageJ software (ImageJ, Bethesda, USA) and 
the p-PKA to total PKA ratio calculated. 
 
Continuous administration of Ang-(1-7) in vivo 
ALZET® osmotic pumps [model 1002; 0.25µl/h] (Charles River Laboratories, Sulzfeld, 
Germany) were loaded with 0.9% saline as control solution or Ang-(1-7) dissolved in 0.9% 
saline. After priming for 1 h at 37°C, pumps were implanted into a subcutaneous pocket 
between the scapulae of isoflurane-anesthetised mice. The wound was closed with a 
wound clip. The pumps remained in the mice for 14 days with a calculated infusion rate of 
2.47 mg kg-1 d-1 of Ang-(1-7).  
 
Oral glucose tolerance test (OGTT) 
Ten days after pump implantation an OGTT was performed with the mice. After 6h 
fasting, plasma insulin concentration and blood glucose were determined 15min before 
OGTT. Glucose was orally administered by gavage (2g/kg body weight). Blood samples 
were taken from the tail vein for blood glucose and plasma insulin analysis thereafter. 
Blood glucose concentrations were measured using a commercial blood glucose meter 
(sample volume 0.3µl; FreeStyle Lite, Abbott, USA) and plasma insulin was determined by 
ELISA (20µl blood).  
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Statistical analysis  
Statistical analyses were performed using GraphPad Prism 6 software (GraphPad, La Jolla, 
USA). P-values <0.05 were considered to indicate statistically significant differences. Non-
parametric data are illustrated as boxplots with medians, quartiles and an interquartile 
range (IQR) ± 1.5 × IQR with outliers as indicated (Tukey method). Parametric data are 
shown as bars with means and standard error of mean (SEM). 
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Results 
Islets of Langerhans express components of the alternative ACE2/Ang-(1-7)/Mas axis of 
the RAS 
The expression of components of the ACE2/Ang-(1-7)/Mas axis of the RAS and of 
neprilysin (NEP, neutral endopeptidase, EC 3.4.24.11), a peptidase generating Ang-(1-7) 
directly out of the Ang precursor Ang I, were verified by RT-qPCR using RNA from isolated 
islets. The analysis revealed the existence of abundant mRNA amounts of Ace2, NEP 
(approx. 10% of the amounts of insulin 1 mRNA), and Mas (approx. 2% of insulin 1 mRNA) 
in murine islets. Figure 6.4.1 A shows the corresponding amplification products of the 
expected size. Immunofluorescence analyses of pancreatic tissue sections (Figure 6.4.1 B) 
indicated predominant detection of ACE2 and Mas in the β-cell population as concluded 
from the co-localization of Mas and ACE2 with insulin-positive rather than with glucagon-
positive cells. NEP appeared to be ubiquitously expressed in all endocrine as well as 
exocrine cells of the pancreas.  
Phenotypical analysis of islets from wild-type (+/+) or Mas-deficient mice (-/-) revealed no 
histological or cytological differences. Explicitly, there were no differences in gross islet 
architecture, vascular density, or β-cell volume fraction (Figure 6.4.2). In detail, pancreatic 
islets of Mas-deficient mice were well circumscribed and mean islet diameter as well as 
the volume fraction of islet tissue on total pancreatic tissue were similar to the wild-type 
mice. Islet cells showed pale cytoplasm and round, uniform nuclei with granular 
chromatin and no nuclear atypia. Composition of pancreatic islets was similar, too, islets 
consisted mainly (> 95%) of insulin-expressing β-cells. Vascularization of pancreatic islets 
was evaluated by histologic presentation of CD34 positive endothelial cells. Islets of wild-
type as well as Mas-deficient mice showed dense capillarization of sinusoidal vessels 
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(Figure 6.4.2). Furthermore, the average number of islets isolated from mouse pancreata 
was not different between wild-type (258.3 ± 79.8; n=134) and Mas-deficient mice (280 ± 
107; n=181).  
 
Figure 6.4.1 Detection of components of the alternative ACE2/Ang-(1-7)/Mas axis of the 
RAS in murine islets of Langerhans  
(A) mRNA amounts of Ace2, NEP, and Mas. Amplificate sizes are given in bp. M=DNA Ladder. (B) 
Specificity of the Mas antibody in WT (+/+) mice was approved by immunostaining of pancreatic 
tissue sections from Mas-deficient (-/-). Insulin and glucagon immunostaining identified the islet 
distribution of β- and α-cells (upper panels). ACE2 and Mas were predominantly detected in β-
cells, while NEP could be detected in endocrine and exocrine cells in WT islets (lower panels). 
Length of lower border of Mas and NEP images: 0.25 mm; lower border of ACE2 images: 0.085 
mm. ACE2, angiotensin-converting enzyme 2; NEP, neprilysin. 
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Figure 6.4.2 Phenotypic description of islets from wild-type and Mas-deficient mice. 
Islets of Langerhans in pancreatic tissue in WT (+/+; upper line) and Mas KO mice (-/-; 
lower line):  
(A, D) Islets presented as sharply circumscribed nests with uniform cells containing round nuclei 
with granular chromatin and abundant pale cytoplasm. (B, E) In both groups islets consisted 
mainly of insulin expressing β-cells. (C, F) Capillary density of islets of Langerhans shown by CD34 
immunostains was similar. Length of lower image border A, B, D, E: 0.16 mm; C, F: 0.23mm. (G) 
Calculated β-cell volume fraction as percentage of pancreas in wild-type mice (set 100%). 
 
 
Pharmacological modulation of the receptor Mas affects insulin secretion 
Exposure of isolated wild-type (WT; +/+) islets to Ang-(1-7) increased GSIS but did not 
significantly increase the KCl-mediated insulin secretion (P = .466 vs KCl-treatment 
without Ang-(1-7)) probably due to the wide scattering of the individual data, but the 
augmentation up to 259% and the 75th percentile of 168.5 could indicate an increase in 
KCl-induced insulin secretion with Ang-(1-7). Administration of the Mas-specific Ang-(1-7) 
antagonist, A779, respectively, provoked a significant decrease in insulin secretion with 
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20mmol/l glucose (-1.5-fold) and KCl treatment (-1.4-fold) (Figure 3A, left part). However, 
Ang-(1-7) led to a 1.4-fold increase at low (5.5mmol/l) and to a 1.4-fold increase at high 
(20mmol/l) glucose concentrations (Figure 6.4.3 A; middle and right part). Consequently, 
pretreatment with A779 was performed to test for its effect on the significant Ang-(1-7) 
effect on glucose-stimulated insulin secretion. For both glucose concentrations, A779 
failed to block the Ang-(1-7)-mediated increase. Therefore, also the second Ang-(1-7) 
antagonist, D-Pro, was used. In contrast to A779, D-Pro significantly blocked the effect of 
Ang-(1-7) (Figure 6.4.3 A, middle and right part).  
 
 
Pharmacological modulation of the receptor Mas affects neither insulin, Pdx1 or Mafa 
mRNA amounts nor intra-islet insulin content 
To examine whether the observed changes in insulin secretion are a result of alterations 
in mRNA amounts of insulin or the main insulin-gene regulating transcription factors 
PDX-1 and MafA, islets were treated with Ang-(1-7) or A779 and mRNA amounts and 
intra-islet insulin content determined. No significant changes in mRNA amounts of Ins1, 
Ins2, Pdx1, or Mafa were observed (Figure 6.4.3 B). Furthermore, administration of Ang-
(1-7) or A779 for 24h did not alter the intra-islet insulin content (Figure 6.4.3 C). 
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Figure 6.4.3 Pharmacological modulation of the receptor Mas ex vivo in WT islets 
A) KCl- and glucose-stimulated insulin secretion in presence of Ang-(1-7), A779, or D-Pro7-Ang-(1-
7) (D-Pro) in WT islets (n ≥ 10; n ≥ 4 for all D-Pro experiments). (B) mRNA amounts of Ins1, Ins2, 
Pdx1 and Mafa in Ang-(1-7)- or A779-treated WT (+/+) islets (n ≥ 4). (C) Intra-islet insulin 
concentrations in Ang-(1-7)- or A779-treated WT (+/+) islets (n ≥ 13). (Mann–Whitney U test; *. P < 
.05; **, P < .01; ***, P < .001). 
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Pharmacological modulation of the receptor Mas does not lead to alterations in 
cytosolic calcium concentrations 
To further investigate the mechanism underlying the effects of receptor Mas modulation 
on insulin secretion, [Ca2+]c was determined in islet cell clusters exposed to Ang-(1-7) or 
A779, respectively. Depending on the glucose concentration, pancreatic β-cells exhibit 
fluctuations of the membrane potential (Vm) where burst phases with action potentials 
alternate with silent interburst phases generating so-called slow waves [410]. The slow 
waves drive oscillations of the [Ca2+]c and insulin secretion. The fraction of plateau phase 
(FOPP; percentage of summed burst-times) correlates with the amount of insulin release.  
As shown in Figure 6.4.4 A, exposure of β-cells to a high glucose concentration (20mmol/l) 
led to significantly increased [Ca2+]c when compared to 10mmol/l glucose. However, 
exposure of β-cells to Ang-(1-7) or A779 did not result in any changes of [Ca2+]c or the 
pattern of Ca2+ oscillations at 20mmol/l glucose (Figure 6.4.4 B).  
In additional experiments Mas-deficient islets showed no differences in the [Ca2+]c in 
response to glucose ore KCl compared to islets from wild-type mice (data not shown). 
 
 
Administration of Ang-(1-7) increases intracellular cAMP concentrations 
The fact that pharmacological modulation of Mas provoked changes in insulin secretion in 
the absence of any changes in [Ca2+]c raised the hypothesis that Mas-dependent 
alteration of β-cells’ Ca2+-sensitivity contribute as an underlying mechanism. Previous 
work identified cAMP as an effective Ca2+ sensitiser and stimulus of insulin exocytosis in 
pancreatic β-cells  [411, 412]. As shown in Figure 6.4.4 C, exposure of isolated WT islets to 
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Ang-(1-7) led to a significant 1.6-fold increase in their cAMP contents. This Ang-(1-7)-
mediated increase could be abolished by the simultaneous administration of A779.  
To test for the critical role of increased cAMP levels for the Ang-(1-7)-mediated 
stimulation of insulin secretion, the two downstream effectors of cAMP, EPAC 2 and PKA, 
have been inhibited under high glucose conditions. While the EPAC 2-inhibitor, HJC 0350, 
completely abolished the Ang-(1-7) effect on insulin secretion, no such effect could be 
detected for the inhibitor of PKA, H89, which suggests that activation of PKA does not 
contribute much to the Ang-(1-7)-mediated increase in insulin secretion (Figure 6.4.4 D). 
To confirm that administration of Ang-(1-7) has an effect on PKA, Western blots have 
been performed showing indeed increased phosphorylation state of PKA in WT islets after 
24 hours, while the total PKA protein amount was not altered. The A779 treatment did 
not result in significant changes in total PKA amounts or phosphorylation state (Figure 
6.4.4 E).  
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Figure 6.4.4 Effects of pharmacological modulation of the receptor Mas on cytosolic 
calcium concentrations ([Ca2+]c) in β-cells and cAMP contents, cAMP-depending 
signalling, and PKA phosphorylation state in mouse islets  
(A) [Ca2+]c and the pattern of Ca2+ oscillations at 10 and 20mmol/l glucose in β-cells using the fura-
2 method. Data are averaged values over 10min intervals. One representative experiment out of 
each group is shown. The n-values within the columns indicate the number of analysed cells (t test; 
***, P < .001). (B) [Ca2+]c and Ca2+ oscillation pattern in β-cells at 20mmol/l glucose in the presence 
of Ang-(1-7) or A779. (C) Intracellular cAMP concentrations in WT (+/+) islets with Ang-(1-7) or 
A779 treatment (mean ± SEM, Mann–Whitney U test; **, P < .01; n = 5; n = 2 for A779). (D) 
Glucose-stimulated (20mmol/l) insulin secretion in presence of H89 or HJC 0350 (n ≥ 4). (E) WT 
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islets were exposed to Ang-(1-7) or A779 for 24h and amounts of p-PKA and PKA were determined 
by immunoblot analysis with intensities analysed using ImageJ software. Calculated p-PKA/PKA 
ratios are presented together with one representative western blot image (Mann–Whitney U test; 
* P < .05; n = 7). 
 
 
Mas-deficiency decreases insulin secretion from isolated islets without affecting insulin 
mRNA amounts or intra-islet insulin content  
 
As already shown for the pharmacological blockade of Mas by A779 (Figure 6.4.3 A), 
genetic Mas-deficiency (-/-) resulted in a similar decrease in GSIS from islets under low 
(5.5mmol/l) as well as high (20mmol/l) glucose conditions (-1.6-fold and -2.1-fold, 
respectively) (Figure 6.4.5 A). Also the KCl-dependent insulin release was diminished (-
2.4-fold) in these Mas-deficient islets. Furthermore, mRNA amounts of Ins1, Ins2, Pdx1, 
and Mafa of such islets lacking Mas were not significantly altered compared to islets 
isolated from WT mice (Figure 6.4.5 B).  
In accordance with these findings, Mas-deficiency did not lead to changes in intra-islet 
insulin content when compared to wild-type islets (Figure 6.4.5 C).  
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Figure 6.4.5 Effects of Mas-deficiency on  
(A) KCl- and glucose-stimulated insulin secretion comparing WT (+/+) and Mas-deficient (-/-) islets 
(Mann–Whitney U test; **, P < .01; ***, P < .001; n ≥ 6), (B) mRNA amounts of Ins1, Ins2, and 
insulin-regulating transcription factors Pdx1 and Mafa in WT (+/+) and Mas-deficient (-/-) islets (n 
≥ 8), and (C) intra-islet insulin concentrations in WT (+/+) and in Mas-deficient (-/-) islets (n ≥ 13). 
 
 
Long-term Ang-(1-7) administration in vivo has minor effects on glucose tolerance  
To determine long-term effects of Mas modulation on glucose tolerance and plasma 
insulin concentrations, Ang-(1-7) or control solution (∅) were administered to wild-type 
and Mas-deficient mice by osmotic mini-pumps. 
After 10 days, no differences in fasting blood glucose concentrations were detected 
between all groups of mice (Figure 6.4.6 A). The fasting plasma insulin concentrations of 
part of the wild-type mice treated with Ang-(1-7) showed a strong elevation, but did not 
reach significance compared to wild-type controls (Figure 6.4.6 B). While the fasting 
plasma insulin of Mas-deficient control mice was not altered in comparison to wild-type 
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controls, there was a significant reduction in fasting plasma insulin concentrations 
induced by Ang-(1-7) treatment in Mas-deficient mice (42.9pmol/l in knockout controls vs 
33.2pmol/l when treated with Ang-(1-7)). Notably, this reduction in plasma insulin did not 




Figure 6.4.6 Effects of continuous Ang-(1-7) administration in vivo on fasting blood 
glucose and fasting plasma insulin concentrations of WT (+/+) and Mas-deficient (-/-) 
mice compared to controls (∅)  
(A) Blood glucose concentrations (n ≥ 5) and (B) plasma insulin concentrations after 6h of fasting 
(Mann–Whitney U test; *. P < .05; n ≥ 5).  
 
 
 After 10 days of continuous administration of Ang-(1-7), the rise in blood glucose during 
OGTT identified slightly, but not significantly higher blood glucose values in Mas-deficient 
compared to wild-type mice (Figure 6.4.7 A). Ang-(1-7) was not capable of significantly 
decreasing blood glucose concentrations in WT mice (Figure 6.4.7 B) or in Mas-deficient 
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mice (Figure 6.4.7 C). The influence of a 10-day Ang-(1-7) treatment on blood glucose 
during OGTT became apparent in Figure 6.4.7 D, where differences in blood glucose 
concentrations between Ang-(1-7)-treated wild-type and Ang-(1-7)-treated Mas-deficient 
mice reached nearly significance at 30 (P = .064) and 60 min (P = .068). This resulted in a 
significantly (P = .011) increased reactive G-AUC 0 – 60 min in Ang-(1-7)-treated Mas-
deficient mice (reactive G-AUC 0 – 60: 540.4 ± 105.5 (mmol/l min)) compared to Ang-(1-7)-
treated wild-type mice (reactive G-AUC 0 – 60: 388.0 ± 84.4 (mmol/l min)). 
Relative changes of blood glucose concentrations during the first 15min after glucose 
administration (0min to 15min) were not significantly different between WT controls 
(+/+), Ang-(1-7)-treated WT and Mas-deficient (-/-) mice (Figure 6.4.7 E). Unexpectedly, 
Ang-(1-7)-treated Mas-deficient mice showed the strongest increase in blood glucose 
during the first 15min (2.8-fold increase), reaching significance when compared to 
Ang-(1-7)-treated wild-type mice (*, P = .038) (Figure 6.4.7 E). Congruent to the ex vivo 
data, plasma insulin concentrations increased 2.5-fold in WT mice treated with Ang-(1-7) 
within 15min after glucose administration, but did not reach significance (P = .089 vs 
solvent-treated WT mice) (Figure 6.4.7 F). This Ang-(1-7)-mediated increase in plasma 
insulin completely disappeared in Mas-deficient mice treated with the heptapeptide. 
Comparing the Ang-(1-7)-treated groups, there was a higher increase of blood glucose 
and a lower change in plasma insulin within 15min after glucose administration in Mas-
deficient compared to wild-type mice (Figure 6.4.7 E, F). 
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Figure 6.4.7 Effects of continuous Ang-(1-7) administration in vivo on glucose tolerance. 
Blood glucose concentrations during OGTT comparing (A) WT (+/+) (black circles, n = 5) and Mas 
KO (-/-) control mice (gray circles, n = 7), (B) WT (+/+) control (black circles, n = 5) and Ang-(1-7)-
treated WT (+/+) mice (white circles with black border, n = 5), (C) Mas KO (-/-) control mice (gray 
circles, n = 7) and Ang-(1-7)-treated Mas KO (-/-) mice (white circles with gray border, n = 7) and 
(D) Ang-(1-7) treated WT (+/+) (white circles with black border, n = 5) and Ang-(1-7)-treated Mas 
KO (-/-) mice (white circles with gray border, n = 7). Data are means with SEM. Changes in (E) 
blood glucose and (F) plasma insulin concentrations during the first 15min after glucose 
administration (Mann–Whitney U test; *. P < .05, n ≥ 4). 
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Long-term Ang-(1-7) administration in vivo affects insulin secretion from isolated islets  
To determine long-term effects of Mas stimulation on insulin secretion, islets from the 
WT and Mas-deficient mice treated 14 days with Ang-(1-7) or solvent alone were used. 
Isolated islets from WT mice exposed in vivo to Ang-(1-7) exhibited a significant increase 
in insulin secretion in response to KCl (1.8-fold) and 20mmol/l glucose (1.3-fold) when 
compared to islets from solvent-treated mice (Figure 6.4.8 A). Of note, this effect was 
observed when islets were kept in culture for 24 h without further addition of Ang-(1-7).  
 
Figure 6.4.8 Effects of continuous Ang-(1-7) administration in vivo on insulin secretion of 
isolated islets.  
KCl- and glucose-stimulated insulin secretion from isolated islets out of Ang-(1-7)-treated (A) WT 
(+/+) or (B) Mas-deficient (-/-) mice compared to their controls (∅). (Mann–Whitney U test; *. P < 
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In islets from Mas-deficient mice, previously exposed to Ang-(1-7), no such changes in the 
KCl- or 20mmol/l glucose-induced insulin secretion could be observed (Figure 6.4.8 B) in 
comparison to the saline-exposed knockouts. Nevertheless, islets from these Ang-(1-7)-
treated Mas-deficient mice showed a significantly increased basal secretion (3.6-fold) at 




The classical RAS with its ACE/Ang II/AT1 axis is a key trigger in the aetiology and severity 
of type 2 diabetes (2). It has been shown that increased Ang II levels are associated with 
the deterioration of β-cell function and adequate production and secretion of insulin 
[413, 414]. Nowadays, it is well accepted that the effects of the detrimental Ang II/AT1 
axis can be blunted or even opposed by the Ang metabolite Ang-(1-7). Therefore, it was 
implicated to investigate, whether there is, besides the fairly well established role of Ang-
(1-7) and its receptor Mas in the improvement of peripheral glucose uptake and insulin 
resistance [73, 125, 349], a considerable effect of this alternative RAS axis on the function 
of and, in particular, on insulin secretion from pancreatic β-cells. 
Using cell biological, immunohistochemical, pharmacological, and biochemical 
approaches, and also genetically modified animal models, we discovered that Ang-(1-7) is 
capable of increasing insulin release from isolated mouse islets, despite the fact that it 
lacks any effects on mRNA amounts of Ins1 and Ins2 or transcription factors which are 
crucially involved in regulating insulin gene expression. This finding together with the 
unchanged islet insulin content strongly suggests that Ang-(1-7) exerts its effects on 
insulin secretion at a post-transcriptional/post-translational level. The observation that 
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Ca2+ oscillations of isolated islets are not altered in response to Ang-(1-7) further supports 
this finding and makes the secretory machinery a likely and reasonable target of Ang-(1-
7)/Mas-dependent signalling. Our observation that even the KCl-induced insulin secretion 
is affected by A779 or Ang-(1-7) strongly supports the hypothesis of exocytosis being 
among the processes targeted by Mas ligands. 
Our finding that Ang-(1-7) augments glucose-induced insulin secretion without affecting 
glucose-induced Ca2+ oscillations strongly suggests that the heptapeptide influences 
processes downstream to Ca2+ influx. The observation that insulin secretion induced by 
KCl depolarisation of the plasma membrane is decreased in islets from Mas-deficient mice 
compared to WT further supports the hypothesis of exocytosis being among the 
processes targeted by Mas ligands. Collectively, the data suggests that Mas ligands 
primarily influence the amplifying and not the triggering pathway of the regulation of 
insulin secretion [415]. Nenquin & Henquin showed that cAMP amplifies insulin secretion 
in islets lacking functional KATP channels via direct activation of EPAC [416]. Thus, 
amplification of insulin secretion by a cAMP-dependent mechanism may also play a 
crucial role for Mas receptor-mediated augmentation of hormone release.  
In accordance with this assumption, Ang-(1-7) increased intracellular concentrations of 
cAMP in isolated islets. cAMP is a well-established key regulator of insulin secretion which 
acts via activation of cAMP-activated protein kinase (PKA) and/or exchange proteins 
activated directly by cyclic AMP 2 (EPAC 2) [417-419]. Besides regulating expression of 
target genes by modulating transcription factor activity, PKA and EPAC 2 proteins regulate 
exocytosis in various cell types, including insulin secretion from pancreatic β-cells [155]. In 
addition, cAMP-dependent phosphorylation by PKA contributes to the regulation of 
calcium-triggered exocytosis by e.g. phosphorylation of the SNARE (soluble NSF 
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attachment protein receptor) protein, SNAP-25, [420] or of the SNARE-binding protein, 
snapin [421]. Insulin exocytosis, thus, is augmented by both increased islet activity of PKA 
and by EPAC 2 signalling via mobilising insulin granules towards the plasma membrane of 
β-cells [422, 423]. However, our data implicate that the Ang-(1-7)-mediated increase in 
insulin secretion in response to high glucose concentration requires EPAC 2 activation but 
not PKA activation. Of note, that Ang-(1-7) acts via increased cAMP formation, as is the 
case with a number of the newer glucose-lowering drug classes (e.g. glucagon-like 
peptide-1 GLP-1 and its analogues), and thus in a glucose-dependent manner, would 
suggest it could be a better drug candidate than the previously used sulfonylureas.  
Interestingly, the stimulatory effects of a 14-day in vivo administration of Ang-(1-7) on 
stimulated insulin secretion (glucose- or KCl-stimulated) of isolated islets were 
maintained ex vivo even when islets were cultured without further addition of Ang-(1-7). 
Thus, Ang-(1-7)-mediated effects can be “memorised” by the islets for at least 24 hours.  
Despite the clear effects of Ang-(1-7) on stimulated insulin secretion of isolated islets, the 
observed effects in vivo on glucose homeostasis and plasma insulin concentrations 
remained marginal. This might be partly explained by the dose of Ang-(1-7) used based on 
literature data. It might not be the most effective dose and perhaps lower or higher 
concentrations may lead to more pronounced signals. Finally, the in vivo experiments 
were performed in healthy animals with naturally well-balanced glucose homeostasis. It 
can be thus hypothesised that the beneficial effects of Ang-(1-7) become more obvious in 
preclinical models of diabetes mellitus (data see Chapter 10.3). This idea is also supported 
indirectly by findings that tissue-nonspecific overexpression of ACE2 led to a slight 
reduction in blood glucose concentration in db/db mice, a model of type 2 diabetes, 
whereby ACE2 did not improve the glucose uptake in these mice, but instead led to an 
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increase in insulin concentration in the blood after glucose administration [424]. The 
ACE2 effect is also supported by our immunohistochemical data showing that ACE2 is 
predominantly expressed on β-cells. It might thus influence insulin secretion by 
generating locally Ang-(1-7) that can stimulate Mas there, as its expression on β-cells has 
been demonstrated, too. 
It should be also stated that the potential Ang-(1-7) effects on the process of insulin 
secretion will be accompanied in the long-term by other beneficial effects of the 
heptapeptide on islet function. Exemplarily, Ang-(1-7) improved the intra-islet 
microvascular density, reduces apoptotic islet cells and increased iNOS expression and NO 
release in a rat model of type 2 diabetes [413, 425]. 
Furthermore, as a substantial number of studies over the past five decades have clearly 
demonstrated that β-cell mass is reduced in patients with type 2 diabetes [426], the 
possibility that Ang-(1-7) therapy may not only improve pancreatic cell function but also 
increase cell mass in patients with type 2 diabetes might therefore generate even more 
excitement. This is supported by data showing substantial effects of Ang-(1-7) on stem 
and progenitor cells [374], and immuno-histochemical images indicating an increase in 
the proliferation of β-cells and an increase in the cell surface per islet in ACE2-
overexpressing mice [424]. Furthermore, bone marrow and circulating endothelial 
progenitors, as well as bone marrow mesenchymal stem cells, were increased in db/db 
mice treated with Ang-(1–7) [427]. 
One of the most interesting findings presented in the present study is the identification of 
Mas-independent Ang-(1-7) function as illustrated by effects of the heptapeptide in Mas-
deficient mice and on islets isolated from such animals. Although there are already 
indications for further Ang-(1-7) receptors based on pharmacological approaches using 
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either different Ang-(1-7) antagonists [357] or receptor transfected cells  [65], it remains a 
very interesting challenge to identify the second receptor Ang-(1-7) can act through when 
affecting β-cell function. Very recently, the authors identified a second receptor for Ang-
(1-7), MrgD [378], which could be a potential candidate for mediating the Mas-
independent effects of the heptapeptide. This hypothesis is also supported by the finding 
that the Ang-(1-7) antagonist, D-Pro7-Ang-(1-7), which has been shown to block both, Mas 
and MrgD, can abolish the Ang-(1-7)-mediated stimulation of insulin secretion, while the 
more Mas-specific antagonist, A779, was much less efficient. This deserves to be 
extensively studied in future work.  
Taken together, clinically established glucose-lowering medications act either via 
increased insulin sensitivity and thus more efficient uptake of glucose (insulin sensitisers 
such as metformin and thiazolidinediones) or by increasing insulin secretion from 
pancreatic β-cells (insulin secretagogues such as sulfonylurea). Our data identify Ang-(1-7) 
as a molecule that can act via both mechanisms, representing a new and promising 
strategy for the treatment of diabetes mellitus, not only improving peripheral insulin 
resistance but also the β-cell function in the form of an adequate glucose-stimulated 
insulin secretion.  
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7 General discussion 
Over the past decades, the knowledge about the RAS has substantially improved. 
However, there are still biological effects of the peptides that cannot be explained with 
the existing knowledge about the structure of the RAS. It is clear that our current 
understanding of the RAS is still incomplete. Complex signalling pathways and the 
continued increase of members (peptidases, peptides, receptors) within the RAS is 
complicating the research. Additionally, the RAS activates pathways with opposing 
biological actions. On the one side we have the often detrimental ACE/ Ang II/ AT1 axis, 
and on the other side the protective ACE2/ Ang-(1-7)/ Mas axis. 
 
7.1 cAMP is the primary second messenger activated by 
Ang-(1-7) 
Ang-(1-7) is a heptapeptide with a lot of beneficial effects, such as vasorelaxation [104-
109], anti-fibrosis [78, 95], neuro protection [111, 119] and anti-proliferation [133-135, 
137-139]. The lack of knowledge about a second messenger stimulated by Ang-(1-7) 
hindered the confirmation of the Ang-(1-7) receptor and investigations of receptor 
pharmacology. Until now, specific blockers such as A779, D-Pro and PD123319, have been 
used to define the receptors through which Ang-(1-7) mediates its effects. Therefore I 
aimed to identify a second messenger to better investigate the receptor targeted by 
Ang-(1-7).  
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In recent studies, Liu et al., and Tallant and Clark described that Ang-(1-7) is able to 
stimulate the increase of intracellular cAMP in rat MC [141] and VSMC [133], respectively, 
suggesting cAMP as a potential second messenger. This work (published July 2016) 
confirms that Ang-(1-7) can indeed increase cAMP in several cell types such as MC, VSMC 
(Figure 6.1.1 A and D) and HUVEC (Figure 6.1.2 A).  This increase in intracellular cAMP was 
not mediated by the inhibition of PDE activity, which is responsible for cAMP degradation, 
since the treatment with IBMX (PDE inhibitor) had no effect on the intracellular cAMP 
levels (Figure 6.1.2 C) stimulated by Ang-(1-7). The AC inhibitor, SQ22536, inhibited the 
increase in cAMP (Figure 6.1.2 D), also confirming that the cAMP increase is mediated by 
AC and not by PDE inhibition. Furthermore, the increase in intracellular cAMP levels also 
mediated further downstream signalling. PKA activity (Figure 6.1.2 E) and CREB 
phosphorylation (Figure 6.1.5 A and B) were increased after Ang-(1-7) stimulation, 
confirming that the cAMP signalling pathway leads to further intracellular responses.  
Besides the PDEs, intracellular cAMP concentrations are also regulated by the transport of 
cAMP into the extracellular space through a specific transport system, which belongs to 
the ATP-binding cassette (ABC) transporter superfamily [428]. The existence of 
extracellular cAMP could be shown for several cell types such as vascular smooth muscle 
cells [429], pulmonary arteries [430] and cardiac myocytes [431]. Extracellular cAMP 
might be able to act as an extracellular signalling molecule [432].  Thus, the level of cAMP 
efflux in the cell types used in this study should be investigated, as cell type specific 
alteration of the cAMP efflux might interfere with the intracellular cAMP concentrations. 
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Despite this, the identification of cAMP as a second messenger activated by the 
heptapeptide will be a helpful tool for further investigations regarding Ang-(1-7) and its 
receptors. 
 
7.2 Mas is a functional receptor for Ang-(1-7) 
For more than a decade, the receptor for Ang-(1-7) remained undiscovered. Initially, AT2 
had been thought to be an Ang-(1-7) receptor. However, the heptapeptide has only low 
affinity to the AT2 receptor [64], but there were reports that Ang-(1-7) effects could be 
blocked by PD123319, a compound which has been assumed to be AT2 specific [433, 
434].  First it was believed that Mas is a receptor for Ang II, but neither binding nor 
signalling could be shown [61]. In 2003, Santos et al. were able to demonstrate that Mas 
is the receptor for Ang-(1-7). They showed that the Ang-(1-7) mediated effects could be 
blocked by A779, a Mas specific antagonist, while Ibersartan (AT1 blocker) or PD123319 
(AT2 blocker) failed to block the Ang-(1-7) mediated effects, indicating that AT1 or AT2 
were not involved in such processes. In addition, aortic rings isolated from animals lacking 
the Mas receptor did not show any response towards stimulation with the heptapeptide 
peptide, which was able to generate vasorelaxation in wild-type aortas [62].  
However, the detailed molecular mechanism behind the Mas signalling mediated by Ang-
(1-7) remained unknown. Most of the studies from the past years were focused on the 
analysis of in vivo/ ex vivo function (e.g. vasorelaxation, fibrosis, endothelial function) [99, 
100, 114] or downstream signalling like AA release and Ca2+-independent activation of 
NOS via PI3K. [62, 65, 232]. Therefore, the aim of this study was to investigate if Mas is a 
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functional receptor for Ang-(1-7) and if cAMP is the secondary messenger activated by 
stimulation with the heptapeptide. It was possible to confirm that Mas is indeed a 
functional receptor for the heptapeptide, as Ang-(1-7) was able to increase intracellular 
cAMP in a dose depended matter (Figure 6.1.4 A). This also illustrates that Mas couples 
not just to Gɑq/11 [240], but also Gαs. 
 
7.3 MrgD is a receptor for Ang-(1-7) 
Interestingly, in contrast to the work performed by Santos et al. in 2003, the increase in 
cAMP in MC, HUVEC and VSMC was not just blocked by A779, but also PD123319 and D-
Pro (Figure 6.1.1 B, D and  Figure 6.1.2 A). Since PD123319 is assumed to be an AT2 
specific blocker [190-192] and D-Pro is known to block MrgD [42] and Mas [65, 254], I 
raised the hypothesis that the increase in cAMP in MC, HUVEC and VSMC was not just 
Mas related, but might also involve other receptors. Thus, the aim was to identify I Ang-
(1-7) can also activate other G-protein coupled receptors. 
Gembardt at al. were previously able to show that Ang-(1-7) could increase AA release 
not just in Mas-transfected, but also in Mrg and MrgD-transfected cells [65]. This finding 
confirms that the high similarity between the Mas like family [65, 215], makes it very 
likely that not just Mas, but also other members of this family might be receptors for Ang-
(1-7). These two facts and my previous finding that D-Pro can block the Ang-(1-7) 
mediated cAMP increase in MC, HUVEC and VSMC led to the conclusion that MrgD might 
be another candidate as an Ang-(1-7) receptor. 
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Indeed, this study was able to demonstrate that not just Mas, but also MrgD is a receptor 
for Ang-(1-7). Using HEK293 cells transfected with the receptors of interest (Mas, MrgD, 
Mrg and AT2), it was possible to demonstrate that Ang-(1-7) is able to increase 
intracellular cAMP, not just in cells expressing Mas, but also MrgD (Figure 6.2.3 A). Both 
Mas and MrgD, had a comparable dose dependent increase in cAMP after Ang-(1-7) 
stimulation (Figure 6.1.4 A and C).  
The fact that the AA release was increased in Mrg-transfected cells [65], but not cAMP 
(Figure 6.2.3 A) confirms that both pathways do not necessarily correlate with each other, 
as AA release PLA2 mediated and Gαs independent [435]. Consequently, other members 
of the Mas family, which did not respond to the heptapeptide with an increase in AA 
release, might still respond with an increase in intracellular cAMP.  Additionally, 
considering the high homology between the Mas-like receptors, the possibility is high that 
other members might also be functional Ang-(1-7) receptors. Therefore, the next step 
would be to screen other receptors of the Mas like family for a response to Ang-(1-7). 
 
7.4 Ala1-Ang-(1-7) can also act through the Mas receptor 
Like Ang-(1-7), Ala1-Ang-(1-7) is able to counteract effects mediated by Ang II and has 
beneficial effects such as vasorelaxation, being anti-hypertrophic, anti-hypertensive and 
anti-fibrotic [42, 246, 250]. Lautner et al. were the first who described and characterised 
Ala1-Ang-(1-7) in 2013 [42]. They were able to demonstrate that this heptapetide acts 
through the Mas-like receptor MrgD, but not Mas [42]. Compared to Ang-(1-7), the 
number of publications on Ala1-Ang-(1-7) over the past 5 years is very small, indicating 
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that still very little is known about the peptide that has been described as endogenously 
occurring in human plasma [42].  Furthermore, the existing publications on Ala1-Ang-(1-7) 
focus on the physiological function of the peptide (in vivo, ex vivo) [42, 249-251], for 
example vasorelaxation. Just very few publications dealed with the intracellular effects 
(for example NO, and AA release) [42, 251].  
However, the fact that MrgD, and not Mas, is the receptor for Ala1-Ang-(1-7) was 
accepted and never questioned over the past years. With the recent identification of 
cAMP as a second messenger increased by activation of Mas and MrgD, a potential tool 
was given to further investigate the receptors for Ala1-Ang-(1-7). The previous finding that 
Ang-(1-7) can also stimulate MrgD, and the fact that both peptides interact with their C-
terminal ends with the receptor, and with that should have comparable interactions, rose 
the hypothesis that Ala1-Ang-(1-7) might also stimulate Mas. Therefore, the aim of the 
study was to investigate, whether Ala1-Ang-(1-7) is also able to stimulate the Mas 
receptor. Firstly, I needed confirmation that MrgD is a functional receptor for Ala1-Ang-(1-
7). Consequently, I also aimed to investigate if Ala1-Ang-(1-7) is able to increase 
intracellular cAMP levels in MrgD transfected cells. It was possible to confirm that MrgD 
indeed is a functional receptor for Ala1-Ang-(1-7). The peptide increased intracellular 
cAMP and this effect was dose dependent (Figure 6.2.2 A). More importantly, Mas could 
be identified as a second functional receptor for the heptapeptide (Figure 6.2.3 A), 
disproving the findings made by Lautner et al. that Ala1-Ang-(1-7) is not able to target 
both receptors [42]. Using MC derived from animals lacking Mas or MrgD, or both 
receptors, the final proof that both Mas and MrgD are important for Ala1-Ang-(1-7) 
mediated effects was received. The MC derived from single knockout animals still showed 
a significant increase in cAMP, which was, however, lower compared to the WT signalling 
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(Appendix part 1: Figure 10.2.1 ). This confirmed that Mas and MrgD are important for 
the Ala1-Ang-(1-7) mediated cAMP increase in MC. Furthermore, the MC derived from the 
double knockout animals have not been able to respond to Ala1-Ang-(1-7) stimulation 
(Figure 6.2.4 C), confirming the previous finding. The finding that Ala1-Ang-(1-7) is not 
MrgD specific interferes with the therapeutic options, as Lautner et al. described the 
increase of Ala1-Ang-(1-7) under pathophysiological conditions [42]. 
The effects on cAMP generation mediated by Ala1-Ang-(1-7) in Mas and MrgD transfected 
cells is comparable. Both dose response curves are bell shaped and the EC50 values are 
comparable (Figure 6.2.2 A and Figure 6.2.3 A). Lautner et al. described in their 
experiments that the vasodilatory effect of Ala1-Ang-(1-7) could not be blocked by A779 
[42]. However, in our experiments, it was possible to block the Ala1-Ang-(1-7) mediated 
cAMP increase in MC and HUVEC with A779, D-Pro and PD123319 (Figure 6.2.1 B and 
Figure 6.2.4 B), further indicating that other receptors, apart from MrgD, are involved in 
the  Ala1-Ang-(1-7) mediated cAMP increase. 
As for Ang-(1-7), the next step would be to screen the Mas like family, as also other 
members might be functional receptors for Ala1-Ang-(1-7).  
 
7.5 Ang-(1-7) and Ala1-Ang-(1-7) possess different 
pharmacodynamics 
Besides the very similar physiological effects of Ang-(1-7) and Ala1-Ang-(1-7) [42, 246, 
250], the results demonstrate that the pharmacological properties are different. The dose 
 _______________________________________________ General discussion 
181 | P a g e  
 
response curve generated with Ala1-Ang-(1-7) is shifted leftwards (lower EC50) compared 
to the one from Ang-(1-7) (Figure 6.2.1 A), indicating a better potency of Ala1-Ang-(1-7). 
Furthermore, the shape of the dose response curves are significantly different (Figure 
6.2.1 A). The bell shaped curve generated by Ala1-Ang-(1-7) indicates the peptide has an 
optimum range of concentration where it shows its being most effective. However, what 
causes this shape of the curve? The G-protein responsible for inhibiting cAMP is Gαi, and 
MrgD is known to couple to Gαi [253]. Therefore, it was hypothesised that Gαi might be 
activated when higher concentrations of Ala1Ang-(1-7) are used. It is not uncommon, that 
one compound can activate different G-proteins. Beyermann et al. [390] confirmed this 
model by using the corticotropin-releasing factor receptor type 1. They demonstrated 
that native ligands stimulated Gαi and Gαs proteins. Indeed, PTX, a potent Gαi inhibitor, 
was able to prevent the reduction of cAMP at higher concentrations of Ala1-Ang-(1-7) 
(Figure 6.2.2 C and Figure 6.2.3 C), confirming that Gαi is involved in the signalling 
mediated by this peptide. The discovery that one compound can activate two different G-
proteins in both receptors is very important, as future non-peptidic agonists should be 
designed in a way that Gαi activation is avoided. 
As Ang-(1-7) and Ala1-Ang-(1-7) are very similar, another question arose: how can the 
difference in potency be explained? First, it was thought that the lack of the carboxylate 
group might releases more energy during interaction with the receptor, but our computer 
model could not confirm this. However, the computer analyses performed by 
collaborators showed, that the missing carboxylate group can stabilize the binding to the 
receptor and that this the reason that Ala1-Ang-(1-7) is more potent than Ang-(1-7). 
While, the negatively charged carboxylate in Asp1 of Ang-(1-7) prevents the interaction 
with a positive chemical group in the receptor (see Figure 6.2.5). Consequently, this 
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knowledge about the interactions of both peptides with the Mas receptor gained from 
this model, will lay a foundation for a screening program to identify agonists stimulating 
either one or both of the receptors. 
 
7.6 The AT2 specific blocker, PD123319, also blocks Mas 
and MrgD 
In AT2 transfected HEK293 cells, Ang-(1-7) failed to increase cAMP (Figure 6.1.3). 
Nerveless, PD12219 was able to block the effects in MC and HUVEC cells, indicating an 
involvement of AT2. However, if AT2 is not responsible for the cAMP increase in those cell 
types, why does PD123319 block the Ang-(1-7) mediated cAMP increase? Additionally, 
other researchers described that under certain circumstances, PD123319 is able to block 
Ang-(1-7) mediated effects [433, 434].  Might PD123319 be not AT2 specific, as it has 
been claimed all the years [190-192]? Indeed, it was possible to demonstrate that this is 
the case. In HEK293 cells expressing Mas or MrgD, PD123319 was able to block the Ang-
(1-7) mediated cAMP increase (Figure 6.1.4 B and D). Furthermore, PD1222139 cannot 
just block Ang-(1-7) mediated cAMP, but also Ala1-Ang-(1-7) mediated effects on cAMP  
levels in Mas or MrgD transfected HEK293 cells (Figure 6.2.2 B and Figure 6.2.3 B).  This 
unspecific receptor profile of PD123319 is not surprising anymore, if its structure is 
compared to Ang-(1-7). PD123319 can be embedded in bioactive conformation of Ang-(1-
7) when it is bound to the Mas receptor (Figure 6.1.6 F).  It displays chemical similarities 
to Ang-(1-7), implicating that both molecules fit into the two Ang-(1-7) receptors, 
whereby PD123319 fails to stimulate intracellular signalling. 
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However, the identification of PD123319 being not AT2 specific has further 
consequences. Papers, which conclude on AT2 function by just using PD123319, might 
need to be re-evaluated, as Mas and MrgD might also be involved in the observed effects. 
But it also might give an explanation for cases where PD123319 was not able to block 
Ang-(1-7) mediated effects. 
 
7.7 The AT2 specific compound C21 also stimulates Mas 
and MrgD 
Since its discovery in 2004 by Wan et al. [185], C21 is widely used to identify and define 
the in vivo function of the AT2 receptor. C21 is claimed to be a highly specific AT2 
receptor agonist and is already used in a wide range of preclinical trials [186-188]. 
Furthermore, this small non-peptidic molecule has a good oral availability, and was very 
well tolerated in phase I studies performed by Vicore-Pharma, the company owning the 
patent for C21 [436].  
Since studies have shown that the Mas receptor blocker A779 can prevent the protective 
C21 effects in an ischemic stroke model [398], and the previous finding that PD123319 
was not AT2 specific, the specificity of this compound is also questionable. Furthermore, 
the chemical structures of C21 and the Mas-specific agonist AVE0991 are very similar as 
Villela et al. [398] and we could demonstrate. The in silico modelling (Figure 6.3.6 A and B) 
in collaboration with Intelligent Pharma illustrates the similarities and differences 
between C21 and AVE0991, the first non-peptidic agonist for the Mas receptor [65], 
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which is another point to speculate that C21 is also able to stimulate the Mas receptor. 
Therefore, it was hypothesised that C21 might be also able to stimulate Mas and MrgD. 
Indeed, in this study it was possible to show that Mas and MrgD are both functional 
receptors for C21. The compound stimulated an increase in intracellular cAMP in MC and 
this effect was abolished by A779, D-Pro and PD123319, indicating that not just AT2, but 
also Mas and MrgD were involved (Figure 6.3.3 A and B). HEK293 cells transfected with 
Mas or MrgD (Figure 6.3.1 A and Figure 6.3.2 A) also showed an increase in intracellular 
cAMP, confirming that both receptors are stimulated by C21. Interestingly, the dose 
response curves observed in Mas and MrgD were different. Mas showed a bell shaped 
dose response curve (Figure 6.3.1 A), like for Ala1-Ang-(1-7), whereas the dose response 
curve in MrgD transfected cells was sigmoidal (Figure 6.3.2 A), like for Ang-(1-7). There is 
no distinct explanation for this behaviour so far. One reason might be that beside the 
structural similarities of both receptors, C21 interacts slightly different with MrgD than 
with Mas. The involvement of Gαi was excluded, as C21 failed to increase the luciferase 
signal in HEK293 cells co-transfected with Mas and an Elk1-promotor, a downstream 
effector of Gαi (Figure 6.3.1 E). However, the observed intracellular cAMP increase was AC 
mediated, as it could be blunted by the AC inhibitor, SQ22536 (Figure 6.3.1 C). C21 
stimulates different receptors in primary cells, which was further confirmed by using a 
second cell type, HUVEC. Figure 6.3.5 A shows a biphasic dose-response curve. The two 
maximum peaks correspond to the peaks in Mas (10-10 M) and MrgD (10-7 M)-transfected 
cells (Figure 6.3.1 A and Figure 6.3.2 A). There is no pharmacological proof existing that 
this is really Mas and MrgD mediated, as no specific blocker for the C21 mediated effect 
exists. 
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Using mesangial cells derived from animals not expressing AT2, the final proof that C21 is 
not AT2 specific was obtained. The cells were still able to respond to C21 stimulation with 
an increase in cAMP (Figure 6.3.3 C). This was confirmed using western blot analysis. AT2 
KO cells still showed an increased CREB phosphorylation after 15min of stimulation with 
C21 (Figure 6.3.4 B). This was also confirmed by using wester blots analysing the 
phosphorylation of PKA substrates (Figure 10.2.2 A and B), as AT2 KO cells still showed an 
increase in the phosphorylation of PKA substrates. Interestingly, in double knockout 
mesangial cells, lacking Mas and MrgD, the signal was not completely blunted, but lower 
than in untreated cells (Figure 6.3.3 C). This drop in Mas/ MrgD-deficient cells allows the 
interpretation of the observation made in AT2-deficient mesangial cells. The increase by 
C21, which is slightly above the level from the untreated cells, might be in reality much 
higher, considering the negative value from the DKO cells. The cAMP-lowering effect 
might be caused be a Gαi coupled receptor, which is also stimulated by C21. Because of 
the structural similarity, one possibility is that a member from the Mas like family also 
responses to C21. Final proof of this fascinating hypothesis could be generated with cells 
deficient in Mas/MrgD and AT2, where any drop in intracellular cAMP after C21 
stimulation would relate to such a postulated unknown receptor. 
Furthermore, it might also be interesting to investigate in follow-up experiments, 
whether in reverse conclusion AVE0991 is not Mas-specific, but can, similar to C21, also 
stimulate MrgD and AT2. 
Taken together, these results improve the understanding of the function of the AT2 
receptor under physiological and pathophysiological circumstances. Concluding on AT2 
function by just using C21 might be incorrect. Publications, which conclude on AT2 
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receptor effects using only C21 need to be re-evaluated, like with PD123319, Mas and 
MrgD might also be involved. Furthermore, the identification of cAMP being regulated by 
C21 will help with the the prediction of potential applications of C21 by identifying 
diseases where elevation of cAMP is assumed to be beneficial, and where target organs 
express either Mas, MrgD or AT2.  
 
7.8 Ang-(1-7) improves beta cell function 
It is well known that the RAS and blood glucose are highly connected. As increased blood 
glucose levels can activate the RAS through several mechanisms [325-331] (Chapter 
4.3.7), it is no surprise that the manipulation of the RAS might be a useful tool to treat 
DM. Many studies could already demonstrate that the blockage of the ACE/ Ang II/ AT1 
axis and the activation of the ACE2/ Ang-(1-7)/ Mas has beneficial effects on glucose 
homeostasis and other DM related symptoms (Chapter 4.3.7). However, many of the 
molecular mechanisms remained unclear. Therefore the aim of this study was to examine 
which molecular mechanism might be involved in the Ang-(1-7) mediated effects in DM. 
Together with our collaborators, we were able to show that Ang-(1-7) can improve the 
insulin secretion in β-cells (Figure 6.4.3 A). Furthermore, this effect was mainly Mas 
dependent, as animals lacking the Mas receptor had a decreased insulin secretion (Figure 
6.4.5 A).  
In addition, cAMP was shown to be the primary secondary messenger responsible for 
Ang-(1-7) mediated insulin secretion (Figure 6.4.4 C). Like in our MC the downstream 
signalling resulted in an activation of PKA, as the increase in PKA phosphorylation 
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confirms (Figure 6.4.4 E). However, as the increase in insulin secretion in islets isolated 
from WT mice could be blocked by an EPAC inhibitor (HJC), but not by a PKA inhibitor 
(H89) (Figure 6.4.4 D and E), indicating that EPAC activation is necessary for insulin 
secretion and not PKA activation. With that, we not only confirmed that Ang-(1-7) has 
beneficial influence on Mas, as other groups already reported [340], but we also 
demonstrated that Mas is involved, and that cAMP is the major second messenger 
activated. 
Although the effects observed in the in vivo studies remained marginal (Figure 6.4.6 A), it 
was possible to show that Ang-(1-7) has beneficial effects on the insulin secretion in β-
cells (Figure 6.4.6 B). Furthermore, this effect showed to be Mas specific, as there was no 
change of insulin secretion in Ang-(1-7) treated animals lacking the Mas receptor (Figure 
6.4.6 B).  This in vivo results might be partly explained by the dose of Ang-(1-7) used 
based on literature data. It might not be the most effective dose and perhaps higher 
concentrations may lead to more pronounced signals. Additionally, the in vivo 
experiments were performed in healthy animals with a well-balanced glucose 
homeostasis. It may be hypothesised that the beneficial effects of Ang-(1-7) become 
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7.9 Ang-(1-7) does not improve the blood glucose levels in 
STZ induced diabetic animals 
Many studies could show that the ACE2/Ang-(1-7)/Mas Axis counteracts Ang II/ AT1 
mediated effects, and also has beneficial effects on DM and associated symptoms as 
described in Chapter 4.3.7.  As there was no effect on the basic blood glucose levels in 
healthy animals (Figure 6.4.6), it was concluded that Ang-(1-7) mediated effect on insulin 
secretion might just be occur under pathophysiological conditions. For this purpose, STZ-
induced diabetic mice were used for further investigations. This model was chosen 
because 1) data provided by Invitek (Figure 10.3.1) and 2) we could use our knockout 
animals. 
The in vivo experiments failed to confirm findings from other researchers, which 
demonstrated that Ang-(1-7) has positive effects on BG levels [73, 349, 350]. There was 
no significant effect on BG levels in animals expressing the Ang-(1-7) receptors, or those 
which lack Mas, MrgD or both receptors (Appendix Part 1: Figure 10.3.2 and Figure 10.3.3 
A-D). Higher concentrations of Ang-(1-7) (2 mg/kg) showed also no beneficial effect, in 
fact they significantly worsened the BG levels (Appendix part 1: Figure 10.3.5). 
Furthermore, 0.5 mg/kg Ang-(1-7) treatment also resulted in an increase in BG levels 
compared to WT, over the whole time of treatment, which is contradictive to the results 
shown in Figure 10.3.3 A. In addition, the spleen and the heart were affected by the high 
glycaemic conditions. The weight of the organs from the high dose Ang-(1-7) treated 
group was significantly lower compared to the control group (Appendix part 1: Figure 
10.3.6). It is well known that high BG levels cause long-term damage of end-organs. 
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Diabetic cardiomyopathy is one example [336, 337], but the spleen also can be affected. A 
study in STZ-induced diabetic rats described that the hyperglycaemia resulted in a 
decrease in the weight of the spleen [437]. Thus, the observed decrease in the weight of 
the heart and the spleen might be a result of the more severe diabetes those animals 
developed compared to the untreated group. 
These findings are contrary to the ones reported in the literature, where mainly beneficial 
effects of Ang-(1-7) on the glucose homeostasis could be described [73, 349, 350], but 
also to the results from the preliminary study performed by Invitek, which showed that 
Ang-(1-7) significantly reduces BG levels (Appendix Part 1: Figure 10.3.1). Besides using 
finally the same standardised protocol in our study and the study performed by our 
collaborator in America used before, we still did not see the same beneficial effects of 
Ang-(1-7) as they described (Figure 10.3.1). This might be explained with the conditions 
the animals were held. Our facility might have used a different food, or exposure to 
pathogens happened (animals were not hold behind completely sterile barrier), which 
could have led to different results, as those animals are very sensitive to external factors. 
On the other hand, other publications also reported that Ang-(1-7) did not affect the BG 
levels in STZ-induced diabetic rats [438, 439], but still was beneficial against diabetic renal 
injury [439].  
Additionally, the data also indicates that endogenous Ang-(1-7) has also no important 
effect in the aetiology of T1DM, as there was no detrimental effect on the BG levels in 
animals lacking Mas, MrgD or both receptors. If Ang-(1-7) would play a role in the 
development of DM, at least the animals lacking both receptors should show a higher 
increase in BG levels compared to WT animals. Taken together, the results from this study 
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confirm, that Ang-(1-7) mediates beneficial effect under high glycaemic conditions, 
without affecting BG levels. 
However, also other reasons might have caused contradictive results to the Invitek-study. 
If we compare the maximum of BG levels reached in our animals with those of the 
animals from the Invitek-study, we see that they are higher in the Cork-setting. This more 
severe diabetic stage might have prevented that Ang-(1-7) treatment was effectiv. In the 
future, lower dose of STZ should be tested to prevent the strong increase in BG levels. 
Another reason might be the concentration of Ang-(1-7) used. As higher concentrations of 
the heptapeptide worsened the BG levels (Appendix part 1: Figure 10.3.5), lower 
concentrations should be tested as well in the future. It could be that higher 
concentrations of Ang-(1-7) activate other receptors, which counteract the beneficial 
effects mediated by Ang-(1-7)/ Mas/ MrgD. Furthermore, fasted BG levels were not 
measured, the animals had always access to food. Thus, more variation was generated, 
because the weaker mice could not drink or eat, which resulted in lower BG caused by the 
lack in food intake, while the less sick animals could still eat, resulting in higher BG levels. 
In the future, fasted BG should be measured to exclude those variations.  In addition, 
compounds such as C21 and Ala1-Ang-(1-7) should be investigated in the future, as they 
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8 Conclusion 
This study, significantly contributed to an expansion and refining of the RAS (Figure 7.9.1). 
It was possible to demonstrate that: 
1) Mas is a functional receptor for Ang-(1-7) 
2) cAMP is the primary second messenger 
3) MrgD is also stimulated by Ang-(1-7) 
4) Ala1-Ang-(1-7) also stimulates the Mas receptor 
5) The AT2 specific antagonist, PD123319, also blocks Mas and MrgD 
6) The AT2 specific agonist C21 also interacts with Mas and MrgD 
The experiments with Ala1Ang-(1-7) makes it clear that even a tiny change in the 
molecular structure of an agonist (here Ang-(1-7)) can create a significant change of its 
pharmacological properties. The gained understanding of the interaction of compounds 
like PD123319, C21, Ala1-Ang-(1-7), and Ang-(1-7) with AT2, Mas and MrgD, can be used 
as a foundation for the development of further agonists, especially non-peptidic small 
molecules, with better potency and specifity.  This will lead to the development of 
pharmaceutical compounds with less side effects, caused by unwanted activation or 
inactivation of other receptors. Furthermore, our findings enforce the revisit of such 
publications, which concluded on AT2 function by only using C21 or PD123319, or both.  
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Figure 7.9.1 The renin-angiotensin system before 2014 and now 
Schematic overview of the RAS before 2014 to now. The blue, black and grey lines show 
the connections, how they were known. Red lines and arrows indicate the new findings.  
 
Additionally, it was not just able to revise the RAS as shown in Figure 7.9.1 and it was also 
possible to improve the understanding of the mechanism of the beneficial effects of Ang-
(1-7) on blood glucose regulation. Although the effects observed in the in vivo studies 
 _____________________________________________________ Conclusion 
193 | P a g e  
 
remained marginal and contradictive, it was possible to show that Ang-(1-7) has beneficial 
effects on the insulin secretion from β-cells. Furthermore, we demonstrated that this was 
mediated through Mas and cAMP and the downstream activation of EPAC and not PKA.  
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9 Perspectives 
The discovery of cAMP as the primary second messenger will be a useful tool to screen 
for further receptors involved in the Ang-(1-7) mediated signalling, and will also help to 
identify compounds, which might be able to stimulate the same signalling as the 
heptapeptide. The data, which will be collected from those experiments, will help in the 
future to create in silico models to identify non-peptidic, small molecules with high 
efficacy and potency, which can be tested using cAMP as a readout. 
The finding that Ang-(1-7) and Ala1-Ang-(1-7) stimulate both Mas and MrgD, but have 
different pharmacodynamics, illustrates that minor changes in Ang-(1-7) (decarboxylation 
on amino acid 1) can lead to major changes in the agonist-receptor interaction. 
Additionally, the finding that C21 can stimulate all three receptors (Mas, MrgD and AT2), 
while Ang-(1-7) and Ala1-Ang-(1-7) just stimulate two of them (Mas and MrgD), will help 
to understand what structural pattern is required to stimulate all three receptors, or only 
one or two of them. Mutagenesis studies might also be helpful to refine the 
understanding of the interaction of the compounds (agonists and antagonists) with the 
receptors, and also for the screening of non-peptidic compounds. The in silico and in vitro 
studies lay the foundation for the development of new non-peptidic analogues, which can 
generate a more potent and selective stimulation of any of the three receptors. That will 
lead to safer and more efficient treatment options for an increasing number of diseases in 
which And-(1-7) and potential analogues might be beneficial. Furthermore, the 
identification of receptor-specific analogous will also allow a more specific treatment 
tragedy   in diseases where only one of the receptors is expressed in the tissue of interest. 
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Future experiments should also focus on the screening of the Mas like receptor family, as 
the structural similarity increases the possibility that also other members might be 
functional receptors for Ang-(1-7) and/ or other angiotensin peptides and non-peptidic 
agonists such as C21. The involvement of one of these receptors might be an explanation, 
why especially in the kidney contradictive effects have been observed.  
Although Ang-(1-7) appears to have beneficial effects on diabetes mellitus (insulin 
secretion and β-cell function), many questions remain open due to the discrepancy 
between the data provided by Invitek and the results obtained in this study. There is no 
doubt that the significant effects of Ang-(1-7) on the hyperglycaemic status in STZ-
induced diabetic mice described by Invitek are real. However, that this could not be 
confirmed in Cork, points to upcoming work, identifying the reason for the efficacy of the 
heptapeptide only under certain experimental conditions and the conditions in the animal 
facility. This will help to set treatment regimes in the future to maximise the Ang-(1-7) 
effects. Furthermore, the evaluation of the study needs to be extended. As the treatment 
with the heptapeptide might have protective effects against diabetic related end organ 
damage. Therefore, the functional analysis of those organs should be included. On 
possibility would be using non-invasive methods such as measuring the blood pressure or 
the glomerular filtration rate. Additionally blood and urine could be examined considering 
albuminuria (albumin-creatinine ration in the urine), blood-urea-nitrogen and blood 
cholesterol (elevated if the kidney is damaged). Moreover, qPCR analysis regarding renin 
expression in kidney tissue, and fibrosis marker for heart/ kidney tissue will be helpful to 
determine the grade of organ damage.  In addition, plasma insulin levels should be 
measured, as the ex vivo experiments could show that Ang-(1-7) had beneficial effects on 
insulin secretion itself.  Finally using histological methods, organs such as pancreas (β-cell 
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damage) heart (regarding fibrosis), kidneys (diabetic nephropathy) and eyes (diabetic 
retinopathy) need to be further investigated. The choice of model may be re-evaluated, 
as there might be a better model available to investigate the effect of Ang-(1-7) on blood 
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10 Appendix part 1: Supplemental data 
10.1 Proof of successful overexpression of Mas and MrgD 
in HEK293 cells 
To confirm the overexpression of both receptors and to illustrate transfection efficacy, 
qPCR analysis was performed for all experiments to measure the amount of receptor 
mRNA in MrgD and Mas-transfected cells. As shown in Figure 10.1.1 A, transfection with 
Mas or MrgD plasmids led to a significant overexpression of the receptor mRNA. 
 
Figure 10.1.1 Successful overexpression of Mas and MrgD in HEK293 cells 
(A) Average of mRNA amounts from all experiments of Mas and MrgD-transfected HEK293 cells 
(pcDNA3.1 values are set as 1). (B) Fluorescence microscopy of HEK293 cells transfected with Mas-
mCherry (red) and MrgD-GFP (green).  
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The analysis of protein levels of both receptors using western blot analysis failed, as none 
of the commercially available antibodies worked (still signals generated in samples 
derived from receptor deficient mice). To finally visualise the transfection efficacy on 
protein level, HEK293 cells were transfected with Mas-mCherry or MrgD-GFP as seen in 
Figure 10.1.1 B. In transfected cells carrying the receptor cDNA, both receptors are 
expressed in the cytoplasmic membranes of these cells. 
 
10.2 Preliminary data for mesangial cells derived from 
single knockout mice 
 
10.2.1 Ala1-Ang-(1-7) stimulates cAMP in single receptor knockout cells 
mesangial cells 
We tested whether the Ala1-Ang-(1-7)-mediated increase in cAMP we observed in wild-
type mesangial cells and which was completely blunted in DKO cells (Figure 6.2.4), was 
already abolished in Mas or MrgD deficient cells.  
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Figure 10.2.1 Ala1-Ang-(1-7) induced signalling is absent in mesangial cells derived from 
Mas/MrgD knockout animals but not in single knockouts. 
WT, Mas KO, MrgD KO and DKO C57BL/6 mesangial cells were stimulated for 15min with Ala1-
Ang-(1-7) (10-11 M). Results are expressed as mean ± SEM; Untreated control values of each 
genotype is set as 100%.  ***P<0.001, **P<0.01, *P<0.05, significantly different from control 
mean; ###P<0.001, significantly different from WT Ala1-Ang-(1-7); ANOVA with Bonferoni post-hoc 
test. 
 
Deficiency in one of the receptors (Mas KO or MrgD KO), only reduced the Ala1Ang-(1-7) 
signal compared to wild-type cells (WT) (Figure 10.2.1), implicating that the other 
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Figure 10.2.2 pPKA substrates levels in WT and AT2 KO mesangial cells 
Western blot of phosphorylated PKA substrates and and the housekeeping protein GAPDH and 
calculation of time-dependent phosphorylation of the PKA substrates after C21 stimulation in wild-
type (WT) mesangial cells (A) and in AT2 knockout (AT2 KO) mesangial cells (B). Results are 
expressed as mean ± SEM. Untreated control values of each genotype are set as 100 %.  *P<0.05, 
**P<0.01 vs. WT control; ANOVA with Bonferoni post-hoc test. n=2 (A), n=3 (B). 
 
As cAMP initiates a variety of downstream signalling pathways including PKA activation, 
we tested whether the Ala1-Ang-(1-7)-mediated increase in cAMP leads to an increased 
PKA activity.  
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Stimulation of HUVEC with Ang-(1-7) for 15min resulted in a significant increase in the 
phosphorylation of PKA substrates, indicating an increase in PKA activity. This effect was 
still present in cells derived from AT2 KO cells, confirming the results seen for CREB 
phosphorylation and the cAMP (shown in Figure 6.3.4). 
 
10.3 Effects of angiotensin-(1-7) administration on blood 
glucose levels in STZ induced diabetic mice 
10.3.1 STZ-study performed by Invitek 
Since there was no significant effect of Ang-(1-7) on blood glucose (BG) concentrations in 
healthy wild-type animals with naturally well-balanced glucose homeostasis, it was 
hypothesised that the beneficial effects of Ang-(1-7) become more obvious in preclinical 
models of diabetes mellitus. The model of STZ (multiple low dose) induced diabetes was 
chosen as β-cell damage is not just a characteristic for T1DM, but also for a late stage 
T2DM (glucose toxicity). The previous experiments performed in chapter 6.4, indicate 
that Ang-(1-7) improves β-cell function, which would be beneficial in both, T1DM and 
T2DM, therefore this model was the best choice to investigate the beneficial effects of 
Ang-(1-7).  For this purpose, our collaborator (Invitek, USA) performed a study using Ang-
(1-7) and analogues in STZ-induced diabetic mice. They were able to demonstrate that 
Ang-(1-7) and analogous were able to improve significantly the BG levels in STZ-induced 
mice (Figure 10.3.1). 
 ________________________________ Appendix part 1: Supplemental data 
202 | P a g e  
 
 
Figure 10.3.1 Preliminary data from the STZ study performed by Invitek 
Blood glucose concentrations in STZ induced diabetic mice; *P< 0.05, **P< 0.01 vs Control, TWO 
WAY ANOVA. 
 
10.3.2 No significant difference in blood glucose concentrations between 
the Ang-(1-7) receptor knockouts and wild-type animals 
 
Since Invitek cold show an effect of Ang-(1-7) on BG levels it was decided to further 
investigate this in our own facilities, using the protocol provided by Invitek (for the exact 
description of the protocol used, see Chapter 11.6.1.). For this purpose, diabetes was 
induced using a multiple dose administration of STZ (50mg/kg), in 12-week-old male mice 
expressing all receptors (WT), lacking Mas (Mas KO), MrgD (MrgD KO), or both receptors 
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Figure 10.3.2 Effect of the receptor knockout on blood glucose in STZ induced diabetic 
animals 
Blood glucose concentrations of STZ induced diabetic mice (male, 12-week old), comparing wild-
type (WT, n=6), Mas knockout (Mas KO, n=7), MrgD knockout (MrgD KO, n=6), and double 
knockouts (DKO, n=8). 
 
After 5 days of STZ administration, the BG levels showed a strong elevation in all groups, 
indicating the effectiveness of the STZ injections. The groups were randomly selected, 
and on day 6, the daily administration of Ang-(1-7) (0.5mg/kg) was started. After 15 days 
of Ang-(1-7) administration, no differences in BG concentrations were detected between 
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10.3.3 No significant effect of Ang-(1-7) administration on the 
hyperglycaemic status  
 
 
Figure 10.3.3 Effects of Ang-(1-7) administration in vivo on blood glucose  
Blood glucose concentrations in STZ induced diabetic mice (male, 12 weeks old), with and without 
Ang-(1-7) administration versus control (NaCl) in A) wildtype (WT, NaCl: n = 6, Ang-(1-7): n=7), B) 
Mas knockout (Mas KO, NaCl: n=7, Ang-(1-7): n=7), C) MrgD knockout (MrgD KO, NaCl: n=7, Ang-



















Ang-(1-7) administration in WT diabetic mice Ang-(1-7) administration in Mas KO diabetic mice
Ang-(1-7) administration in MrgD KO diabetic mice Ang-(1-7) administration in DKO diabetic mice
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Figure 10.3.4 Effect of Ang-(1-7) administration in vivo on organ weights  
Weight of kidney (A), liver (B), spleen (C), lung (D), and the heart (E) from STZ induced diabetic 
mice (male, 12 weeks old), with and without Ang-(1-7) administration versus control (NaCl) in A) 
wildtype (WT, NaCl: n=6, Ang-(1-7): n=7), B) Mas knockout (Mas KO, NaCl: n=7, Ang-(1-7): n=7), C) 
MrgD knockout (MrgD KO, NaCl: n=7, Ang-(1-7): n=7) and D) double knockouts (DKO, NaCl: n=8, 
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No significant differences in BG concentrations were detected between NaCl and 
Ang-(1-7) treated mice in all groups. (Figure 10.3.3 A-D). Furthermore, heart, lung, kidney, 
liver and spleen were dissected to evaluate any changes in organ weight. There was no 
significant difference in the weights of kidney, liver, spleen, heart and lung between the 
most of the groups (Figure 10.3.4).  
 
10.3.4 Negative effects of high concentrations of Ang-(1-7) on blood 
glucose concentration in wild-type mice 
 
As there was no significant effect with 0.5mg/kg Ang-(1-7), it was hypothesised that this 
might not be the effective dose. To test whether higher concentrations of the 
heptapeptide might have beneficial effects we treated STZ induced diabetic animals 
(male, 12 weeks old) for 13 days with 2mg/kg Ang-(1-7) and compared with 0.5mg/kg 
Ang-(1-7) and the NaCl control (Figure 10.3.5). 
Surprisingly, the 2mg/kg significantly, and 0.5mg/kg of Ang-(1-7) worsened the diabetes 
and further increased the BG concentration in those animals compared to the control. 
That also 0.5mg/kg Ang-(1-7) treatment resulted in an increase in BG compared to WT is 
contradictive to the results shown in Figure 10.3.3 A.  
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Figure 10.3.5 Effect of different Ang-(1-7) concentrations in vivo on blood glucose  
Blood glucose concentrations in STZ induced diabetic mice (male, 12 weeks old), comparing 0.5 
mg/kg Ang-(1-7), 2.0 mg/kg Ang-(1-7) administration to control (NaCl) in wild-type animals (WT, 




10.3.5 Effects of high concentrations of Ang-(1-7) on organ weights 
The animals treated with the high concentration of Ang-(1-7) showed a significant 
reduction of the heart weight (Figure 10.3.6 E) and a reduction of the weight of the 
spleen (Figure 10.3.6 C), which was not significant. There was no significant effect on the 
other organs (Figure 10.3.6 B, C, D). 




























Ang-(1-7) (2mg/kg) (n=6) **
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Figure 10.3.6 Effect of different Ang-(1-7) concentrations in vivo on organ weights  
Weight of kidney (A), liver (B), spleen (C), lung (D), and the heart (A) from STZ induced diabetic 
mice (male, 12 weeks old), comparing 0.5mg/kg Ang-(1-7), 2.0mg/kg Ang-(1-7) administration 
and control (NaCl) in wild-type animals (WT, NaCl: n=7, 0.5mg/kg Ang-(1-7): n=7, 2mg/kg 
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10.3.6 Gender depending effects of Ang-(1-7) on blood glucose 
concentration in wild-type mice 
 
As higher concentrations of Ang-(1-7) had rather negative effects on the BG, we went back to 
using the lower concentration of the heptapeptide (0.5mg/kg), which also Invitek used. After 
consulting Invitek again, it turned out that they used 6-7 week old females for the study 
shown in Figure 10.3.1. To have a better comparison to their preliminary data it was 
decided to use 6-7 week old female animals. Additionally, it is known the vasodilatory effect 
of the heptapeptide is gender specific [110]. Consequently, it was hypothesised that this 
might also be the case for the effects on BG regulation under diabetic conditions. For this 
purpose, we induced diabetes in 12-week-old male and female mice and compared the 
basic BG, and also the effect of Ang-(1-7) administration in both genders.  
Male mice showed a significant stronger increase in BG level than female mice (Figure 
10.3.7 A), indicating that female animals less affected by the STZ treatment than the male 
mice. However, in female animals the Ang-(1-7) administration showed beneficial effects 
on the BG concentration after 14 days, although this effect was not significant (Figure 
10.3.7 B). In contrast, there was no noticeable effect observed in male mice (Figure 10.3.7 
C), indicating a gender dependent effect of Ang-(1-7) on BG concentration. There was no 
significant difference in the organ weights between NaCl and Ang-(1-7) treated mice 
(Figure 10.3.8). 
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Figure 10.3.7 Gender specific effects in vivo on blood glucose with and without Ang-(1-7) 
administration 
A) Blood glucose concentrations in STZ induced diabetic mice (12 weeks old), comparing male and 
female wild-type (WT) animals with NaCl. B) Blood glucose concentrations in female STZ induced 
diabetic mice (12 weeks old), comparing 0.5mg/kg Ang-(1-7) and control (NaCl) (NaCl: n=5, 
0.5mg/kg Ang-(1-7): n=5). C) Blood glucose concentrations in male STZ induced diabetic mice (12 
weeks old), comparing 0.5mg/kg Ang-(1-7) and control (NaCl) (NaCl: n=4, 0.5mg/kg Ang-(1-7): 
n=5); ** P < 0.01 vs NaCl female, TWO WAY ANOVA. 
A
B C
Male versus Female mice
Ang-(1-7) administration in female mice Ang-(1-7) administration in male mice
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Figure 10.3.8 Effect of Ang-(1-7) administration in vivo on organ weights of female and 
male mice 
Weight from kidney (A), liver (B), spleen (C), lung (D), and the heart (A) from STZ induced diabetic 
mice (male, 12 weeks old), comparing 0.5mg/kg Ang-(1-7), administration and control (NaCl) in 
female and male wild-type animals (12 weeks old). (NaCl: n=4, 0.5mg/kg Ang-(1-7): n=5). All 
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11 Appendix part 2: Materials and methods 
11.1 Materials 
11.1.1 Special equipment 
 
  
Cryo freezing container Nalgene (Nalge Nunc, Rochester, NY, USA) 
Electrophoresis chamber 
Mini-PROTEAN Tetra Cell (Bio Rad Laboratories, Hercules, 
California, USA)
Luminometer
Orion L Microplate Luminometer (Berthold Detection 
Systems GmbH, Pforzheim, Germany)
Luminescence and UV 
detection system
Syngene GBox - EF Gel Documentation System (Syngene 
UK, Cambridge, United Kingdom)
Microscope
CKX41 inverted microscope (Olympus europe Se & Co. KG, 
Hamburg, Germany 
Nano Drop
Nano Drop 2000 Spectrophotometer (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA) 
Plate reader
Tecan Sunrise 96 well Microplate Readers (Tecan Group 
Ltd., Männedorf, Switzerland)
qPCR-cycler 
StepOne™ Real-Time PCR System (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA) 
Semidry blot chamber
PEGASUS (PHASE Gesell. für Phorese, Analytik und 
Separation mbH, Luebeck, Germany)
Thermocycler 
Pro Flex Pcr-System (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA) 
Ultrasound homoginator 
Ultrasonic homogeniser 470 series (Cole-Parmer, St. Neots 
, United Kingdom)
Machine Manufacturer
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11.1.2 Complete systems (kits) 
 
 
11.1.3  Oligonucleotides 
 
BCA Protein Assay Kit
Determination of 
protein concentration
Thermo Fisher Scientific (Waltham, 
Massachusetts, USA) 
PKA activity kit
Determination of PKA 
acitvity
Arbor Assays (Michigan, USA)
Direct cAMP elisa kit cAMP measurement
Enzo Life Sciences Ltd. (Exeter, United 
Kingdom)
Polyfect Transfection Qiagen (Venlo, Limburg, Netherlands)
PureYield™ Plasmid Maxiprep System Plamsid isolation Promega (Madison, Wisconsin, USA)
NucleoBond Xtra Midi RNA
Purification Kit
RNA-Isolation Macherey-Nagel (Dueren, Germany)
SYBR Green qPCR SuperMix Kit qPCR Invitrogen (Carlsbad, California, USA)
RevertAid H Minus First Strand
cDNA Synthesis Kit
cDNA-Synthese Fermentas (St. Leon-Rot, Germany)
ECL Western Blot-Substrate Immundetection
Thermo Fisher Scientific (Waltham, 
Massachusetts, USA) 
System Application Manufacturer
Gene Ref-Nr. Forward primer Reverse primer
A) qPCR
mmMas NM_008552.5 CCTCCCATTCTTCGAAGCTGTA GCCTGGGTTGC-ATTTCATCTTT
mmMrgD  NM_203490.3 TCTACTGGGTGGATGTGAAACG TCATTAGTACACGTGGATGGCG
mmAT2 NM_000686.4 GAATTACCCGTGACCAAGTCCT GGAACTCTAAACACACTGCGGA
hMas NM_002377.2 TTTATAGCCATCCTGAGCTTCC AATGTGGTGTAGGTTCCCAAAG
hMrgD NM_198923.2 AAACTATTCCAGAGGGAGCACA TGGACCTTGTCAGTGGTATTGA
hAT2 NM_000686.4 CATCATTTGCTGGCTTCCCTTC ATTGGAACCCTAAACACACTGC
GAPDH NM_002046 GGACTCATGACCACAGTCCAT AGGTCCACCACTGACACGTT
HPRT NM_000194 GCTGGATTACATCAAAGCACTG CTGACCAAGGAAAGCAAAGTCT
β-Aktin NM_001101 TCCTGTGGCATCCACGAAACT GAAGCATTTGCGGTGGACGAT
B) Genotyping
Mas wt - CTGGTTCCTCTGCTTCCGGATGAGG (Mas11) GCCGTTGCCCTCCTGGCGCCTGGG (Mas12)
Mas ko - GCCGTTGCCCTCCTGGCGCCTGGG (Mas12) GGCAGCGCGGCTATCGTGG (NeoPVU)
MrgD wt - CTGCTCATAGTCAACATTTCTGC (MrgD1) CATGAGATGCTCTATCCATTGGG (MrgD8)
MrgD ko - CATGAGATGCTCTATCCATTGGG (MrgD8) GGAGAAACAGCTAAAGTGCG (rtTA1)
AT2 wt -  CCACCAGCAGAAACATTACC (AT2 5) GAACTACATAAGATGCTTGCCAGG (AT2 3)
AT2 ko - GAACTACATAAGATGCTTGCCAGG (AT2 3) GGCAGCGCGGCTATCGTGG (NeoPVU)
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Antibody Manufacturer Mw Source Dilution
5 % Milk/




60 kDa Rabbit 1:1000 BSA
Erk1/2 Cell Signaling 42/44 kDa Rabbit 1:1000 BSA
CREB Cell Signaling 43 kDa Rabbit 1:1000 BSA
GAPDH
Sigma Aldrich ( St. 
Louis, Missouri, United 
States
40 kDa Rabbit 1:10000 Milk
pAkt (Ser473) Cell Signaling 60 kDa Rabbit 1:1000 BSA
pErk1/2 Cell Signaling 42/44 kDa Rabbit 1:1000 BSA
pCREB Cell Signaling 43 kDa Rabbit 1:1000 BSA
PKA Chemicon 68 kDa Rabbit 1:1000 BSA
pPKA Cell Signaling 20 kDa Rabbit 1:1000 BSA
PKA substrate Cell Signaling - Rabbit 1:1000 BSA
Anti-Rabbit* Sigma Aldrich 1:2000 Milk
Anti-Rabbit* Cell Signaling 1:2000 Milk
A) Primary antibody
B) Secundary antibody
* immunoglobulin G (IgG), horseradish peroxidase (HRP)-coupled
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Bovine serum albumin (BSA) Sigma-Aldrich
Calcium chloride (CaCl2) Sigma-Aldrich
Citric acid monohydrate Merck-Millipore (Darmstadt, Germany)
Compound 21 (C21) Axon Medchem (Groningen, Netherlands)
DMSO (Dimethylsulfoxid) Sigma-Aldrich
DMEM (cell culture media) Lonza (Basel, Switzerland)
DTT (Dithiothreitol) Sigma-Aldrich
EDTA (Ethylendiamintetraacetat) Sigma-Aldrich
EGM-2 (cell culture media) PromoCell (Heidelberg, Germany)
Ethanol -
Fetal calf serum (FCS) GIBCO (Thermo Fisher Scientific, Waltham, Massachusetts, USA) 
Forskolin Sigma-Aldrich
Gel Red (Nucleic acid stain) Cambridge Bioscience (Camebridge, UK)
Glucose Sigma-Aldrich
GlutaMax (L-Glutamine, L-Alanine) Lonza
Glycerol Roth (Karlsruhe, Germany)
Glycin Sigma-Aldrich
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) Sigma-Aldrich
HEPES (for cell culture) Sigma-Aldrich
IBMX (3-isobutyl-1-methylxanthine) Sigma-Aldrich
Isopropanol Roth 
L-Alanyl-L-Glutamine (GlutaMax) GIBCO 
LB-Broth (Miller) Sigma-Aldrich
Mangesium chloride (MgCl2) Sigma-Aldrich




PD123319 Parke-Davis Pharmaceutical Research (Detroit, Michigan, USA)
Penicillin/ Streptomycin (100x) Sigma-Aldrich
Peptides and A779 and D-Pro Biosynthan (Berlin, Germany)
Pertussis toxin (PTX) Merck-Millipore
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich
Phosphate buffert saline PAA (Pasching, Austria)
Phosphatase inhibitor cocktail 2 and 3 Sigma-Aldrich
Ponceau S Sigma-Aldrich
Potassium chloride (KCL) Merck-Millipore
Potassium dihydrogen phosphate (KH2PO4) Sigma-Aldrich
Protease inhibitor cocktail Sigma-Aldrich
RPMI (cell culture media) Sigma-Aldrich
SDS (Sodium dodecylsulfat) Sigma-Aldrich
Sodium chloride Sigma-Aldrich
Sodium hydroxide Sigma-Aldrich




Tris (Tris(hydroxymethyl)-aminomethan) (HCL and Base) Sigma-Aldrich
Trisodium citrate, dehydrate Sigma-Aldrich
Triton-X Sigma-Aldrich
Trypsin/EDTA (0,5 % (w/v)) Sigma-Aldrich
Tween 20 Sigma-Aldrich
β-Mercaptoethanol Sigma-Aldrich
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40 % (v/v) Glycerol
1 x Tris-Acetate-EDTA-(TAE)-Buffer
Spatula tip Bromphenolblue
add 50 ml H2O
4x DNA loading buffer
Concentration Chemical
2 M Tris (Tris(hydroxymethyl)-aminomethane)
1 M Acetic acid
50 mM EDTA
add 1 l H2O
50x Tris-Acetate-EDTA-(TAE)-buffer (pH 8.0):
Concentration Chemical
0.5 M Tris
10 % (v/v) Glycerol
2 % (w/v) SDS
0.1 M DTT (Dithiothreitol)
Spatula tip Bromphenolblue
add 50 ml H2O
Laemmli-sample buffer (pH 6.8)
Concentration Chemical
25 mM Tris (Tris(hydroxymethyl)-aminomethane)
250 mM Glycine
1 % (w/v) SDS (Natriumdodecylsulfate)
add 2 l H2O




add 1 l H2O
20 x Tris buffert saline (TBS) (pH 7.5)
 _____________________________ Appendix part 2: Materials and methods 









0.1 % (v/v) Tween-20
add 1 l H2O
TBS-Tween-20
Concentration Chemical
0.3 M Tris (Tris(hydroxymethyl)-aminomethane)
20 % (v/ v) Methanol
add 1 l H2O
Anode buffer I (pH 10.4):
Concentration Chemical
0.3 M Tris (Tris(hydroxymethyl)-aminomethane) base
20 % (v/ v) Methanol
add 1 l H2O
Cathode buffer II (pH 10.4):
Concentration Chemical
40 mM ε-aminocaproic acid
20 % (v/ v) Methanol
add 1 l H2O
Cathode buffer III (pH 7.6):
Concentration Chemical
0.3 % (w/ v) Ponceau S
30 % (v/ v) trichloroacetic acid 
add 1 l H2O
Ponceau S solution:
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0.1 % (w/ v) BSA
1x PenStrep (10x)
3 mM Glucose
add 1 l H2O









0.5 % (w/ v) BSA
add 1 l H2O
Krebs Ringer buffer (pH 7.4)
Concentration Chemical
0.1 M Citric acid monohydrate (Solution A)
0.1 M trisodium citrate, dehydrate (Solution B)
Citrate buffer (pH 4.5)
Mix 47 ml of A and 53 ml of B and adjust pH
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11.2 Cell biological methods 
11.2.1 Cultivation of eukaryotic cells 
Eukaryotic cells (Table 7.1) were cultivated in an incubator at 37°C and 5% CO2. Every two 
to three days the cell culture medium was changed (cell line and corresponding media see 
table 3). At about 90% confluence, the cells were passaged. For this purpose, the culture 
medium was completely removed, the cells were washed with PBS to remove remaining 
cell culture medium, and incubated with trypsin for 5min at 37°C. The trypsin reaction 
was stopped by adding a ten-fold volume of cell culture medium to the dish. The cell 
suspension was centrifuged at 1100rpm at room temperature and the pellet re-
suspended in complete media. The suspension was placed in a cell depending ratio into 
new cell culture dishes or flasks. 
 
11.2.2 Isolation of mesangial cells from mouse kidney 
In order to obtain murine glomerular mesangial cells (MC), kidneys from two mice were 
dissected. Subsequently, the organ capsule was removed and the kidney homogenised. 
Fifteen ml of pure cold RPMI media was added to the homogenate and filtered using a 
cell strainer (100μm).  The remaining kidney fragments in the cell strainer were rinsed 
with 15ml cold RPMI media. The filtered homogenate (now in 30ml media) was again 
filtered using a cell strainer (75μm). Subsequently, the filtrate was suspended 3 times 
using a 21G needle. Afterwards the solution was centrifuged at RT at 1100rpm for 10min. 
The pellet was re-suspended in a solution of 4mg/ml collagenase type II in pure RPMI. The 
cell suspension was incubated for 30min at 37°C. After incubation, the digestion was 
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stopped by adding 30ml complete RPMI (Table 7.2) and the solution was centrifuged for 
10min at 1100rpm at RT. The supernatant was discarded and the pellet re-suspended in 
complete RPMI medium. The cells were plated in one 75cm2 flask and cultivated in an 
incubator at 37°C and 5% CO2. 
No media was changed during the first three days. At the end of the three days, the 
glomeruli were differentiated into mesangial cells.  The media was removed, the cells 
washed with PBS and new media was added. The MCs were passaged as soon as the cells 
reached 90 % confluence. In order to prevent the negative influence of low cell density on 
cell growth, the cells were split at a maximum ratio of 1:5. The MCs were used between 
passage numbers P2 and P3 for the experiments to ensure the functionality of the cells. 
 







human embryonic kidney 
cells
semi-adherent Sigma-Aldrich (St. Louis, MO, USA)
BALB/3T3 mouse embrionic fibroplast cells adherent
LGC Standards (ATCC), 
(Teddington, UK)
HUVEC human
human umbilical cord 
(primary cells)
adherent PromoCell (Heidelberg, Germany)
Mesangial Cells mouse
glomerular mesangial cell 
(primary cells)
adherent isolated from mouse tissue
OriginCell line Species Description Adhesion
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Table 11.2 Cell culture media 
 
 
11.2.3 Cell count 
The cell count was carried out using a “Neubauer counting chamber” (Neubauer 
improved, LO-Laboroptik, Friedrichsdorf, D). First, the cells were trypsinised (as described 
in Chapter 11.2.1) and centrifuged for 5min at 1100 rpm. The cell pellet was re-suspended 
in 5-10mL complete media. Next, 10μl of a 1:20 dilution of this cell suspension was 
pipetted into the counting chamber and the cell number was determined at 10x 
magnification in four large squares. Since the dimensions of the counting chamber (the 
volume between the cover glass and the object carrier) are firmly defined, the cell 
number per ml can be calculated using following formula. 










5 ng / ml Epidermal Growth Factor
10 ng / ml Basic Fibroblast Growth Factor
20 ng / ml Insulin-like Growth Factor (Long R3 IGF)
0.5 ng / ml Vascular Endothelial Growth Factor 165
1 μg / ml Ascorbic Acid
22.5 μg / ml Heparin






Media Concentration Add ins Cell line
 _____________________________ Appendix part 2: Materials and methods 
222 | P a g e  
 
cells per ml = sum of cells  in 4 quadrants × 
 dilution factor 
4 × depth × area
 
For example: 
cells per ml = 42+45+38+41 × 
 1:20 
4 × 0.1mm  × 0.0025mm2
  = 8,300 cells per ml 
 
11.2.4 Cryopreservation and reactivation of eukaryotic cells 
For permanent storage, the cells were cryopreserved in liquid nitrogen. For this purpose, 
90 % confluent cells were trypsinated like previously described. The pellet was re-
suspended in 10% (v/v) dimethylsulfoxide (DMSO) and complete media (2ml per 100mm 
dish), and 1ml was transferred in to each cryogenic tubes (Nalgene, Rochester, NY, USA). 
After transferring the cryogenic tubes into a freezing vessel filled with isopropanol, the 
cells were frozen at -80°C for at least 24h. The isopropanol ensures a continuous lowering 
of the temperature by 1°C per hour. For long-term storage, the frozen cells were 
transferred to liquid nitrogen the next day. To revitalize the cells, they were re-suspended 
in 10ml of warm cell culture medium and centrifuged at 1100rpm for 5min. Afterwards 
the cell pellet was resuspended in 5ml of culture medium and the mixture was 
transferred to a 100mm cell culture dish. To remove dead cells, the media was changed 
the next morning. 
 
11.2.5 Transfection of eukaryotic cells 
Transfection is a method of introducing foreign DNA into eukaryotic cells. Various 
methods are known. For example, calcium phosphate precipitation [440, 441], 
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electroporation [442] or viral transfection [443]. Within the scope of this study, 
lipofection was carried out exclusively. The liposome-forming reagent PolyFect (Qiagen, 
Limburg, Netherlands) was used for the DNA transfer into the cells. PolyFect contents a 
mixture of activated-dendrimers. Those dendrimers build a spherical architecture with 
branches radiating from a central core. The branches are positively charged and can 
interact with the negatively charged phosphate groups of the DNA. After the addition of 
the mixture to the cells, the formed complexes bind to the cell surface, and get absorbed 
by the cell through endocytosis [444]. 
For the lipofection, 75,000 cells (HEK293) were seeded into the cavity of a 48-well plate 
and left over night. The next day the transfection was carried out. For this purpose, the 
reaction mixture was prepared as shown in Table 11.3 and incubated for 10min at room 
temperature and complete media was then added. Next, 70µl of the reaction mix was 
pipetted into each well.  After 18-20h the cells were stimulated as described in Chapter 
11.2.6. 
Table 11.3 Transfection mix 
 
pure DMEM 10ul
plasmid DNA 150ng * 
PolyFect 2ul
complete DMEM 60ul
10min incubation at RT
* cAMP-Assay: 100ng receptor and 50ng 
pCDNA3.1
* Dual Luciferase Assay: 25ng Reporter-
Firefly luciferase construct, 25ng Renilla, 
add in amount
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11.2.6 Stimulation and treatment of eukaryotic cells 
To investigate the effect of certain compounds, the transfected cells were treated 18-20h 
after transfection (Chapter 11.2.5). HUVEC and MC were treated the day after seeding. 
For this purpose, the cell culture media was removed and pure media was added. After 
1h of starving, the treatment took place. For cAMP-assay (Chapter 11.5.5), the cells were 
treated for 15min with the compound of interest. If blockers were used, a 15min pre-
treatment took place followed by a 15min stimulation. For the dual luciferase assay the 
cells were treated 6h with the compound of interest. After treatment, the cells were 
harvested depending on the assay used. 
To examine the effect of the compounds on intracellular signalling in HUVEC and 
mesangial cells using immunoblot analysis, the cells were seeded in to 60mm dishes. The 
next day the cells were starved for 1h and treated for 15min, or certain time points, with 
the compound of interest. If needed a 15min pre-incubation with blockers took place. 
After treatment the cells were harvested like described in Chapter 11.5.1. 
 
11.2.7 Isolation and stimulation of mouse islets of Langerhans 
The islets of Langerhans are located within the pancreas. They consist the insulin-
producing beta cells, the glucagon-producing alpha cells and somatostatin-producing 
delta cells. Their isolation requires the gentle enzymatic and mechanical digestion of the 
exocrine tissue without causing damage to the islets. Depending on the mouse, 200-400 
islets can be isolated. For this purpose, all media and solvents were warmed up to 37°C. 
One ml collagenase P (2mg/ml) (Roche, Basel, Switzerland) in Krebs Ringer buffer was 
injected into the mouse pancreas through the common bile duct. The whole pancreas 
 _____________________________ Appendix part 2: Materials and methods 
225 | P a g e  
 
was removed and digested in 2 ml collagenase P solution for 6 min at 37 °C with 
continuous, gentle shaking. Ice-cold islet isolation buffer (Chapter 11.1.6) was added, 
samples were shaken vigorously for 15 s and centrifuged (500×g, 2min, 4°C). Pellets were 
resuspended in islet isolation buffer and islets were hand-picked and collected in 
RPMI1640 (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% FBS, and 1x 
penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO, USA). Twenty islets per well isolated 
from wild-type or Mas-deficient mice were cultured for 24h in 12 well plates with 500µl 
RPMI1640 (supplemented as described above) at 37°C with 5% CO2. After 24h, islets were 
incubated in Krebs Ringer buffer (Chapter 11.1.6) with 2.8mmol/l glucose for 90min, with 
buffer exchanged once after 30min. Islets were exposed to different glucose 
concentrations (2.8mmol/l glucose, 2.8mmol/l glucose + 40mmol/l KCl, or 20mmol/l KCl) 
for 2h. For the treatments, Ang-(1-7) (0.2µmol/l), A779 (1µmol/l), and D-Pro (1µmol/l) 
were added. Supernatants were collected, centrifuged at 100xg for 2min at 4°C and 
insulin concentrations in the supernatants determined by ELISA (Mercodia, Uppsala, 
Sweden). 
For cAMP analysis, islets were treated as described in Chapter 11.2.6. 
 
11.3  Microbiological methods 
11.3.1 Transformation of prokaryotic cells 
The bacterial strain used in this work was Escherichia Coli (E. Coli) DH5α. These cells are 
engineered in order to maximize the transformation efficiency. They are defined by 3 
mutations (The Coli Genetic Stock Center). Those mutations are recA1, endA1 and 
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lacZM15. The first two mutations help with plasmid insertion, while the other mutation 
enables the blue white screening [445]. 
For the transformation of E.coli, the heat shock method was used [446]. For this purpose, 
100μl of chemo competent E. coli DH5a were thawed on ice and then incubated with 
400 ng of plasmid DNA for 30min, allowing the precipitation of the DNA due to the high 
salt concentration. A heat shock for 45s at 42°C causes pores in the bacterial membrane, 
where the plasmid DNA can enter the cells. After two-minutes incubation on ice, 1000μl 
of LB medium was added to the cells and the mixture was left shaking for one hour at 
37°C on a thermo-block (Eppendorf, Hamburg, Germany). After centrifugation at 110rpm 
for 5min the supernatant was decanted. The bacteria pellet was resuspended in 50μl LB-
Media. The suspension was plated on antibiotic containing agar plates using a Drygalski 
spatula and left overnight at 37°C in an incubator. The choice of antibiotic was based on 
the resistance contained in the vector backbone used (indicated in the vector card). The 
plasmids used in this work (pcDNA3.1, Mas-pcDNA3.1, MrgD-pcDNA3.1, AT2-pcDNA3.1, 
or Mrg-pcDNA3.1) were provided by the group [65]. 
 
11.3.2 Multiplication of prokaryotic cells 
After transformation and selection on antibiotic-containing agar plates, a single cell 
colony was picked and added to 200ml Lysogeny broth (LB) media, supplemented with 
100μg/ml antibiotics. The bacterial culture was incubated for 16-18h overnight with 
shaking at 37°C. After centrifugation for 20min at 14000rpm, the bacterial pellet was 
stored at -20°C until plasmid purification. 
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11.3.3 Isolation of plasmid DNA 
The plasmid DNA from E. Coli DH5a was prepared from a 5ml pre-culture with the 
QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany) and from a 200ml bacteria culture 
with the PureYield™ Plasmid Maxiprep System (Promega GmbH, Mannheim, Germany) 
according to manufacturer's instructions. The preparation took place according to the 
manufacturer’s protocol after the principle of alkaline lysis [447].  
Briefly, the cell pellet was resuspended in 12ml of “Cell Resuspension Solution” (provided 
in kit) by vortexing or pipetting. Then, 12ml of “Cell Lysis Solution” (included in kit) was 
added and the vial was gently inverted 3–5 times to mix. After 3min incubation at room 
temperature, 12ml of “Neutralization Solution” (included in kit) was added and the mix 
gently inverted 10–15 times to mix. Subsequently, the lysate was centrifuged at 
maximum speed for 30min at room temperature.  
For the next steps the blue PureYield™ Clearing Colum and the white PureYield™ Maxi 
Binding Column were assembled in a stack, with the clearing column on top. This column 
stack was then placed on the vacuum manifold. The lysate was poured on to the column 
and vacuum maintained until the liquid had cleared both columns. Then, the blue 
PureYield™ Clearing Column was discarded and the PureYield™ Maxi Binding Column was 
left on the vacuum manifold. Next, 5ml of Endotoxin Removal Wash was added to the 
PureYield™ Maxi Binding Column, vacuum was applied and the solution was allowed to be 
pulled through the column. After that, 20ml of Column Wash was added to the binding 
column, and the vacuum was applied to pull the solution through the column. Next, the 
membrane was dried by applying the vacuum for 10minutes. The PureYield™ Maxi 
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Binding Column was removed from the vacuum manifold and the tip of the column was 
tapped on a paper towel to remove any remaining ethanol.  
For the elution, the column and a 1.5 ml micro-centrifuge tube were placed into the base 
of the Eluator™ Vacuum Elution Device. Next, this Device was placed on to the vacuum 
manifold and 1ml of Nuclease-Free Water was added to the DNA binding membrane in 
the binding column. After 1min incubation the maximum vacuum was applied until all 
liquid had passed through the column. 
The concentration of the plasmid DNA was determined by using the Nano-Drop (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA) 
 
11.4 Molecular biological methods 
11.4.1 Genotyping mice 
11.4.1.1 Preparation of ear biopsies 
The animals were marked on the ears for later identification.  The generated ear biopsies 
were used for the isolation of genomic DNA. For this purpose the ear pieces were 
transferred into a 1.5ml reaction tube and incubated with 100µl earhole buffer and 12µl 
proteinase K solution at 37°C overnight with gentle shaking. The next day, the proteinase 
K was inactivated by heating the samples at 95°C for 10min. After short centrifuging, 
400μl of TE buffer and 13μl of RNase A solution were added to the samples. The prepared 
samples were directly used for PCR or stored at -20°C. 
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11.4.1.2 Polymerase chain reaction (PCR) for genotyping  
The genotyping of the animals was carried out by using PCR [448]. Specific sections of the 
target gene in the genomic DNA were amplified by PCR and separated on an agarose gel. 
The first PCR was used to amplify the sequence in the natural, unaltered target gene. The 
second PCR was used to amplify the change in the DNA sequence of the target gene, 
which leads to its elimination (knockout). In this way, the genotype of the animals was 
clearly determined. The general reaction mixtures used for each PCR is listed in Table 11.4.  
 










PCR reaction mix genotyping
Mas WT Mas KO MrgD WT MrgD KO AT2 WT AT2 KO
H
2
O 30.45 30.45 29.95 30.25 30.25 30.45
NH4 4.5 4.5 4.5 4.5 4.5 4.5
MgCl2 1.8 1.8 2.3 2 2 1.8
dNTPs 2.4 2.4 2.4 2.4 2.4 2.4
Forward primer* 1.8 1.8 1.8 1.8 1.8 1.8
Reverse Primer* 1.8 1.8 1.8 1.8 1.8 1.8
Taq 0.25 0.25 0.25 0.25 0.25 0.25
* Primer were diluted 1:10 before used for PCR
Volume
Reagent
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Table 11.5 PCR conditions 
 
 
11.4.1.3 Agarose gel electrophoresis 
The gel electrophoretic separation of PCR products was carried out in horizontal running 
chambers. For PCR products generated in the PCRs for Mas (WT/ KO), MrgD (WT/ KO) and 
AT2 (WT/ KO), 1.5% (w/v), agarose gels were used. For this purpose, the agarose (Sigma-
Aldrich, St. Louis, MO, USA) was dissolved in TAE buffer (1x) under heat using a 
microwave. After cooling down to about 50°C, 0.5µl/ml Gel Red (Cambridge Bioscience, 
Camebridge, UK) was added and the mixture poured into the gel carrier. Gel Red is a DNA 
intercalating dye, which can be detected using ultraviolet light. The loading of the 
Mas WT PCR Mas KO PCR
Temperature Time Step Cycles Temperature Time Step Cycles
 94 °C 5 min initial denaturation 1 x  94 °C 5 min initial denaturation 1 x
94 °C 30 s denaturation 94 °C 30 sec denaturation
59 °C 30 s annealing 62 °C 30 sec annealing
72 °C 1 min 5sec amplification 72 °C 1 min 5sec amplification
72 °C 7 min final amplification 1x 72 °C 7min final amplification 1x
4 °C unlimited end 4 °C end
MrgD WT PCR MrgD KO PCR
Temperature Time Step Cycles Temperature Time Step Cycles
 94 °C 5 min initial denaturation 1 x  94 °C 5 min initial denaturation 1 x
94 °C 30 sec denaturation 94 °C 30 sec denaturation
54.6 °C 30 sec annealing 60 °C 30 sec annealing
72 °C 59 sec amplification 72 °C 1 min 5 sec amplification
72 °C 7min final amplification 1x 72 °C 7min final amplification 1x
4 °C end 4 °C end
AT2 WT PCR AT2 KO PCR
Temperature Time Step Cycles Temperature Time Step Cycles
 94 °C 5 min initial denaturation 1 x  94 °C 5 min initial denaturation 1 x
94 °C 30 sec denaturation 94 °C 30 sec denaturation
51.3 °C 30 sec annealing 51.3 °C 30 sec annealing
72 °C 27 sec amplification 72 °C 35 sec amplification
72 °C 10 min final amplification 1x 72 °C 10 min final amplification 1x
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samples and a corresponding molecular weight marker (lambda marker) was carried out 
after the addition of ¼ volume of DNA loading buffer. The gel electrophoresis was 
performed at 100V. The visualization/digitization was carried out using the Syngene GBox 
- EF Gel Documentation System (Syngene UK, Cambridge, United Kingdom). Figure 11.4.1 
shows an example of the expected signal combinations and their interpretation. 
 
Figure 11.4.1 Example for genotyping PCR 
Example of the combination of results that can be expected. 
 
 
11.4.2 Isolation of RNA 
RNA was isolated using the NucleoSpin RNA Kit (Macherey-Nagel, Dueren, Germany). The 
following steps were carried out according to the manufacturer's protocol. Cells were 
lysed in 350μl of lysis buffer (RA1) supplemented with 1% (v/v) of β-mercaptoethanol. 
The lysate was transferred to the filtration column and centrifuged for 1min at 10000×g, 
to remove cell debris. The supernatant was collected and the filter discarded. In order to 
achieve optimal binding to the affinity column, the RNA was pre-precipitated by the 
 _____________________________ Appendix part 2: Materials and methods 
232 | P a g e  
 
addition of 350μl of 70% (v/v) ethanol to the column, and centrifugation at 10000×g for 
30s at RT. After desalination of the column with 350μl of Membrane Desalting Buffer 
(MDB) and subsequent centrifugation at 10000×g for 1min, genomic DNA was degraded 
by the addition of 95μl of prepared DNase solution and incubation for 15min. 
Subsequently, the column was washed three times and the RNA eluted in 40μl of water 
by centrifugation at 10000×g for 2min. The RNA was either immediately quantified or 
stored at -80°C. 
 
11.4.3 Quantification of nucleic acids 
For the determination of the concentrations, 1µl of the isolated RNA or DNA was applied 
to the NanoDrop (Thermo Fisher Scientific, Waltham, Massachusetts, USA) and quantified 
at a wavelength of 260nm (absorption maximum of the nucleic acids). At the same time, a 
measurement was carried out at 280nm (absorption of aromatic amino acids). The 
quotient of the absorbance at 260nm and 280nm gives an indication of the purity of the 
preparation. For pure DNA/RNA, the quotient is between 1.7 and 2.0, and below 1.6 
when protein impurities are in the sample. For each sample, the concentration was 
determined in duplicates, from which the mean value was calculated. 
 
11.4.4 Synthesis of complementary DNA (cDNA) 
The reverse transcription of mRNA into cDNA was carried out using the RevertAid H 
Minus First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, Massachusetts, 
USA) according to the manufacturer's instructions. Two μg of isolated RNA was mixed 
with 1μl oligo-(dT)18 primer in a final volume of 12μl. The use of these primers allowed 
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the transcription of biologically active mRNA species possessing a corresponding poly (A) 
tail. After incubation at 65°C for 5min, a mix of 4μl of 5× reaction buffer, 2μl of 
deoxyribonucleoside triphosphate (dNTP) mix, and 1μl of ribonuclease inhibitor and 
reverse transcriptase were added from the kit for each reaction.  
 
Table 11.6 cDNA synthesis mix 
 
 
The reverse transcription was carried out in a thermocycler using the following program: 
37°C for 5min, 42°C for 1h and 70°C for 10min. Subsequently, the cDNA was diluted 1: 5 in 
water. 
 
11.4.5 Quantitative teal time PCR (qRTPCR) 
The qPCR allows the relative quantification of mRNA levels using DNA intercalating dyes 
like SybrGreen. The more DNA is synthesized during the PCR the more dye is deposited in 
it. By measuring the fluorescence intensity after each PCR cycle, the amount of the 
amplification product can thus be measured and quantified by means of special analysis 
Amount reagent
1 μl Oligo-d(T)18-Primer 
2 μg RNA
add 12µl ddH2O
2 μl 10 mM dNTPs
4 μl 5x Reaction buffer 
1 μl Reverse Transcriptase (200 U/μl) 
1 μl RNase-Inhibitor (20 U/μl) 














 _____________________________ Appendix part 2: Materials and methods 
234 | P a g e  
 
programs compared to other PCR [148]. The complete system Platinum SYBR Green qPCR 
SuperMix-UDG Kit (Invitrogen, Carlsbad, California, United States) was used for the qPCR 
experiments. The corresponding primer sequences are summarized in Chapter 11.1.3. A 
reaction approach included:  
 
Table 11.7 qPCR reaction mix 
 
 
The PCR was performed in a StepOne qPCR cycler (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA). The determination of the melting point was used to check whether 
the PCR product was synthesized and to see if other nonspecific PCR products or primer 
dimers were generated. The evaluation was carried out using the raw data exported from 
the StepOne software. The raw data shows the threshold cycle (Ct), which represents the 
transition of the PCR into the exponential phase and is a measure of the mRNA quantity. 
The PCR efficiency (E), was assumed to be 1.8 as the machine doesn’t give this 
information. In theory this value is 2 as with each cycle the amount of DNA gets 
duplicated. In the past it was shown, that this value usually is between 1.7 and 1.9. The 
ΔCt method was used for the calculation of normalized expression (Expnorm), from the 
Reagent volume [µl]
SYBR Green qPCR Mix 10.0
H2O 8.5
Forward primer (100 pmol/μl) 0.25
Reverse primer (100 pmol/μl) 0.25
cDNA 1.0
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relative expression of the control (Exprel (control)) and that of the target gene (Exprel (target 
gene)). 
The calculation was carried out using the following formulas: 
 
  E = increase from the linear regression of the exponential phase 
 
 ∆  =  	
 −  








The relative expressions of the investigated genes were compared with those of 
constitutively expressed household genes, e.g. Hypoxanthine phosphoribosyltransferase 
(HPRT), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin, to reduce 
variance between the samples by methodological errors. Three independent biological 
replicates were used to analyse gene expression using qPCR. 
 
11.4.6 Dual luciferase assay (DLR) 
For the examination of receptor activity, transcription factors and intracellular signaling 
the Dual Luciferase Reporter (DLR) Assay kit (Promega GmbH, Mannheim, Germany) was 
used. The “dual” refers to the consecutive expression and measurement of two individual 
reporter enzymes within one system. In this DLR, the activities of Firefly (Photinus pyralis) 
and Renilla (Renilla reniformis, also known as sea pansy) luciferases are measured (Figure 
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11.4.2). Whereas the firefly luciferase is coupled to the reporter, the Renilla luciferase is 




Figure 11.4.2 Light emission from firefly and Renilla luciferase 
Schematic overview of the reactions of the Firefly and Renilla luciferase, which result in the 
emission of light. 
 
For the DLR assay, HEK293 cells were seeded as previously described in Chapter 11.2.5. 
About 24h later, cells were transiently transfected (see Chapter 11.2.5) with 100ng 
eukaryotic expression vectors of AT1 [65], AT2, Mas, MrgD or Mrg together with 25ng 
pNFAT-TA-Luc-, (BD Biosciences; Heidelberg; Germany) or pELK-Luc Reporter Vector 
(Signosis, Santa Clara, California, USA) luciferase reporter plasmids and 25ng pRL-TK 
(Promega GmbH, Mannheim, Germany). Next day, the stimulation took place as 
described in Chapter 11.2.6. After 6 hours of stimulation, the cells were lysed with 70µL 
passive lysis buffer per well (provided with the kit) and incubated on a shaker for 15min 
at RT. The activity for Firefly and Renilla Luciferase was measured with Orion-L Microplate 
Luminometer (Berthold Detection Systems GmbH, Pforzheim, Germany) according to the 
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manufactures protocol. Briefly, 30µL of lysed cells were transferred into a white 
96-MicroWell plate (Thermo Fisher Scientific, Waltham, Massachusetts, USA), and 100µL 
of Luciferase Assay Reagent II was added. After quantifying the Firefly luminescence, the 
reaction was quenched by adding 100µL of Stop&Glo reagent and Renilla activity was 
measured. For calculations, the ratio of firefly and Renilla luciferase was used. 
 
11.5 Protein biochemical methods 
11.5.1 Protein extraction 
In order to examine the expression and phosphorylation of intracellular proteins, the 
proteins were isolated by directly lysing the cells as quickly as possible as phosphorylation 
is a very unstable state. For this purpose, the medium of a 100mm (HUVEC and MC) or 
60mm (HEK293) cell culture dish was completely aspirated and 500μl/200μl of ice-cooled 
RIPA buffer (Thermo Fisher Scientific, Waltham, Massachusetts, USA) was added 
immediately. The buffer was mixed with 1% (v/v) phosphatase inhibitor mix 2 and 3 
(Sigma Aldrich, St. Louis, MO, USA) and protease inhibitor mix (Sigma Aldrich, St. Louis, 
MO, USA) to prevent dephosphorylation and protein degradation. After rapid removal of 
the cells from the bottom of the cell culture dish with a cell scraper, the cell lysate was 
transferred to a pre-cooled 1.5ml reaction tube. After 20min of incubation on ice, the cell 
was further processed by using ultrasound (10 pulses of ultrasound at a power of 60%). 
After a further 10min incubation on ice, non-lysed cells or cell debris were removed by 
centrifugation at 13,000×g and 4°C for 20min. The protein lysate was transferred to a new 
pre-cooled reaction tube. The protein concentrations were determined by using the 
biuret reaction (see Chapter 11.5.2). 
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11.5.2 Protein concentration determination according to Biuret (BCA) 
Protein determination using the biuret reaction was carried out using the BCA protein 
assay kit (Thermo Fisher Scientific, Waltham, Massachusetts, USA). The reduction of the 
Cu2+ ions in alkaline solution to Cu+ ions by proteins is exploited. The resulting Cu+ ions 
building complexes with two molecules of bicinchonic acid (BCA) which leads to a 
bathochromic shift which can be measured at 562nm [450]. Ten microliter each of a 1:10 
dilution of proteins were pipetted in triplicates into a 96-well plate, and mixed with 200μl 
of BCA reagent, consisting of 50 parts of solution A and 1 part of solution B. In addition, 
10μl of pure standard solutions with known concentrations of bovine serum albumin 
(BSA, 0 to 2mg/ml) were prepared in duplicates. After incubation at 60°C for 20min, the 
absorbance of each sample was determined at 562nm on a plate reader. The protein 
concentration of the samples was calculated by linear regression of the BSA standard with 
correction of the substrate blank. 
 
11.5.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE is a gel electrophoretic separation process for proteins under denaturing 
conditions [451]. The anionic detergent SDS binds to proteins in a ratio of approx. 1.4:1 
and superimposes the charge of the proteins with its strong charge. By the addition of 
thiols, for example dithiothreitol (DTT), the tertiary structures are destroyed, which is 
caused by the disruption of disulfide bridges. In this way, the proteins are separated in 
the electric field only by their molecular weight and not by their charge or globularity. 
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In this work chemically inert acrylamide bisacrylamide gels of size 83 x 73 x 1.5mm were 
used. The composition of the separating and stacking gels were as follows: 
 
Table 11.8 Acrylamide gel composition 
 
For sample preparation, 20μg protein per sample was added with ¼ of the final volume 4-
fold Laemmli sample buffer and 0.1M DTT. Subsequently, the proteins were denatured by 
incubation at 95°C for 5min. After applying the samples to the gel pockets, the proteins 
were electrophoresed in The Mini-PROTEAN Tetra hand cast systems in 1x SDS-Tris-
Glycine running buffer. A voltage of 50V was applied until the separating gel was reached, 
then a voltage of 120-150V was applied. A pre-colored protein size marker (PageRuler 
Prestained Protein Ladder, Fermentas) was included for the purpose of later size control. 
 
11.5.4 Immunoblot analysis 
The immobilization of the proteins separated in the SDS-PAGE onto a nitrocellulose 
membrane (Macherey-Nagel, Dueren, Germany) was carried out by the so-called electro 
10 % 12 %
H2O 2.95 2.45 2.06
30 % Acrylamide 2.5 3.0 0.5
1.5 M Tris (pH 8,8) 3.8 1.9 -
1.5 M Tris (pH 6,8) - - 0.375
10 % (w/v) SDS 0.075 0.075 0.03
10 % (w/v) APS 0.075 0.075 0.03
TEMED 0.004 0.004 0.003
seperating gel 1x [ml]
Chemical stacking gel 1x [ml]
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blot method. The negatively charged proteins migrate in the electric field to the anode of 
the blotting system and bind covalently to the membrane [452]. 
Both a discontinuous buffer system and a semidry blotter chamber were used in this 
work. Three-layer filter paper were each soaked in anode solution I or II, as well as in the 
cathode solution. The nitrocellulose membrane was incubated for 10min in the anode 
solution II. The structure of the apparatus is shown in Figure 11.5.1. 
 
 
Figure 11.5.1 Application of the semi dry blot  
Schematic overview of the application of the semi dry blot. 
 
At a constant current intensity of 0.85mA per cm2 of membrane area, the proteins were 
transferred to the membrane for 1h. The quality and efficiency of the transfer was 
checked with a Ponceau S staining. For this, the membrane was shaken for about 2min in 
the Ponceau S solution, then the excess dyeing solution was tipped off and the membrane 
was decolourised by washing several times in water. 
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The immunostaining of the protein bands was carried out by using epitope-specific 
primary antibodies and horseradish peroxidase (HRP) -conjugated secondary antibodies 
(Chapter 11.1.4) followed by chemiluminescence detection. First, free binding sites of the 
nitrocellulose membrane were blocked with 5% (w/v) low-fat milk powder (Roth, 
Karsruhe, Germany) in TBS-T for about 1h. Subsequently, the incubation with the primary 
antibody (dilutions and incubation solutions are listed in Chapter 11.1.4) were performed 
at 4°C overnight. After washing 3 times with TBS-T for 5min each, an HRP-conjugated 
secondary antibody specific to the species of primary antibody was incubated for 2h at 
RT. Unbound antibodies were removed by washing three times for 5min each with TBS-T 
and twice in TBS. Subsequently, the immunoblots were analysed by means of the 
chemiluminescent reaction by adding a 1:1 mixture of peroxide and luminol enhancer 
solution of the ECL Western blot substrate (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA). Luminol is oxidized by the HRP using hydrogen peroxide. The 3-
aminonaphthalic dianion is formed as an energetic intermediate product with the 
emission of photons (Figure 11.5.2). The released photons were detected with the help of 
the luminescence detection device.  
 
Figure 11.5.2 Luminol reaction 
A subsequent quantification of the relative protein levels of five independent biological replicates 
was carried out using the AIDA program. 
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11.5.5 Cyclic Adenosine monophosphate enzyme-linked immunosorbent 
assay (cAMP ELISA) 
Like immune blot analysis, an ELISA is an immune based assay. In general, one primary 
antibody is immobilised on the bottom of a well of a 96-well plate. The antigen can bind 
and is detected in different ways. Several types of ELISAs exist: direct, indirect, sandwich 
and competitive ELISA [453]. The ELISA used in this work is the competitive ELISA. In this 
case, no second labelled antibody is used for detection, but a labelled competitor antigen 
(a synthetic compound that is structurally similar to the analysed substance and also 
binds to the antibody) is used. Thus, the competition between the analysed substance 
and the competitor leads to a binding site on the antibody. The signal behaves in the 
opposite direction to the concentration of the analysed substance: little amount of 
analysed substance means that almost all antibody binding sites can be occupied by the 
labelled competitor, which leads to a strong colour reaction; while huge amount of 
analysed substance leads to weak colour reaction. The detection systems used (enzymes / 
substrates) are usually the same as for the ELISA. 
Intracellular cAMP concentration was determined using the Direct cAMP ELISA kit (Enzo 
Life Sciences Ltd., Exeter, United Kingdom). This is a colorimetric competitive 
immunoassay. All steps were performed according to the manufacturer’s protocol (Figure 
11.5.3). Briefly, samples and standards (20pmol/l, 5pmol/l, 1.25pmol/l, 0.321pmol/l and 
0.078pmol/L) were acetylated by adding 5µl acetylation reagent (0.5mL of 
acetic anhydride to 1mL of triethylamine) to 100µl sample/ standard. The wells of 96-well 
plate (Goat Anti-Rabbit IgG pre-coated) were neutralized with 50µl of Neutralizing 
Reagent. Next, 100μl of acetylated cAMP standard or cell lysate was added, followed by 
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50µl of blue cAMP-Alkaline Phosphatase Conjugate and 50µl of yellow EIA Rabbit Anti-
cAMP antibody. The plate was then incubated on a shaker (~ 400rpm) at RT for 2h. Next, 
the wells were aspirated and rinsed three times with Wash Buffer (1:10, TBS containing 
detergents and sodium azide in deionized water). After the final wash, the plate was 
tapped against clean paper towel to remove any remaining Wash Buffer. To each well 
200µl p-Nitrophenyl Phosphate Substrate Solution was added, and the plate was 
incubated for 1h at RT. The enzymatic reaction was stopped by adding 50µl of Stop 
Solution, and the absorbance at 405nm was measured immediately. The cAMP 
concentration was determined from non-linear standard curve using GraphPad Prism 5.0 
software.  
 
Figure 11.5.3 cAMP assay 
Schematic overview of the cAMP assay. The sample antigen (cAMP) and the alkaline phosphatase 
(AP) ladled cAMP compete for the binding to the primary antibody. The signal behaves in the 
opposite direction to the concentration of the analysed substance. 
 
11.5.6 Protein kinase A (PKA) activity analysis 
The measurement of Protein Kinase A (PKA) activity was performed using the PKA 
Colorimetric Activity Kit (Arbor Assays Headquarters, Ann Arbor, Michigan, USA) following 





Well coated with affinity purified antibody
(Goat anti-Rabbit IgG)
3) Primary antibody against cAMP 
(yellow solution)
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the next day, cells were transiently transfected using PolyFect reagent as described in 
Chapter 11.2.5. For HUVEC cells, 24-well plates (75,000 per well) were used and plated 
overnight. Sixteen to 20h later, the stimulation took place (Chapter 11.2.6). Then, the 
cells were lysed in 50µL (HEK293) or 100µL (HUVEC) activated cell Lysis Buffer provided by 
the kit, containing 1mM PMSF (phenylmethylsulfonyl fluoride), 1µl/ml protease and 
phosphatase inhibitor cocktail (Sigma Aldrich, St. Louise, Missouri, USA) and incubated for 
30min on ice. The lysates were transferred to 1.5ml reaction tubes and centrifuged at 
10,000rpm at 4°C for 10min. The supernatant was directly used for the analysis or stored 
at -80°C until the measurement.  
For measurement, all samples were diluted 1:10 in Kinase Assay Buffer provided by the 
Kit. For the measurement, 40µL of the sample (in triplicates) or standard (in duplicates) 
were pipetted in to each well. Afterwards, 10µl of ATP was added to each well and 
incubated for 1.5h at 30°C on a shaker. Next, the wells were aspirated and rinsed four 
times with Wash Buffer (1:20 in deionized water). After the final wash, the plate was 
tapped against clean paper towel to remove any remaining Wash Buffer. Twenty-five μL 
of the Goat anti-rabbit IgG HRP and 25μL of the Rabbit Phospho PKA Substrate antibody 
were added to each well and incubated at RT for 60min with shaking. The wells were 
aspirated again and rinsed four times with Wash Buffer (1:20 in deionized water). After 
the final wash, the plate was tapped against clean paper towel to remove any remaining 
Wash Buffer. Next, 100μL of the TMB Substrate Solution were added to each well and 
incubated for 30min at RT. Afterwards, 50µL of stop solution was added to each well and 
the optical density was measured at 450nm using a plate reader. The PKA activity (U/ml) 
was determined from the linear standard curve using linear regression from Excel. 
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11.6 In vivo studies 
11.6.1 STZ induced diabetes 
For this purpose, 12 week old mice deficient in Mas [120], MrgD [359] (strain #36050, 
B6.129S1-Mrgprdtm5Mjz/Mmnc The Mutant Mouse Regional Resource Center 
8U42OD010924-13, Chapel Hill, NC, USA), or both receptors, and the corresponding wild-
type animals were used.  
The diabetes was induced by using streptozotocin (STZ). The structural similarity with 
glucose allows STZ to bind to the Glucose receptor (GLUT2) leading to damage of the 
pancreatic β-cells, which results in hypoinsulinemia and hyperglycemia [454]. Depending 
on the dose, STZ induces diabetes in two ways. At high doses (single dose administration), 
STZ destroys the β-cells through its alkylating property [455]. At low doses (multiple dose 
administration), STZ provokes an immune and inflammatory response. An autoimmune 
response like mechanism destroys the β-cells and leads to the hyperglycaemic conditions 
[456].  
For the purpose of our studies, we used multiple dose administration of STZ. The injection 
of STZ took place in the first 5 days of the study. For this purpose, 50mg/kg STZ (Sigma 
Aldrich, St. Louis, MO, USA) dissolved in citrate buffer (Chapter 11.1.6) was injected 
intraperitoneal. Additionally the bodyweight from each animal was determined on day 
one. After five days, the body weights were determined, and blood glucose levels were 
measured through tail clip and by using the Contour Blood Glucose Meter (Bayer, Berlin, 
Germany). From day 6 on, a daily subcutaneous (neck) injection of Ang-(1-7) (relevant 
dose was dissolved in 0.9% NaCl solution) was performed. Every 3 days the body weight 
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and blood glucose was determined (day: 8, 11, 14, 17, 20). On day 20, the animals were 
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[Ca2+]c   Cytosolic calcium concentration 
7TMR   Seven transmembrane receptors 
AA   Arachidonic acid 
AC   Adenylyl cyclase 
ACE   Angiotensin converting enzyme 
Ang   Angiotensin 
AP   Aminopeptidase 
AT1   Angiotensin receptor type 1 
AT2   Angiotensin receptor type 1 
ATP   Adenosine triphosphate 
BCA   Bicinchonic acid 
BCL-2   B-cell lymphoma 2 
BG   Blood glucose 
C21   Compound 21 
CAMK   Calmodulin-dependent kinase 
cAMP   Cyclic adenosine monophosphate 
cGMP   Cyclic guanosine monophosphate 
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CML   Nepsilon-(carboxymethyl)-lysine 
CRE   CREB response element 
CREB   cAMP response element-binding protein 
DAG   Diacylglycerol 
DKO   Double knockout 
DLR   Dual luciferase assay 
DM   Diabetes mellitus 
DMSO   Dimethyl sulfoxide 
DUB-1   Dual-specificity phosphatase 1 
ECL   Enhanced chemiluminescence 
ELISA   Enzyme-linked immunosorbent assay 
eNOS   Endothelial nitric oxide synthase 
EPAC   Exchange factor directly activated by cAMP 
ER   Endoplasmic reticulum 
FBS   Foetal bovine serum 
GABA    Gamma-aminobutyric acid 
GAG   Diacylglycerol 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GDP   Guanosine diphosphate 
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GEF   Guanine exchange factor 
GLP-1   Glucagon-like peptide-1 
Gly Phos   Glycogen phosphatase 
Gly Synth  Glycogen synthase  
GPCR   G-protein coupled receptor 
GSIS   Glucose-stimulated insulin secretion 
GTP   Guanosine triphosphate 
HEK   Human embryonal kidney cells 
HPRT   Hypoxanthine-guanine phosphoribosyltransferase 
HRP   Horseradish peroxidase 
HUVEC   Human umbilical vein endothelial cells 
IFN-γ   Interferon gamma 
IgG   Immunoglobulin G 
IL   Interleukin 
iNOS   Inducible nitric oxide synthase 
IP3   Inositol trisphosphate 
IRAP/ AT4  Insulin regulating amino peptidase 
JNK   c-Jun n-terminal kinase 
KO   Knockout 
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LB   Lysogenic broth 
MAPK/Erk  Mitogen activated protein kinase 
MC   Mesangial cells 
MEK   Mitogen-activated protein kinase kinase 
MKP-1   MAP kinase phosphatase-1 
Mrg (Mrgpr)  Mas related G-protein coupled receptor 
NADPH  Nicotinamide adenine dinucleotide phosphate 
NEP   Neprilysin 
NFAT   Nuclear factor of activated T-cells 
NFκB   Nuclear factor kappa-light-chain-enhancer of activated B cells 
nNOS   Neuronal nitric oxide synthase 
NO   Nitric oxide 
NOX   Nicotinamide adenine dinucleotide phosphate oxidase 
pAkt   Phospho Akt 
PBS   Phosphate-buffered saline 
PCR   Polymerase chain reaction 
PDE   Phosphodiesterase 
PGE2   Prostaglandin E2 
PGI2   Prostacyclin 
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PhosK   Phosphorylase kinase 
PI3K   Phosphatidylinositide 3-kinases 
PIP2   Phosphatidylinositol 4,5-bisphosphate 
pJNK   Phopho JNK 
PKA   Protein kinase A  
PKB/Akt  Protein kinase B 
PKC   Protein kinase C 
PLA2   Phospholipase A2 
PLCβ    Phospholipase C beta 
PP2A   Protein phosphatese 2A 
PTX   Pertussis toxin 
PYK2   Protein tyrosine kinase 2 
Raf   Family of serine/threonine-specific protein kinases 
RAP   GTP-binding protein or Ras-related protein 
RAS   Renin-angiotensin system 
Ras   Family of small GTPases 
Rho   Small GTPase 
ROCK   Rho-associated protein kinase 
ROS   Reactive oxygen species 
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RT   Room temperature 
RT-qPCR  Reverse transcription and quantitative polymerase chain reaction 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SGLT2   Sodium–glucose cotransporter 2 
SHP-1   Src homology region 2 domain-containing phosphatase-1 
Src   Pyrosine-protein kinase 
STZ   Streptozotocin 
T1DM   Diabetes mellitus type 1 or Type 1 diabetes 
T2DM   Diabetes mellitus type 2 or Type 2 diabetes 
TAE   Tris-acetate-EDTA 
TBS   Tris-buffered saline 
TGFβ   Transforming growth factor beta 
TNF-α   Tumour necrosis factor alpha 
VEGF   Vascular endothelial growth factor 
VSMC   Vascular smooth muscle cells 
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